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To  date,  a  mutation  of   the  glucocerebrosidase  gene  (GBA)   is   the  strongest  genetic  
risk   factor   associated   to   Parkinson’s   disease   (PD).   This   leads   to   my   prospective  
cohort  study  of  a  GBA  mutation  positive  cohort  for  early  features  of  PD.    This  study  
indicates   that   as   a   group,  GBA  mutation   positive   individuals   show   deterioration   in  
clinical  markers  consistent  with  the  prodrome  of  PD.    
I   have   generated   cell   culture   models   from   individuals   within   the   clinical   cohort  
studied,   in   order   to   delineate   the   molecular   mechanism   of   mutant   GBA   to   the  
pathogenesis  of  PD.      
My   results   on   skin   fibroblast   cultures   reproduce   the   glucocerebrosidase   enzyme  
(GCase)   enhancement   seen   from   previous   studies   following   treatment   with  
pharmacological  chaperone  (PC)  molecules.  These  data  further  provide  support  for  a  
link   between  GBA  mutations   and   changes   in   the   autophagic/lysosomal   system,  
which  could  predispose  to  neurodegeneration.    
Due  to  the  limitation  of  fibroblasts  as  a  model  for  interrogating  the  complete  pathway  
in  PD,  I  studied  human  adipose  neural  crest  stem  cell  (NCSC)  derived  dopaminergic  
(DA)  neurons.  This  model  recapitulated  the  defects  identified  in  the  fibroblast  model  
including:   reductions   in   GCase   activity   and   protein   level,   and   lysosomal  
abnormalities   including   impairments  of  autophagy.   In  addition,  reduced  GCase  was  
associated   with   increased   α-­synuclein   (SNCA).   PC   treatment   restored   GCase  
function,  upregulated  macroautophagy  and  lead  to  a  reduction  in  SNCA  levels.  
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Chapter  1:  The   Association   Between   Glucocerebrosidase  




1.1  Gaucher  disease  
Named   after   the   French   physician   Philippe  Gaucher,   who   originally   described   the  
clinical   features   in   1882,   Gaucher   disease   (GD)   is   the   most   common   lysosomal  
storage  disorder   (Grabowski,   2008)   and   is  more   frequent   in   the  Ashkenazi   Jewish  
population.  It  follows  an  autosomal  recessive  mode  of  inheritance  and  is  caused  by  
mutations   in   both   copies   (homozygous   or   compound   heterozygous)   of   the  
glucocerebrosidase  (GBA)  gene.  GBA  encodes  a  lysosomal  enzyme  (GCase),  which  
cleaves   the   β-­glucosyl   linkage   of   glucosylceramide   (GC)   and   glucosylsphingosine  
(GS).  GD   patients   have   reduced  GCase   activity,   while   heterozygote   carriers   have  
varying  degrees  of  enzyme  activity  ranging  from  50%  to  normal  levels  (Raghavan  et  
al.,   1980).   However,   although   mutations   in  GBA  are   usually   associated   with   a  
reduction  in  GCase  activity,  the  exact  mechanism  that  mediates  the  pathogenesis  of  
GD  is  unknown.  The  effects  of  reduced  GCase  and  lysosomal  activity,  mis-­trafficking  
of  glucocerebrosidase  protein  (GBA),  and  endoplasmic  reticulum  (ER)  stress  are  all  
thought   to   be   contributory.   GD   is   characterized   by   widespread   accumulation   of  
substrates  GC  and  GS  within  the  lysosomes  of  several  cell  types,  in  particular  cells  
of   mononuclear   phagocyte   origin,   and   in   several   tissues,   including   brain.  
Macrophages   with   GC-­laden   lysosomes,   or   ‘Gaucher   cells’,   are   a   classic   cellular  
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hallmark   of   GD   and   infiltrate   the   liver,   spleen,   and   bone   marrow.   Common  
manifestations   of   the   disease   include   anaemia,   thrombocytopenia,  
hepatosplenomegaly,  and  bone  disease  (Beutler  and  Grabowski,  2001).  
GD  has  historically  been  classified  into  three  main  clinical  subtypes  based  on  age  of  
onset,   clinical   presentation,   and   nervous   system   involvement   (Cox   and   Schofield,  
1997).   Type   1  GD   is   the  most   common   phenotype   and   can  manifest   at   any   age.  
Although   pan-­ethnic,   it   is   more   frequent   among   persons   of   Ashkenazi   Jewish  
heritage  (Zimran  et  al.,  1991).  The  neuronopathic   forms  of   the  disease,   type  2  and  
type  3,  usually  appear  in  infancy  or  adolescence,  respectively,  and  typically  present  
with  a  more  severe  clinical  phenotype.  The  wide  spectrum  of  clinical  manifestations  
seen   in   patients   with   type   1   GD   has   led   many   to   argue,   however,   that   this  
classification   system   is   too   simplistic   (Sidransky,   n.d.).   Indeed,   the   observation   of  
parkinsonism,  dementia,  and  subclinical  peripheral  neuropathy  in  patients  with  type  1  
GD  has  challenged  its  more  traditional  definition  as  non-­neuronopathic.  
Clinically,   GD   is   highly   variable,   and   genotype-­phenotype   correlations   are   limited.  
Although  the  spectrum  of  disease  is  thought  to  correlate  in  part  with  residual  enzyme  
activity   (Cox   and  Schofield,   1997),   there   is   substantial   clinical   heterogeneity,   even  
among   siblings   and   identical   twins   (Lachmann   et   al.,   2004;;   Biegstraaten   et   al.,  
2011).  
Current   treatment   for  patients  with  GD   include  enzyme  replacement   therapy   (ERT)  
(but   this   does   not   cross   the   blood-­brain   barrier   and   is   very   expensive)   and  
alternatives  such  as  substrate  reduction  therapy  (SRT)  or  the  use  of  small  molecule  
enzyme-­chaperone  therapy  (Beutler  and  Grabowski,  2001).  The  last  mentioned  has  
the   added   benefit   of   crossing   the   blood–brain   barrier,   providing   an   opportunity   to  
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treat  additional   features  of   the  disease,  e.g.   the  neurological  manifestations  of  GD.  
Pharmacological  chaperones,  e.g.  ambroxol  and   isofagomine,  have  been  shown   to  
bind   mutant   misfolded   GCase   stalled   in   the   ER,   assisting   in   the   refolding   and  
passage  to  the  lysosome,  where  the  chaperone-­enzyme  complex  dissociates  in  the  
low  pH  and  the  residual  activity  of   the  enzyme  can  hydrolyse  substrate  (Sun  et  al.,  
2012;;  Bendikov-­Bar  et  al.,  2013).  
  
1.2  Glucocerebrosidase  gene  (GBA)  
The  gene  encoding  GBA  is   located  on  chromosome  1q21  and  comprises  11  exons  
and  10  introns,  spanning  7.6  kb  of  sequence.  Located  16  kb  downstream  and  2  kb  
shorter  is  a  highly  homologous  pseudogene  (GPAP),  which  has  >  96%  identity  to  the  
coding   regions   of   the   functional   gene.   This   complicates   sequencing,   as   many  
mutations   encountered   in   GD   patients   are   identical   to   sequences   ordinarily   found  
only  in  the  pseudogene.  Thus,  for  diagnostic  purposes  it   is  essential  to  differentiate  
between   sequences   from   the   gene   and   the   pseudogene.   So   far   300   pathogenic  
mutations   throughout   the  GBA  gene   have   been   identified   (Hruska   et   al.,   2008),  
including   point   mutations,   insertions,   deletions,   frameshift   mutations,   splice-­site  
alterations,   and   recombinant   alleles   that   encompass   segments   of   the   pseudogene  
sequence.  The  c.1226A  >  G   (N370S)  mutation   is   the   commonest  GBA  mutation   in  
the  literature  followed  by  c.1448T  >  C  (L444P)  (Beutler  and  Grabowski,  2001).  The  
frequency  of  GBA  mutations,  however,  varies  according  to  the  different  ethnicity.  For  
instance,   in   the   Ashkenazi   Jewish   population,   1   in   14–18   carries   a  GBA  mutation.  
Therefore,  screening  for  GBA  mutations  common  in  Ashkenazi  Jews  could  be  cost-­
effective   but   is   not   a   reliable   strategy   for   other   ethnic   groups,   in  
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which  GBA  mutations   are   found   in   less   than   1%   and   a   large   number   of   different  
mutations  are  seen.  Moreover,  the  N370S  variant,  although  frequent  among  those  of  
European,   American,   or  Middle   Eastern   origin,   is   not   typically   seen   in   Chinese   or  
Japanese  populations  (Mitsui  et  al.,  2009;;  Huang  et  al.,  2011).    
  
1.3  The  link  between  GBA  mutations  and  Parkinson’s  disease  
Among   the   neurological   complications   of   type   1   GD   is   parkinsonism.   This   has  
challenged   the   traditional   classification   of   type   1   GD   as   non-­neuropathic.   The  
possibility  of  a  link  between  the  two  diseases  was  first  suggested  in  the  clinic  setting  
where   a   small   number   of   case   reports   described   parkinsonian   features   in   GD  
patients  (Van  Bogaert,  1939;;  Sack,  1980;;  Turpin  JC,  Dubois  G,  Brice  A,  Masson  M,  
Nadaud  MC,  1987).  Larger  studies  have  since  been  published  which  have  confirmed  
these   findings   (Bembi   et   al.,   2003;;   Tayebi   et   al.,   2003).   Heterozygote   carriers   of  
mutations  in  the  GBA  gene  also  have  an  increased  frequency  of  PD  (Halperin  et  al.,  
n.d.;;   Goker-­Alpan   et   al.,   2004),   and   approximately   5–10%   of   PD   patients  
have  GBA  mutations   (Mata   et   al.,   2008;;   Sidransky   et   al.,   2009a),   confirming  
mutations  of   this  gene  as  numerically   the  most   important  genetic  predisposing   risk  
factor  for  PD  identified  to  date.  
Studies   describing   the   penetrance   and   lifetime   relative   risk   (RR)   of  PD   in   patients  
with  GD  and  heterozygote  GBA  mutation  carriers  are  summarized  in  Table  1.1.  Data  
are   conflicting,   with   some   studies   reporting   a   slightly   higher   estimated   penetrance  
and   lifetime   RR   of   PD   in   heterozygous  GBA  mutation   carriers   compared   to   GD  
patients.   This   may   reflect   differences   in   the   size   and   ethnicity   of   the   cohorts   that  
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were  evaluated,  rather  than  a  significant  difference  in  the  overall  risk  of  PD  between  
the  two  groups.    
Studies  have  investigated  the  frequency  of  GBA  mutations  in  patients  with  sporadic  
PD   and   have   shown   that   the   odds   ratio   for   a   known   patient  with   idiopathic   PD   to  
harbour  one  GBA  mutation  is  5.4  (Sidransky  et  al.,  2009a).  In  other  words,  patients  
with   PD   are   five   times   more   likely   to   carry  GBA  mutations   than   healthy   controls.  
Moreover,  when  compared  to  other  PD-­related  genes,  such  as  α-­synuclein  (SNCA)  
and   Parkin,   the   frequency   of  GBA  mutations   is   higher   in   individuals   with  
parkinsonism   (Lwin   et   al.,   2004).   Of   further   interest   is   a   recent   study   that   has  
identified  a  GBA  mutation,  E326K,  that  causes  loss  of  GCase  activity  (McNeill  et  al.,  
2014)  and  can  predispose  to  PD,  but  is  a  variant  that  does  not,  when  homozygous,  
cause  GD  (Duran  et  al.,  2013).    
GBA  mutations   have   been   identified   in   other   Lewy   body   disorders   including  
dementia  with  Lewy  bodies  (DLB),  Lewy  body  variant  Alzheimer  disease  (LBV-­AD),  
but   not   multiple-­system   atrophy   (MSA).   These   disorders,   known   as  
synucleinopathies,   are   characterized   by   the   deposition   of   fibrillated   SNCA   within  
brainstem   or   cortical   inclusion   bodies.   In   an   autopsy   study   of   75   cases   with  
pathologically  confirmed  Lewy  body  (LB)  disorders,  GBA  mutations  were  identified  in  
23%  of  cases  with  DLB,  4%  of  those  with  PD,  and  none  with  MSA  (Goker-­Alpan  et  
al.,   2006).   Furthermore,   in   a   recent   report,   those  with  DLB  were   eight   times  more  
likely   to   carry   a   mutation   in  GBA  than   healthy   controls,   suggesting  GBA  mutations  
may  play  an  even  greater  role  in  the  genetic  aetiology  of  DLB  than  in  PD  (Nalls  et  al.,  
2013).   Conversely,   studies   in   MSA   patients,   including   108   British   pathologically  
confirmed  cases  (Segarane  et  al.,  2009),  have  not  identified  significant  differences  in  
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the  GBA  mutations   observed   in   cases   and   controls.   This   suggests   a   distinct  
pathogenesis   for   MSA,   a   disease   in   which   SNCA   is   deposited   in   oligodendroglial  
cytoplasmic   inclusions   rather   than   neurons,   that   is   not   just   related   to   PD   but   also  
shares   traits   of   a   demyelinating   disorder.   This   also   emphasizes   the   relationship  
between  GBA  mutations   and   SNCA   neuronal   aggregation   in   PD   and   DLB.  
Moreover,  GBA  mutations   have   not   been   identified   in   patients   with   progressive  




Table   1.1   Age-­specific   penetrance   rates   and   lifetime   relative   risk   of  
Parkinson’s   disease   in   Gaucher   disease   patients   and   heterozygote   GBA  
mutation  carriers.  






Women   Men  
                 
Penetrance  of  PD  at  65  years,  %           1.5   7.7   (Chetrit  et  al.,  2013)   2.2   (Rana  et  al.,  2013)  
Penetrance  of  PD  at  70  years,  %   1.5   15.2   (Chetrit  et  al.,  2013)   21.4   (Anheim  et  al.,  2012)  
  5.0       7.0   (Rosenbloom  et  al.,  
2011)  
Penetrance  of  PD  at  75  years,  %   -­   -­   6.8   (Rana  et  al.,  2013)  
Penetrance  of  PD  at  80  years,  %     9.0   12.0   (Rosenbloom  et  al.,  
2011)  
29.7   (Anheim  et  al.,  2012)  
Penetrance  of  PD  at  85  years,  %   -­   -­   10.9   (Rana  et  al.,  2013)  
Overall  lifetime  RR  of  PD  
compared  to  that  in  the  general  
population  
21.4   (Bultron  et  al.,  
2010)  






1.4  GBA-­associated  PD  
GBA-­related   parkinsonism   largely   resembles   sporadic   PD,   but   it   has   been  
characterized   by   some   subtle   differences,   for   instance   a   younger   age   of   onset  
(Neumann  et  al.,  2009),  a  higher  frequency  of  cognitive  decline  (Goker-­Alpan  et  al.,  
2008;;   Neumann   et   al.,   2009),   bradykinesia   (Gan-­Or   et   al.,   2009),   olfactory  
dysfunction  (Goker-­Alpan  et  al.,  2008),  and  a  lower  frequency  of  rigidity  (Clark  et  al.,  
2007).  
  
  Clinical  phenotype  
Parkinsonism  in  GD  patients  and  GBA  heterozygotes  
PD  is  typically  characterized  by  the  motor  symptoms  of  resting  tremor,  bradykinesia,  
rigidity,  and  postural  instability.  Patients  with  GD  who  develop  parkinsonism  typically  
exhibit   the  symptoms  of  sporadic  PD.  The  majority  of  patients  with   type  1  GD  who  
developed   PD   therefore   present   with   asymmetric   onset,   tremor,   and   bradykinesia  
(Goker-­Alpan   et   al.,   2008),   the   cardinal   features   of   ‘idiopathic’   PD.   Table  
1.2  summarizes   all   the   published   studies   looking   at   the   frequency   and   clinical  
features   of   PD   patients   with   mutations   in  GBA.   In   patients   with   PD   who   had  
heterozygous  mutations   in  GBA,   Neumann   et   al.   (Neumann   et   al.,   2009)   reported  
hallucinations  in  45%  and  signs  of  cognitive  decline  or  dementia  in  48%  by  the  time  
the  patient  died.  A  study  of  Spanish  PD  patients  with  heterozygous  GBA  mutations  
confirmed   an   increased   frequency   of   dementia   (Setó-­Salvia   et   al.,   2012).  
Furthermore,  in  a  recent  longitudinal  (~71  months)  community-­based  unselected  PD  
cohort,   there   was   a   significantly   greater   risk   for   progression   to   dementia   in  
heterozygote  GBA  mutation  carriers  (Winder-­Rhodes  et  al.,  2013).  
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  Response  to  treatment  
Reports   on   the   efficacy   of   L-­dopa   treatment   in   patients   with   PD   and   mutations  
in  GBA  have  been  conflicting.  Most  studies  report  a  good  or  excellent  response  to  L-­
dopa   treatment   in   heterozygote  GBA  mutation   carriers   (Ziegler   et   al.,   2007;;  
Neumann   et   al.,   2009),   as   would   be   expected   in   the   presynaptic   dopamine  
deficiency   seen   in   PD   with   and   without  GBA  mutations,   but   some   report   a   less  
favourable  response  (Tayebi  et  al.,  2003).  
  
  Cognitive  impairment  and  neuropathological  findings  
The  pathological  hallmarks  of  PD   include  a   loss  of  dopaminergic  neurons   from   the  
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the   remaining   nerve   cells   of   affected   brain   regions.   Neuropathological   findings  
demonstrate  that  GBA-­PD  brains  show  the  typical  hallmarks  of  sporadic  PD,  such  as  
brainstem  and  cortical   LBs   (Wong  et   al.,   2004;;  Neumann  et   al.,   2009).  GBA   is  an  
important   component   of  SNCA-­positive  pathological   inclusions   (Goker-­Alpan  et   al.,  
2010).   Immunohistochemistry   of   seven   brain   samples   from   subjects  
carrying  GBA  mutations   (three   individuals   with   GD   and   four   with   heterozygous  
mutations  in  GBA)  and  with  pathological  diagnoses  of  PD  and/or  DLB  demonstrated  
a   co-­localization   of   mutant   GBA   and   SNCA   in   protein   aggregates   and   LBs.   In  
contrast,   in   samples   from   those  without  GBA  mutations,   <   10%  of   LBs  were  GBA-­
positive  (Goker-­Alpan  et  al.,  2010).  
There  are  several  reports  now  demonstrating  more  cognitive  impairment  in  GBA-­PD  
(Sidransky   et   al.,   2009a;;   Brockmann   et   al.,   2011;;   Alcalay   et   al.,   2012).   It   is  
interesting   to   speculate   that   the   cognitive   impairment   in  GBA-­related  parkinsonism  
results  from  a  higher  burden  of  LB  disease  than  sporadic  PD.  Two  autopsy  studies  
demonstrated   that,   in   addition   to   the   classic   PD   pathology,   in   PD   patients   with  
heterozygous  GBA  mutations,   SNCA   inclusions   were   detectable   in   cortical   areas  
corresponding   to  Braak   stages  5   to   6   suggesting  GBA  mutation   carriers  may  have  
more  extensive  neuropathological  disease  (Clark  et  al.,  2009;;  Neumann  et  al.,  2009).  
However,  in  a  later  study  on  the  same  autopsies,  authors  did  not  identify  increased  
LB   pathology   in   PD   associated   with  GBA  mutations   (Parkkinen   et   al.,   2011).   The  
findings  from  both  cellular  and  animal  studies  suggest  that  mutant  GBA  can  promote  
the  accumulation  of  SNCA  (Sardi  et  al.,  2011)  and   led  authors   to  propose  that  any  
subsequent   formation   of   SNCA   oligomers   could   kill   the   cell   prior   to   LB   formation  




  Non-­motor  symptoms  
By  the  time  the  classic  motor  problems  of  PD  develop,  it  is  estimated  that  over  50%  
of  dopaminergic  neurons  in  the  substantia  nigra  (SN)  have  degenerated  (Lees  et  al.,  
2009).  There   is  now  evidence   that   the  PD  neurodegeneration  process  begins   long  
before  the  onset  of  the  motor  involvement  (Savica  et  al.,  2010;;  Schapira  and  Tolosa,  
2010).  During  this  period,  other  neurotransmitter  systems  may  also  degenerate  and  
are  associated  with  non-­motor  symptoms  (NMS),   including  olfactory  and  autonomic  
dysfunction,  sleep  disorders,  mood  changes,  and  cognitive  decline.  The  recognition  
that  the  pathological  process  may  start  outside  of  the  SN  (Braak  et  al.,  n.d.)  explains  
why  some  of  these  NMS  manifest  before  motor  problems  emerge,  and  can  therefore  
precede   the   diagnosis   of   PD.   Moreover,   NMS   occur   more   frequently   in   GBA-­PD  
(McNeill  et  al.,  2012a).  Therefore,   further  screening  for  non-­motor  manifestations   is  
needed  in  GBA  mutation-­positive  individuals  prior  to  conversion  to  PD,  to  develop  an  




Dopamine  imaging  by  single  photon  emission  tomography  (SPECT)  of  the  dopamine  
transporter  and  positron  emission   tomography   (PET)  are  abnormal   in  patients  with  
PD   and  GBA  mutations,   in   a   pattern   that   is   similar   to   sporadic   PD   (McNeill   et   al.,  
2013a).   In   a   PET   study   to   investigate   underlying   dopaminergic   dysfunction  
in  GBA  mutation   carriers  with   and  without   parkinsonism,  Kono   et   al.   demonstrated  
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presynaptic  dopaminergic  dysfunction  characteristic  of  sporadic  PD  in  both  a  patient  
with   GD   and   PD,   and   three   subjects   with   heterozygous  GBA  mutations   and   PD  
(Böttcher   et   al.,   2013).   In   another   study,   homozygous   and   compound  
heterozygous  GBA  mutation   carriers   identified   through   screening  of   250  Ashkenazi  
Jewish   parkinsonian   individuals   were   assessed   with   18F-­fluorodopa   PET   and  
showed   bilateral   reductions   in   striatal   F-­dopa   uptake,   similar   to   idiopathic   PD  
(Saunders-­Pullman  et  al.,  2010).  However,  findings  from  a  larger  study  showed  that  
although  the  pattern  of  dopamine  loss   is  similar   in  patients  with  GD  and  PD  to  that  
seen   in   patients   with   sporadic   PD,   H215O   PET   demonstrates   reduced   resting  
regional   cerebral   blood   flow   in   additional   areas   (precuneus   and   lateral   parietal-­
occipital  association  cortex  bilaterally)   in  patients  with  PD  and  GBA  mutations,   in  a  
pattern  characteristic  of  diffuse  LB  disease  (Kono  et  al.,  2010).  
In   idiopathic   PD,   transcranial   sonography   (TCS)   detects   SN   hyper-­echogenicity   in  
90%  of   patients,  which   likely   reflects   increases   in   local   iron   content   and  microglial  
activation.  However,   there   are   concerns   regarding   the   specificity   and   sensitivity   of  
this  technique  in  PD.  SN  echogenicity  is  a  finding  that  may  also  change  over  time  in  
a  normal   individual   (Hagenah  et  al.,  2010).  Furthermore,   there   is  no  relationship  of  
the   TCS   abnormalities   to   PD   stage   or   progression.   Nevertheless,   SN   hyper-­
echogenicity  has  also  been  a  reported  feature  of  PD  associated  with  GBA  mutations,  
and   there   is  a  comparable  degree  of  SN  hyper-­echogenicity  and  common   features  
regarding   SN   pathology   (Berg   et   al.,   2008).   Recent   evidence   suggests,   however,  
that   this   is   a   frequent   finding   in   GD   patients,   irrespective   of   whether   they   had  
developed  PD  or  not,  and  could  be  related  to  disturbances  of  iron  metabolism  in  GD  
(Goker-­Alpan  et  al.,  2012).  
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  Cerebrospinal  fluid  findings  
In   patients  with  PD  and  GBA  mutations   there  are  altered   cerebrospinal   fluid   (CSF)  
fatty  acid  levels  compared  with  patients  with  idiopathic  PD  (Schmid  et  al.,  2012).  In  a  
study  comparing  CSF  fatty  acid  concentrations  in  41  patients  with  idiopathic  PD  and  
8   patients   with   PD   associated   with   heterozygous  GBA  mutations,   results  
demonstrated   specific   abnormalities   of   fatty   acid   metabolism   in   those  
with  GBA  mutations,  which  authors  propose  may  be  involved  in  the  pathogenesis  of  
PD  (Schmid  et  al.,  2012).  Larger  studies  would  be  needed  to  confirm  this.  Of  further  
interest  is  a  12-­year  follow-­up  study  of  a  case  of  PD  in  a  patient  who  later  developed  
GD  (Machaczka  et  al.,  2012).  The  cognitive  decline  and  cortical  atrophy  seen  in  this  
patient   were   not   paralleled   by   any   change   of   dementia   markers   in   the   CSF.  
Concentrations   of   tau   and   β-­amyloid   (proteins   elevated   in   Alzheimer   disease)  
remained   normal,   while   concentrations   of   monoamine   metabolites   were   low.   This  
could   suggest   the   cognitive   decline   observed   in   this   patient   with  GBA  mutations  
involved   pathogenetic   pathways   other   than   those   typically   found   in   Alzheimer  
disease.  
  
1.5  Proposed   mechanisms   linking   GBA   and   Parkinson’s   disease  
pathogenesis  
The   mechanisms   by   which  GBA  mutations   result   in   PD   are   not   yet   understood  
(Figure   7.1).   Most   autosomal   recessive   forms   of   PD,   such   as   PINK1,   DJ-­1,   and  
parkin,   are   associated   with   loss-­of-­function   mutations   and   early   onset   disease.   In  
contrast,  autosomal  dominant  forms  are  attributed  to  a  gain-­of-­function  mutation.  GD  
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is   an   autosomal   recessive   disorder.   However,   the   inheritance   of   PD   caused  
by  GBA  mutations  does  not  follow  a  strict  Mendelian  pattern.  Therefore,  in  GBA-­PD,  
both  gain-­of-­function  and  enzymatic   loss-­of-­function  models  have  been  put   forward  
(Sidransky   and   Lopez,   2012)   to   explain   how   mutations   in  GBA  contribute   to   the  
pathogenesis   of   PD.  Mutations   in  GBA  could   result   in   a  mutant  misfolded   protein.  
Misfolded   GBA   could   lead   to   the   development   of   PD   by   promoting   SNCA  
accumulation  or  preventing  its  degradation.  Alternatively,  the  misfolded  protein  could  
cause   lysosomal   dysfunction   by   overwhelming   the   ubiquitin-­proteasome   pathway  
(UPS)   or   by   impairment   of   autophagy.   Most   mutations   in  GBA  are   missense  
mutations  that  give  rise  to  a  misfolded  protein,  and  therefore  this  favours  a  gain-­of-­
function  model.  However,  some  studies  have   implicated  GBA  mutations   that  do  not  
encode  the  glucocerebrosidase  protein,  e.g.  84GG  null  allele,  in  patients  who  also  go  
on   to   develop   PD   (Gan-­Or   et   al.,   2008).   Albeit   rare,   these  mutations   could   argue  
against  an  exclusively  gain-­of-­function  mechanism.  Alternatively,  parkinsonism  could  
arise   from  a  deficiency/reduction  of  wild-­type   (WT)  GCase   resulting   from  a   loss-­of-­
function   mutation,   with   subsequent   substrate   accumulation   and   altered   lipid  
homeostasis,  or  lysosomal  dysfunction.  Neither  model,  however,  explains  why  only  a  
minority  of  patients  with  mutations  in  GBA  go  on  to  develop  PD.  
  
  A  Synucleinopathy  
The  synucleinopathies  are  all  characterized  by  the  presence  of  aggregated  insoluble  
SNCA,   in   the  form  of  amyloid   fibrils,  within  LBs  of   the  central  nervous  system.  The  
presence   of   mutant   GBA   in   SNCA-­positive   LBs,   as   demonstrated   by  
immunohistochemistry   studies   (Goker-­Alpan   et   al.,   2010),   has   suggested   a  
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relationship  could  exist  between  the  two  proteins.  GCase  deficiency,  overexpression  
of  mutant  GBA,   or   inhibition  of  GCase  by  condruitol  β-­epoxide   (CBE)  can   interfere  
with   the   clearance   of   or   promote   the   aggregation   of   SNCA   (Manning-­Boğ   et   al.,  
2009;;  Cullen  et  al.,  2011;;  Mazzulli  et  al.,  2011;;  Xu  et  al.,  2011;;  Gegg  et  al.,  2012;;  
Cleeter  et  al.,  2013;;  Osellame  et  al.,  2013).  Furthermore,  augmenting  GCase  activity  
can  reduce  SNCA  levels  (Sardi  et  al.,  2011).  Albeit,  a  recent  report  did  not  find  any  
significant   alteration   in   SNCA   levels   following   GCase   inhibition   with   CBE  
(Dermentzaki   et   al.,   2013),   but   this   probably   reflected   too   short   a   period   of   toxin  
exposure  (Cleeter  et  al.,  2013).  
Increased  SNCA   results   in  a  decrease   in  GBA  protein  and  GCase  activity   in  cells.  
SNCA   can   also   affect   the   transport   of   GBA   from   the   ER/Golgi   apparatus   to   the  
lysosome  (Mazzulli  et  al.,  2011;;  Gegg  et  al.,  2012).  Recent  evidence  has  suggested  
a   self-­propagating   feedback   loop   in   GD   and   synucleinopathies.   A   deficiency   of  
GCase  may  lead  to  an  accumulation  of  substrate,  which  could   in  turn   influence  the  
amyloid  formation  of  SNCA,  and  the  resulting  toxic  build-­up  of  insoluble  SNCA  within  
lysosomes   could   compromise   lysosomal   protein   degradation.   SNCA   could   then  
impair   the   trafficking   of   GBA,   exacerbating   substrate   accumulation   and   SNCA  
aggregation  (Mazzulli  et  al.,  2011).  The  further  finding  that  GCase  is  reduced  in  the  
SN   in   PD   brains  with   or   without  GBA  mutations   (Gegg   et   al.,   2012)   suggests   that  
SNCA   could   cause   GCase   deficiency   directly,   even   in   the   absence   of   mutant  
enzyme,   and   this   could   be   exacerbated   in   GBA-­PD   and   hold   significance   for   the  
wider  PD  population.  
Experimental   evidence   now   suggests   that   GBA   interacts   directly   with   SNCA   at  
membranes,   within   lysosomes   (Yap   et   al.,   2013).   The   interaction   site   has   been  
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mapped   to   the   C-­terminus   of   SNCA.   It   has   also   been   suggested   that   the   binding  
between   the   WT   GBA   and   SNCA,   under   lysosomal   conditions,   could   have   a  
beneficial   effect   by   either   promoting   SNCA   degradation   by   the   lysosome   and/or  
preventing   aggregation   (Yap   et   al.,   2011).   The   authors   propose   another   self-­
perpetuating   model.   Mutant   GBA   or   reduced   levels   of   WT   GBA   reaching   the  
lysosome  could  weaken  the  beneficial   interaction  between  SNCA  and  GBA,  reduce  
lysosomal   protein   degradation,   and   contribute   to   the   SNCA   aggregation  
characteristic  of  PD  pathology.  The   resultant  accumulation  of   substrate  and  SNCA  
would   then   mediate   the   interaction   of   the   SNCA-­GBA   complex   on   intralysosomal  
vesicles,  leading  to  a  further  loss  of  GCase  activity  (Yap  et  al.,  2013).  
Recent  studies  therefore  demonstrate  a  reciprocal  relationship  between  GCase  and  
SNCA   (Mazzulli   et   al.,   2011;;   Gegg   et   al.,   2012),   which   not   only   contribute   to   our  
understanding  of   the  pathogenesis  of  GBA-­PD  and   idiopathic  PD  but  also  highlight  
an   important   therapeutic   target.  Modulating  GCase  activity  or   improved  targeting  of  
GBA   to   lysosomes   could   be   an   important   therapeutic   approach   for   PD   (Sidransky  
and  Lopez,  2012;;  Schapira  and  Gegg,  2013).  
This   gain-­of-­function  model,   however,   does  not   explain  why  only   a  minority   of  GD  
patients   or   carriers   of  GBA  mutations   ever   develop   PD.   Other   pathological   factors  
may  be  at  work  and  help  determine  whether  a  positive   feedback   loop  can  surpass  
the  cellular  homeostatic  mechanisms  to  an  extent   that   the   levels  of  SNCA  become  
toxic.  It  could  be  that  GBA  contributes  to  SNCA  pathology,  but  only  in  the  presence  
of  other  insults,  e.g.  increasing  age,  where  the  number  of  lysosomes  and  lysosome  
function  decreases  and  cellular  SNCA  concentrations  increase.  Another  possibility  is  
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that  GBA  may   act   as   a   ‘second   hit’   in   some   individuals   who   are   genetically  
predisposed  to  develop  PD  (Sidransky  and  Lopez,  2012).  
  
  Autophagic  dysfunction  
In   PD,   the   accumulation   of   SNCA   and   other   ubiquitinated   proteins   within   LB  
inclusions   has   implicated   protein   mishandling   in   the   pathogenesis   of   the   disease.  
Abnormal  protein  accumulation  appears   in  both  PD  and  GD  and  may   influence  the  
severity  of  disease.  Proteins  are  degraded  via  the  lysosome  or  the  proteasome.  The  
lysosome   is   the  major   cellular   compartment   for   protein   degradation   (De  Duve  and  
Wattiaux,  1966),  and  within  the  lysosome  the  degradation  of  proteins  occurs  through  
three  distinct  pathways:  macroautophagy,  microautophagy,  and  chaperone-­mediated  
autophagy  (CMA).  The  lysosomal  autophagy  process  destroys  misfolded,  long-­lived  
or  aggregate-­prone  proteins  in  the  cell  and,  in  doing  so,  confers  a  cytoprotective  role  
(García-­Arencibia  et  al.,  2010).  Defective  autophagy  and/or  depletion  of   lysosomes  
have  been  implicated  in  PD  pathogenesis  (Cuervo  et  al.,  2004;;  Alvarez-­Erviti  et  al.,  
2010;;  Dehay  et  al.,  2010;;  Wong  and  Cuervo,  2010)  and  in  a  Gaucher  mouse  model  
(Cullen  et  al.,  2011).    
Evidence  for  the  role  of  the  lysosome  under  conditions  of  protein  burden  came  from  
a  study  looking  at  the  overexpression  of  SNCA  in  transgenic  mice  (Mak  et  al.,  2010).  
Overexpression   led   to   its   subsequent   enhanced   clearance   by   the   lysosomal   CMA  
pathway.   This   was   demonstrated   by   an   up-­regulation   of   lysosome-­associated  
membrane  protein  type  2A  (LAMP-­2A)  and  lysosomal  heat  shock  cognate  protein  of  
70  kDa  (hsc70),  two  mediators  of  CMA.  An  important  point  to  note,  however,   is  the  
compensatory  action  of  macroautophagy  on  specifically  blocking  CMA  (Alvarez-­Erviti  
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et   al.,   2010).   Rapamycin,   an   inducer   of   macroautophagy,   reverses   the   SNCA  
accumulation   caused  by   the  overexpression  of  D409V  glucocerebrosidase   (Goker-­
Alpan   et   al.,   2012).   Despite   this,   any   up-­regulation   of   macroautophagy   may   be  
unable  to  compensate  for  all  functions  of  CMA  (Massey  et  al.,  2006).  
SNCA  is  degraded  by  proteasomal  pathways,  but   to  a  greater  extent   through  CMA  
(Cuervo  et  al.,  2004).  It  has  been  suggested  that  the  efficacy  of  CMA  declines  with  
age   (Kiffin   et   al.,   2007),   with   decreasing   lysosomal   numbers   and   function.   Of  
particular  interest  is  the  evidence  of  defective  CMA  in  the  PD  brain.  In  a  post-­mortem  
study  of  seven  PD  brains,   there  was  a  significant   reduction  of  CMA  markers  within  
the  SNpc  and  amygdala  compared  to  controls,  and  autophagy-­related  proteins  were  
shown   to   accumulate   in   LBs   (Alvarez-­Erviti   et   al.,   2010).   Moreover,   gene  
replacement  of  beclin  1,  which  activates  autophagy,  has  been  shown  to  ameliorate  
the  neurodegenerative  pathology   in  animal  models  of  PD  and  DLB  (Spencer  et  al.,  
2009).  
The   mechanism   by   which   mutant  GBA   causes   lysosomal   dysfunction   is   not   yet  
understood.   The   decrement   in   lysosomal   function   that   would   result   from  
mutant  GBA  or  decreased  amounts  of  WT  GBA  reaching  the  lysosome,  could  in  turn  
reduce  SNCA  turnover  through  CMA  and  lead  to  its  accumulation  and  aggregation.  
The  suggested  beneficial  interaction  between  SNCA  and  WT  GBA  proposed  to  occur  
under   lysosomal   conditions   (Yap   et   al.,   2011)   may   suggest   that   techniques   to  
increase   GCase   activity   and   improve   its   delivery   to   the   lysosome   could   promote  




  Endoplasmic  reticulum  stress  and  disruption  of  the  ubiquitin-­proteasome  
pathway  
The  ER  operates  a  stringent  quality  control  system  to  ensure  proper  protein  folding,  
trafficking,   and   degradation.   Misfolded   proteins   are   degraded   via   the   UPS.   Some  
studies   have   demonstrated   defects   of   the   UPS   in   sporadic   PD   (Furukawa   et   al.,  
2002;;  McNaught  et  al.,  2003).  Despite  this,   the  application  of  proteasome  inhibitors  
to   induce   PD   in   animal   models   has   produced   conflicting   results   (Beal   and   Lang,  
2006).  
Mutations   in  GBA  can  cause  GCase  to   fold  abnormally,  whereupon   it   is  arrested   in  
the   ER,   targeted   by   endoplasmic   reticulum-­associated   degradation   (ERAD),   and  
translocated  to  the  cytoplasm  for  degradation  by  the  UPS.  This  results  in  decreased  
amounts   of  GBA  protein   present   in   the   lysosome,   and   the   degree  of  ER   retention  
and   proteasomal   degradation   is   thought   to   correlate  with   the   severity   of  GD   (Ron  
and  Horowitz,  2005).  
The  unfolded  protein  response  (UPR)  is  activated  in  response  to  ER  stress,  aids  the  
elimination   of   misfolded   proteins,   and   is   neuroprotective   (Wang   et   al.,   2010).  
Misfolded  GCase  arrested   in   the  ER   can   cause  ER   stress,   activate   the  UPR,   and  
affect   the  UPS  degradation  of  other  proteins,  e.g.  SNCA,   thereby  allowing   them   to  
accumulate.  Markers   of   the  UPR  are   increased   in   both  GBA-­PD  and   sporadic  PD  
brains  and  may  play  a  role  in  reducing  protein  levels  (Gegg  et  al.,  2012).  
However,   only   one   study   has   shown   a   direct   relationship   between   PD  
and  GBA  which   involves   ERAD   (Ron   et   al.,   2010).   Parkin   and   mutations   in   its  
encoding   gene   (PARK2)   cause   early-­onset   PD.   Parkin   is   an   E3   ubiquitin   lipase,  
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ubiquitinating  proteins  for  destruction  by  the  lysosome  or  the  proteasome.  A  loss  of  
normal   parkin   leads   to   impaired   degradation   of   some   of   its   substrates,   including  
SNCA,   and   to   their   accumulation.   Parkin   also   forms   part   of   the   UPR,   enhancing  
removal  of  misfolded  proteins  from  the  ER  (Imai  et  al.,  2000).  One  theory  proposed  
is   that   mutant  GBA  could   interact   with   parkin   to   block   its   interaction   with   other  
substrates,   impairing   their   degradation   via   the   UPS   and   exacerbating   ER   stress,  
leading  to  neuronal  death  with  the  development  of  PD  (Ron  et  al.,  2010).  This  theory  
has  attracted  some  criticism.  The  role  of  parkin  is  not  restricted  to  the  UPS  and  the  
targeting  of  proteins  for  degradation,  and  evidence  from  a  recent  report  in  fibroblasts  
suggests  parkin  is  not  a  critical  ubiquitin  ligase  for  GBA  (McNeill  et  al.,  2013b).  
  
  Dysfunctional  mitophagy  
The  turnover  of  mitochondria  by  mitophagy,  a  form  of  autophagy,  is  essential  for  the  
protection   of   neurons.   If   damaged  mitochondria   are   not   removed,   reactive   oxygen  
species   and   free   radicals   are   allowed   to   accumulate,   causing   damage   to   neurons  
and   eventual   cell   death.   Therefore,  mitochondrial   dysfunction   and   oxidative   stress  
are   thought   to   be   important   in  PD  pathogenesis   (Schapira,   2008).  Several   studies  
have   shown   that   PD   causative   genes   are   implicated   in   mitochondrial   morphology  
and   function   (Schapira   and   Gegg,   2011).   For   instance,   PINK1   and   parkin   play   a  
pivotal   role   in  mitochondrial  quality  control   (Poole  et  al.,  2008).  Parkin  binds   to   the  
mitochondrial  membrane   in   response   to   a   fall   in  membrane  potential   (Narendra   et  
al.,   2008),   and   the   selective   recruitment   of   parkin   to   damaged   mitochondria   is  
mediated  by  PINK1  through  direct  phosphorylation  (Kim  et  al.,  2008).  
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Despite  this,   the  evidence  in  the   literature  for  a  role  of  mitochondrial  dysfunction  or  
mitophagy  in  PD  patients  with  GBA  mutations  remains  limited.  Of  recent  interest  was  
a  study  suggesting  that  inhibition  of  GCase  activity  could  induce  the  abnormalities  in  
mitochondrial   function   and   oxidative   stress   previously   only   seen   in   sporadic   or  
familial   PD.   Authors   showed   that   inhibition   of  GCase   in   cell   culture   leads   to  
decreased   ADP   phosphorylation,   reduced   mitochondrial   membrane   potential   and  
increased  free  radical  damage,  together  with  accumulation  of  SNCA  (Cleeter  et  al.,  
2013).   This   implies   that   mutations   in  GBA  could   increase   the   risk   of   PD   through  
abnormalities   in   mitochondrial   function.   However,   the   mechanism   for   this   remains  
uncertain.  Of  further  relevance  is  a  recent  mouse  model  of  GD  where  there  was  an  
accumulation   of   dysfunctional  mitochondria   as   a   result   of   impaired   autophagy   and  
proteasomal  pathways.  Both  lysosomes  and  mitochondria  have  a  role  in  autophagy  
and   organelle   turnover,   and   authors   suggest   that   the   pathogenesis   of  
neurodegeneration   seen   in   both  GD  and   in  PD   could   result   from  global   defects   in  
proteostasis  (Osellame  et  al.,  2013).  
  
  Altered  lipid  metabolism  
Deficiencies   in  GBA  can   cause   lipids   to   accumulate.   GCase   normally   degrades  
glucosylceramide   to   glucose   and   ceramide.   It   has   been   proposed   that   changes   in  
ceramide  metabolism  are  associated  with  LB  formation,  and  ceramide-­related  genes  
have  been   implicated   in  PD.  For   instance,  a  number  of  genes  have  been   identified  
which  interfere  with  ceramide  metabolism  associated  with  LB  pathology  (Bras  et  al.,  
2008).   It   is   also   thought   that   focal   accumulation   of   lipids   in   specific   brain   regions  
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could   impair   protein   degradation   through   the   lysosomal   autophagy   pathway,   and  
SNCA  could  accumulate.  
SNCA   binds   to   lipids   in   the   plasma   membrane   and   synaptic   vesicles   (Jo   et   al.,  
2000).   The   helical   binding   of   SNCA   to   lipid  membranes   is   thought   to   prevent   the  
formation  of  its  fibrillar  forms.  This  property  of  SNCA  to  form  amyloid  fibrils  is  thought  
critical   for   the  development  of  neurotoxicity  (Mazzulli  et  al.,  2011).  The   lipids  which  
accumulate   as   a   result   of   deficiencies   in  GCase  could   alter   the   sphingolipid  
composition   of   membranes   and   prevent   the  membrane   binding   of   SNCA,   thereby  
enhancing  its  aggregation  in  the  cytoplasm  (Piccinini  et  al.,  2010).  
Despite   this,   there   are   limitations   to   the   hypothesis   that  GBA  mutations   in   patients  
with   PD   cause   alterations   in   lipid   metabolism   due   to   a   loss   of   functional   GCase  
activity.   Ceramide   metabolism   is   thought   to   be   a   tightly   regulated   process,   and  
ceramide  can  be  derived  from  several  different  degradative  and  synthetic  pathways.  
In  addition,   it   is  not  clear  how  a  partial  deficiency   in  GCase  seen   in  heterozygotes,  
insufficient   to   cause   substrate   accumulation,   would   impact   lipid   metabolism  
significantly.   Furthermore,   there   is   no   evidence   that   ceramide   is   deficient   in   those  
with  GD,  even  those  with  severe  forms  of  the  disease  (Velayati  et  al.,  2010).  
  
1.6  The  future:  a  role  for  modulating  GCase  activity?  
GBA  has  now  been   identified  as  numerically   the  most   important  genetic   risk   factor  
for  the  development  of  PD,  and,  unlike  other  PD-­related  genes,  considerably  more  is  
known  about  this  protein,  its  processing,  and  how  it  functions  (Sidransky  and  Lopez,  
2012).  Although  the  mechanisms  underlying  the  association  between  GBA  mutations  
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and  PD  remain  unclear,  further  investigation  and  understanding  of  the  involvement  of  
this  protein  as  a  susceptibility   factor   for  PD  and  other  synucleinopathies   is   likely   to  
prove  valuable.  So   far   to  date,   the  delineation  of   the  different  molecular  pathways,  
which   underlie   the   pathogenesis   of   GBA-­PD,   has   shown   there   is   considerable  
connection  between  them.  
Recent   findings   suggest   that   SNCA   and  GBA  are   implicated   in   a   common   cellular  
pathway  and  are  of  great  significance  in  understanding  the  pathogenesis  of  GBA-­PD  
as   well   as   sporadic   PD.   SNCA   propagation   by   templating   could   be   promoted   by  
GCase   deficiency,   e.g.   increased   SNCA   levels,   promotion   of   fibril   formation,   and  
increased   SNCA   endosomal   release   through   lysosomal   inhibition.   Furthermore,  
Sardi   et   al.   demonstrate   that   augmenting   GCase   activity   can   modulate   SNCA  
aggregation   and   could   represent   a   novel   therapeutic   strategy   for   PD   (Sardi   et   al.,  
2013;;   Schapira   and   Gegg,   2013).   In   a   mouse   model   of   GD   (D409V/D409V  
genotype),   there   was   a   progressive   accumulation   of   SNCA,   tau,   and   ubiquitin  
aggregates   in   hippocampal   neurons   and   a  measurable  memory   deficit.   Increasing  
GCase  activity   in   this  mouse  model,   through  adeno-­associated  viral  vector  delivery  
(AAV)   of   the   recombinant   enzyme   into   the   brain,   modulated   the   accumulation   of  
protein  aggregates  such  as  SNCA  and   improved  memory  defects.   It   is  notable  that  
the  memory  improvement  observed  by  Sardi  and  colleagues,  in  response  to  GCase  
administration   into   the  CNS,  was  seen   in  both  pre-­symptomatic  (Sardi  et  al.,  2011)  
and   symptomatic   mouse   models   (Sardi   et   al.,   2013),   and   before   any   significant  
protein   accumulation   had   established   itself.   This   has   implications   for   the  
asymptomatic   population  at   risk   of   development   of  PD,   e.g.  GBA  mutation-­positive  
carriers,  where  modulating  GCase  activity   could   be   a   potential   strategy   to   prevent  
the   onset/conversion   to   clinical   PD.   Moreover,   the   clinical   evaluation  
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of  GBA  mutation-­positive   individuals   for   pre-­motor   signs   of   PD   could   be   important  
not  only   in  developing  a  clinical  biomarker  set  to  predict   individual  pre-­symptomatic  
risk   of   conversion   to   clinical   PD,   but   this   cohort   would   also   be   invaluable   to   the  
assessment   of   any   future   therapy   to   manipulate   GCase   activity   and   slow   PD  
progression.   Strategies   to   modulate   GCase   activity   include   the   use   of  
pharmacological  chaperones  such  as  ambroxol  or  isofagomine,  histone  deacetylase  
inhibitors  which   reduce   the   recognition  of  misfolded  GBA  by   the  chaperone  protein  
Hsp90β,   and   increasing  GBA   expression,   e.g.   using   gene   therapy   (Schapira   and  
Gegg,  2013).  Enhancing  GCase  activity  in  this  way  and  improving  lysosomal  function  
could  also  hold   relevance   for   those  with  GD,  where   there   is  currently  no   treatment  
that   can   cross   the   blood–brain   barrier   and   treat   the   neurological   forms   of   the  
disease.  
Why  a  global  genetic  defect,   such  as   that  which   is   seen   in  patients  with  GBA-­PD,  
shows   selective   neuronal   pathology,   including   LB   formation   and   loss   of  
dopaminergic   neurons,   remains   unclear.   Defects   in   autophagy   and   the   UPS   have  
been   implicated   in   neurodegenerative   disease   (Korolchuk   et   al.,   2009),   and   it   has  
been   proposed   that   lysosomal   storage   disorders   could   be   diseases   of   autophagy  
(Settembre  et   al.,   2008).  The   level   of   intracellular  SNCA   is   critical   for   the  onset  of  
neurodegeneration  with  LBs  and  dependent,  to  a  large  extent,  on  degradation  via  the  
lysosomal   autophagy   pathway.   Therefore,   impairment   of   lysosomal   pathways   is  
increasingly  viewed  as  a  major  pathogenic  event  and  unifying  theme  in  PD  (Dehay  et  
al.,   2013).   Depletion   of   GCase   may   result   in   the   toxic   accumulation   of   insoluble  
SNCA  within  lysosomes,  compromise  lysosomal  protein  degradation,  and  promote  a  
bidirectional   feedback   loop   in   which   SNCA   accumulates   and   causes   a   self-­
propagating  disease  (Mazzulli  et  al.,  2011;;  Gegg  et  al.,  2012).  
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Recent   developments   in   this   field   have   put   forward   an   interesting   concept.   The  
suggested  interaction  between  SNCA  and  GCase  and  the  ability  to  manipulate  this,  
using  strategies  to  enhance  GCase  activity  and  in  turn  modulate  SNCA  aggregation,  
could   provide   a   novel   therapeutic   approach   for   the   treatment   of   PD   (Figure   7.2)  
(Schapira   and   Gegg,   2013).   This   could   be   significant   for   those   with   GBA-­PD,  
asymptomatic  GBA  mutation  positive  carriers  at  risk  of  conversion  to  clinical  PD,  or  
even  those  with  sporadic  PD,  where  reductions  in  GCase  have  also  been  noted  and  














1.7  Aims  of  this  PhD  project  
PD   is   the   second   most   common   neurodegenerative   disease   after   Alzheimer’s  
disease  with  a  lifetime  risk  in  the  UK  population  of  5%.  There  is  currently  no  therapy  
to  slow  progression  in  PD.  Apart  from  aging,  the  most  important  risk  factor  known  for  
the  development  of  PD  is  certain  mutations  of  GBA.  This  knowledge  has   led  to  my  
hypothesis  that  GBA  mutations  are  pathogenic  in  PD.    
I  began   to  continue   the  clinical  evaluation  of   individuals  carrying   the  GBA  mutation  
for  prodromal  features  of  PD.  This  unique  cohort  (n=135)  has  proved  of  great  value  
in  identifying  risk  factors  for  individuals  carrying  the  GBA  mutation  prior  to  developing  
PD,  and   is  being  used   to  develop  an  early  biomarker   set   to  predict   individual   pre-­
symptomatic  GBA  mutation  carrier  risk  of  conversion  to  clinical  PD.  This  cohort  and  
these   results   will   be   invaluable   to   the   assessment   of   any   future   therapy   to  
manipulate  mutated  GBA  and  thereby  restore  enzymatic  activity  (GCase)  in  view  of  
delaying   the   development   of   PD.      To   date,   the   pharmacological   chaperones   (PC)  
that  I  have  chosen  to  study  are  considered  the  most  promising  approach.    
My   laboratory   studies   involve   generating   cell   culture   models   from   the   individuals  
within   the  cohort  studied,   in  order   to  delineate   the  molecular  mechanism  of  mutant  
GBA   to   the   pathogenesis   of   PD.      In   addition,   these   cell   models   support   my  
investigation  for  assessing  the  efficacy  of  PC  treatment  in  restoring  GCase  function,  
and   reversing   the   underlying  molecular   events.     My   goal   is   to   generate   solid   data  
from  the  cell  models  to  support  the  use  of  PC  therapy  in  PD.  
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2.1  The  clinical  prodrome  of  Parkinson’s  disease  
PD  is  a  very  common  disorder  with  a  lifetime  risk  in  the  UK  population  of  4%  over  the  
age  of  80.  It  is  the  second  most  common  neurodegenerative  disease  worldwide  after  
Alzheimer’s  disease  and  the  incidence  is  rising  with  an  aging  population  (Pringsheim  
et  al.,  2014).  There  is  currently  no  therapy  to  slow  disease  progression  in  PD,  current  
treatment  is  aimed  at  improving  symptoms,  but  increasing  efforts  are  being  made  to  
trial   neuroprotective   drugs   that   potentially   slow   or   prevent   the   development   of  
symptoms   (Lang   et   al.,   2013).   It   is   thought   that   these   drugs   may   be   more  
advantageous  if  used  early  in  the  disease  process,  before  substantial  neuronal  loss  
has  occurred  (Bar-­Or  et  al.,  2011;;  Lang  et  al.,  2013).    
It   is   now   acknowledged   that   PD   can   have   a   prodromal   period,   during   which  
neurodegeneration   has   begun,   but   disease   is   not   yet   clinically   evident.   Therefore,  
the   PD   neurodegeneration   process   begins   long   before   the   onset   of   the   motor  
involvement   (Savica  et  al.,  2010;;  Schapira  and  Tolosa,  2010).  The   rational   for   this  
prodrome   is   based   on   the   staging   system   of   Braak,   which   suggested   that   the  
pathological  process  may  not  start  in  the  SNpc  (Braak  et  al.).  Examination  of  SNCA  
deposition  patterns  shows  that  the  deposition  of  SNCA  is  not  restricted  to  the  brain,  
with  deposits  found  in  the  olfactory  bulb,  peripheral  nervous  system,  enteric  nervous  
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system  (ENS),  cardiac,  and  pelvic  plexuses,  etc   (Wakabayashi  et  al.,  2010).  Braak  
proposed   that   the   first   stage   of   PD   involves   deposition   in   the   anterior   olfactory  
nucleus  and  dorsal  motor  nucleus  of  the  vagus.  Stage  2  consists  of  pontomedullary  
involvement   (lower   raphe,   reticular   formation,   coeruleus/subcoeruleus   complex),  
Stage   3   affects   the   midbrain   (including   SNpc),   and   at   Stages   4   to   6,   cortical  
structures   are   affected.   Investigators   in   other   groups   have   also   confirmed   these  
findings   (Halliday   et   al.,   2008;;   Zaccai   et   al.,   2008).   However,   there   are   some  
limitations  to  this  model.  The  brains  selected  for  analysis  included  those  with  SNCA  
deposition   in   the   dorsal   motor   vagus,   a   potentially   important   selection   bias.   It   is  
unlikely   that   the   pattern   of   pathology   is   universal;;   the   dorsal  motor   nucleus   of   the  
vagus   is   not   the   obligatory   trigger   site   of   PD   (Kalaitzakis   et   al.,   2008).   There   are  
variable   progression   patterns   and   disease   can   begin   in   the  SNpc.   It   is   also  worth  
noting  that  SNCA  deposition  does  not  necessarily  correlate  with  neurodegeneration;;  
advanced  stages  of  SNCA  deposition  can  be  present  without  clinical  parkinsonism  or  
dementia   (Parkkinen   et   al.,   2008).   The   speed   of   progression   through   the   early  
stages   remains   unclear.   If   the   premotor   interval   is   short,   this   could   limit   the  
effectiveness  of  predictive  markers.  In  spite  of  these  limitations,  the  recognition  that  
initial  pathology  of  PD  may  occur  outside  the  SNpc  suggests  that  screening  for  non-­
motor  manifestations  may  detect  earlier  stages  of  PD.  
The  early  non-­motor  manifestations  of  prodromal  PD  may  precede  the  onset  of  more  
typical  motor  symptoms  by  several  years  (Braak  et  al.,  n.d.).  During  this  period,  other  
neurotransmitter   systems  may  also  degenerate  and  are  associated  with  non-­motor  
symptoms   (NMS)   including   olfactory   and   autonomic   dysfunction,   sleep   disorders,  
mood   changes,   and   cognitive   decline.   This   implies   the   potential   to   predict   PD   by  
detecting   prediagnostic   markers   several   years   before   the   diagnosis.   When   in   the  
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disease  course  each  of  these  non-­motor  symptoms  first  occurs  is  unknown  (Hawkes  
et   al.,   2010).   Insight   into   the   first   clinical   presentations   of   these   prediagnostic  
features  would  help  to  delineate  the  pathophysiology  of  early  PD  progression  and  to  
identify  people  at   increased  risk  of  development  of  overt  PD,  who  would  be  eligible  
for   inclusion   in   clinical   trials   of   neuroprotective   strategies.   The   ultimate   goal   in  
neurodegeneration   is   a   neuroprotective   agent   to   slow   or   stop   the   underlying  
degenerative   process.   If   a   neuroprotective   treatment   becomes   available,   it   will  
become  essential   to   identify  patients  as  early  as  possible.  An  agent  that   is  partially  
effective   in   established   disease   could   slow   or   halt   the   onset   of   clinical   disease   if  
given   in  preclinical  stages.  Therefore,  every  effort   to  design  and  validate  predictive  
markers  should  be  made  to  plan  for  future  neuroprotective  therapy.    
  
2.2  Biomarkers  for  Parkinson’s  disease  
Candidate  biomarkers  have  been  proposed,  and  may  be  useful  objective  measures  
for  the  early  detection  of  PD  (Postuma  et  al.,  2012),(Schapira,  2013).  A  biomarker  is  
defined   as   a   characteristic   that   can   be   objectively  measured   and   evaluated   as   an  
indicator  of  normal  biological  processes,  pathogenetic  processes  or  pharmacologic  
responses   to   a   therapeutic   intervention   (Anon,   2001).   There   are   a   considerable  
number  of  potential  markers  for  prediction  of  PD  including  clinical,  biochemical  and  
imaging  markers.  
Despite   rigorous   research,   patient   management   and   clinical   research   are   still  
hindered   by   suboptimal   methods   for   diagnosis,   refining   prognosis,   predicting  
individual  response  to  therapeutic  interventions,  and  tracking  disease  progression.  A  
51  
  
biomarker  for  PD  may  be  useful  to  aid  in  the  diagnosis  of  PD  or  the  early  prodromal  
premotor   period,   follow   disease   progression,   test   the   efficacy   of   potentially  
neuroprotective   interventions,   and   risk-­stratify   asymptomatic   individuals   in   order   to  
assess   potential   preventive   approaches.   The   application   of   a   single  marker   alone  
may   be   insufficient   to   fulfil   all   of   these   criteria   in   the  majority   of   cases.   However,  
when  used  in  combination,  it  is  reasonable  to  think  that  a  combination  of  biomarkers  
might  achieve  some.  
  
  Clinical  markers  
PD   is   diagnosed  when   typical  motor   features  occur   but   numerous  motor   and  non-­
motor  features  can  occur  before  diagnosis,  early  in  the  disease  process.    
  
Motor  prodrome  
The  diagnosis  of  PD  is  clinical  and  dependent  on  identification  of  the  classical  motor  
symptoms,  which  are  integral  to  the  clinical  diagnostic  criteria  (Hughes  et  al.,  1992).  
This   has   led   several   researchers   to   use   quantitative   motor   tests   to   detect   subtle  
motor   changes.   Potential   tests   include   the   alternate   tap   test,   Purdue   PegBoard,  
precision  grip  and   lift   task,  alternate   finger   tap,  and  Timed  up  and  Go  (Postuma  et  
al.,   2006).   However,   by   the   time   the   classic   motor   problems   of   PD   develop,   it   is  
estimated  that  over  50%  of  dopaminergic  neurons  in  the  SNpc  have  degenerated,  so  
they  are  not  useful  as  an  early  marker  of  disease  (Lees  et  al.,  2009).  Furthermore,  
the  rate  at  which  motor  features  progress  is  variable  in  different  individuals. Another  
potential   limitation  to  quantitative  motor  testing  is  that  up  to  40%  of  elderly  persons  
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Several  non-­motor  symptoms  occur  more   frequently   in  patients  with  PD  before   the  
onset   of   typical   motor   symptoms,   including   hyposmia,   rapid   eye   movement   sleep  
behaviour  disorder  (RBD),  depression,  autonomic  dysfunction  and  constipation.  The  
sensitivity,   specificity,   positive   and   negative   predicted   values   of   these   clinical  
features  have  recently  been  reviewed  (Chahine  and  Stern,  2011).  
  
Olfaction  
Olfactory  abnormalities  are  found  in  those  with  PD  with  mutations  in  GBA  (Saunders-­
Pullman  et  al.,   2010),  but  are  not  a   reported   feature  of  GD  or   its   treatment.   It   has  
been  proposed  that  the  earliest  SNCA  changes  occur  in  the  dorsal  motor  nucleus  of  
the  vagus  and  olfactory  bulb   (Braak  et  al.,  n.d.),  and  evidence  suggests   that  smell  
impairment   is   not   simply   a   consequence   of   aging   but   rather   is   a   prodromal  
phenomenon   that   may   predict   PD   (Hawkes   et   al.,   2010).   Accordingly,   the   large  
majority  of  PD  patients  have  severe  olfactory  loss  at  disease  onset  (Hawkes,  2003).  
Olfactory   loss  may  also  be  an   important   preclinical  marker  of   dementia,   especially  
DLB  (Olichney  et  al.,  2005)  and  Alzheimer's  disease.  A  major  advantage  of  olfactory  
tests  is  that  they  are  inexpensive  and  non-­invasive.  The  commonest  test  includes  the  
University  of  Pennsylvania  Smell  Identification  Test  (Doty  et  al.,  1984).    
One  of  the  drawbacks  of  olfactory  loss  as  a  predictor  of  PD  is  the  interval  between  
detection   of   the   olfactory   abnormality   and   clinical   disease   may   be   short.   In   the  
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Honolulu   study,   olfactory   loss   did   not   predict   PD   when   assessed   >4  years   before  
disease  onset  (Ross  et  al.,  2008).  Olfactory  impairment  can  be  a  sensitive  marker  for  
an   impending   diagnosis   of   PD.   However,   it   is   non-­specific,   because   olfaction   is  
impaired  in  many  disorders.  Of  all  those  in  the  lowest  quartile  of  the  Honolulu  study  
who  had  severe  hyposmia,  only  2%  developed  PD  (Ross  et  al.,  2008).  This  suggests  
that  olfactory  testing  alone  will  be  insufficient  to  indicate  the  need  for  neuroprotective  
therapy.  Finally,   olfactory   loss  may  also   screen   the  preclinical   stages  of   dementia,  
implying  that  olfactory  testing  would  be  a  more  effective  screen  for  a  neuroprotective  
therapy  that  has  a  non-­disease-­specific  action.  
  
Rapid  eye  movement  sleep  behaviour  disorder  
Rapid  eye  movement  sleep  behaviour  disorder   (RBD)   is  characterised  by  a   loss  of  
the  normal  atonia  of  REM  sleep.  Affected  patients  typically  thrash  out  in  association  
with   dream  content   (Gagnon  et   al.,   2006).  RBD  occurs   in   approximately   a   third   of  
patients  with  PD.  Due  to  its  high  specificity  and  long  latency  to  clinical  disease,  RBD  
is   one   of   the   strongest   clinical   predictors   of   neurodegenerative   disease,   and   a  
potential  prodromal  marker  for  preventative  therapy  (Postuma  et  al.,  2012).  It  has  a  
strong   male   predominance.   RBD   is   predominantly   linked   with   brainstem   lesions,  
especially   those   involving   the   pons   (Boeve   et   al.,   2007).   These   pontine   areas  
correspond  most  closely  to  Braak  stage  2.   In  those  with   idiopathic  RBD,  the  risk  of  
developing  a  neurodegenerative  disease  ranges  from  19  to  38%  at  5  years  of  follow-­
up,   and   from   40   to   65%   after   10  years.   Approximately   half   develop   PD,   and   half  
develop  dementia  (most,  if  not  all,  of  these  are  DLB).  This  high  risk  and  long  latency  
to  PD  makes  RBD  an   ideal  biomarker.  RBD  carries  a  high  sensitivity,  and   in   those  
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without   existing   neurological   or   sleep   disorders,   a   high   specificity,   and   therefore,  
represents  a  good  tool  to  detect  subjects  with  RBD  (Stiasny-­Kolster  et  al.,  2007).  
However,  some  caveats  must  be  noted.  Firstly,  the  majority  of  RBD  patients  do  not  
present  to  physicians.  This  presents  a  challenge  to  those  who  want  to  identify  RBD  
patients   for  neuroprotective   therapy.  Second,  RBD  diagnosis   is  not  simple  and   the  
definitive   diagnosis   requires   polysomnography.   Third,   as   recognition   of   RBD  
improves,   it   is   likely   that  milder  cases  will  come  to  medical  attention  and  therefore,  
disease  risk  may  not  be  the  same  in  these  cases.    
Despite   these   limitations,   RBD   has   considerable   potential   as   a   predictive  marker.  
The   high   conversion   rate   to   disease   implies   a   marker   with   immediate   clinical  
application.  If  a  safe  and  effective  neuroprotective  agent  were  developed  tomorrow,  
RBD  patients  may  have   to   consider   taking   it.  Also,   patients  with  RBD  may  be   the  
ideal  candidates  for  clinical  trials  of  neuroprotective  agents,  since  their  earlier  stage  
of  neurodegeneration  provides  an  additional  window  of  opportunity.    
  
Autonomic  dysfunction     
The  incidence  of  autonomic  dysfunction  is  higher  in  people  who  go  on  to  develop  PD  
compared   with   controls   (Schrag   et   al.,   2014).   In   particular,   constipation   is   more  
common  in  patients  than  in  controls  10  years  before  diagnosis  (Schrag  et  al.,  2014).  
According   to   Braak’s   staging,   peripheral  PD  pathology,   including   SNCA  
neuropathology  in  the  enteric  nervous  system,  might  precede  the  classic  changes  in  
the  midbrain  and  limbic  areas.  Moreover,  the  recent  detection  of  SNCA  pathology  in  
colon   biopsies   obtained   from   individuals  without   parkinsonian   symptoms  who   later  
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developed   PD   is   promising   (Lebouvier   et   al.,   2010).   In   the   Honolulu–Asia   Aging  
Study,   less   than   one   bowel   movement   per   day   was   associated   with   a  more   than  
three   times   increased   risk   of  PD   (Ross   et   al.,   2012).   However,   this   symptom   is  
common   in   the   general   population   and   therefore,   its   specificity   in   identifying  
preclinical  PD   is   low.  Other  autonomic   features  with  which   individuals  present  with  
are   dizziness,   urinary   dysfunction,   hypotension,   and   erectile   dysfunction   (in  men),  
which   are   also   pre-­diagnostic   features   of   PD   (Schrag   et   al.,   2014).   Erectile  
dysfunction   has   also   been   associated  with   a   diagnosis   of  PD  more   than   10   years  
later   (Gao   et   al.,   2007).   However,   erectile   dysfunction  is   under-­reported  and/or  
patients  do  not  complain  about  this  symptom  in  the  face  of  other,  more  troublesome  
symptoms.    
  
Assessment   of   the   autonomic   nervous   system   using  MIBG,   which   is   taken   up   by  
postganglionic   adrenergic   neurons   like   norepinephrine,   demonstrates   a   significant  
reduction   of  MIBG   uptake   in   cardiac   sympathetic   efferents   irrespective   of   disease  
severity,  disease  duration,  treatment,  and  pre-­existing  dysautonomic  signs  (Mitsui  et  
al.,   2006).   Other   studies   indicate   that   a   large   majority   of   PD   patients   have  
abnormalities   on   MIBG   scintigraphy,   even   early   in   disease.   However,   it   remains  
unclear  if  MIBG  scintigraphy  can  identify  prodromal  PD.  
  
In  summary,  the  evidence  that  autonomic  dysfunction  predicts  disease  is  less  strong  
than   it   is   for   olfaction.   Symptoms   and   signs   of   autonomic   dysfunction   are   not  
universally  present  early   in  disease  and   frequently  progress,  which  may   indicate  a  
lower   sensitivity.   As   a   further   limitation,   specificity   of   autonomic   dysfunction   is  
probably   low,   as   other  medical   conditions   (e.g.   diabetes,   drug   treatment)   can   also  
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lead  to  autonomic  dysfunction.  Finally,  a  marker  such  as  MIBG  scintigraphy,  which  is  
potentially  more  specific,  is  time-­consuming  and  expensive.  
  
Cognitive  impairment  
Mild   cognitive   impairment   (MCI)   can   occur   as   a   prodrome   to   parkinsonism  
(Dalrymple-­Alford  et  al.,  2010)  or  DLB  (Williams  et  al.,  2009).  MCI  in  PD  indicates  a  
shorter   time  to  dementia  and  represents  a  poor  prognostic  marker  (Aarsland  et  al.,  
2009).   Whether   cognitive   impairment   without   dementia   is   a   possible   target   for  
treatment   is   still   an   unresolved   question.   In   PD   patients   without   dementia,   clinical  
trials   might   explore   two   concepts:   (i)   whether   drugs   modifying   impaired   cognition  
produce  an  improvement  in  either  practical  function  or  quality  of   life  of  PD  patients;;  
(ii)  if  disease  modifying  agents  may  prevent  the  progression  from  MCI  to  dementia.  
  
Depression  
Depression  can  precede  the  onset  of  the  motor  symptoms  of  PD  and  is  a  presenting  
complaint  in  12-­22%  of  patients  (O’Sullivan  et  al.,  2008).  Depression  in  PD  has  been  
explained   by   multiple   neurotransmitter   dysfunctions,   including   dopamine   (SNpc),  
serotonin  (raphe  nuclei),  and  noradrenaline  (locus  coeruleus).  At  Braak  stage  2,  the  
involvement  of  both  raphe  nuclei  and  locus  coeruleus  might  indicate  depression  as  a  
prodromal  symptom  of  PD.  Additionally,  personality  changes  are  associated  with  PD  
(Arabia  et  al.,  2010),  although  whether  these  represent  a  lifelong  personality  trait  or  a  
marker   of   preclinical   PD   is   unclear.   The   eventual   use   of   depression   as   a   disease  
predictor  will   likely  be   limited  by   low  specificity   since   the   large  majority   of   persons  
with  depression  will  never  develop  PD.  
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  Biochemical  markers  
Biochemical   markers   have   been   developed   based   on   the   understanding   of   the  
pathogenesis   of   disease.   There   are   several   pathogenetic   pathways   which   are  
considered   relevant   including   mitochondrial   dysfunction,   oxidative   stress,  
inflammation  and  protein  accumulation,  aggregation  and  propagation  (Obeso  et  al.,  
2010;;   Schapira,   2012).   Advances   in   the   genetics   of   PD   have   also   aided   the  
identification  of  potential  markers,  for  example  the  use  of  SNCA  or  DJ-­1.    
  
Alpha  synuclein  
The  rationale  for  SNCA  as  a  biomarker  of  PD  stems  from  the  key  role  of  this  protein  
in   the   pathogenesis   of   PD.   SNCA   is   the   main   protein   contained   in   the   defining  
neuropathological   lesions   (LBs)   of   PD.   Initially   thought   to   be   a   strictly   intracellular  
protein,   SNCA   has   also   been   detected   in   plasma,   saliva   and   cerebrospinal   fluid  
(CSF).  Efforts   to   study  CSF  SNCA  have   showed  some  promise  with   reductions   in  
SNCA  noted  in  the  CSF  of  PD  and  other  parkinsonian  syndromes  (Devic  et  al.,  2011;;  
Mollenhauer   et   al.,   2011).   Lower   levels   of   SNCA   in   PD   may   reflect   increased  
clearance,   or   alterations   in   transcription,   splicing   and   processing.   Recent   studies  
suggest   that  data  should  be  expressed  as   the   ratio  of  oligomeric   to   total  SNCA.   In  
one   study,   this   ratio   demonstrated   89.3%   sensitivity   and   90.6%   specificity   for   the  
diagnosis   of   PD   (Tokuda   et   al.,   2010).   Two   additional   studies   have   supported   the  
application  of  a  oligomer:total  SNCA  ratio  (Park  et  al.,  2011;;  Sierks  et  al.,  2011).  The  
relationship  between  SNCA  levels  and  the  stage  of  disease  and/or  its  evolution  over  
time  is  unknown.    
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A  blood  based  SNCA  biomarker  has  not  fared  as  well.  There  have  been  attempts  to  
measure  oligomeric  species  of  SNCA  (El-­Agnaf  et  al.,  2006),  total  SNCA  (Tinsley  et  
al.,   2010),   and   phosphorylated   SNCA   (Foulds   et   al.,   2011)   in   plasma.   In   a   study  
comparing  oligomeric  SNCA   levels   in  34  PD  patients  with  age-­matched  controls,  a  
high   signal   occurred   in   approximately   3.5   times   more   PD   patients   compared   to  
controls  (El-­Agnaf  et  al.,  2006).  Another  study  by  the  same  group  comparing  levels  
of   different   forms   of   SNCA   in   32   PD   patients   and   30   controls   was   not   able   to  
reproduce   this   (Foulds   et   al.,   2011).   Various   technical   difficulties   such   as   high  
abundance  of  SNCA  within  red  blood  cells  as  well  as  confounding  variables,  such  as  
other  comorbidities,  could  account   for   this.  Subsequent  studies  have   reported  both  
increases  (Lee  et  al.,  2006)  and  decreases  (Li  et  al.,  2007)   in  plasma  SNCA  in  PD  
patients  compared  to  controls.  
DJ-­1  
DJ-­1  emerged  as  a  candidate  biomarker  in  PD  after  mutations  in  the  gene  encoding  
this  protein  were  identified  in  familial  PD  (Bonifati  et  al.,  2003).  The  function  of  DJ-­1  
is  still  unknown;;  however,   it   is  associated  with  various  cellular  processes,   including  
response  to  oxidative  stress,  and  signalling  with  mitochondria.  The  CSF  and  plasma  
levels  of  DJ-­1  have  been  found  to  be  unaffected,  elevated  or  reduced  compared  with  
controls  (Hong  et  al.,  2010;;  Shi  et  al.,  2011).    
  
Others  
Other   potential   protein   markers   investigated   in   PD   include   urate,   β-­amyloid,   tau,  
neurofilaments,   interleukins,   osteopontin   and   hypocretin.   However,   results   have  
been  negative  or  inconclusive.    
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The   association   between   PD   and   uric   acid   levels   has   gained   interest   in   recent  
years.  Studies  have  shown  that   lower   levels  of  the  antioxidant  urate  are  associated  
with  an  increased  risk  of  PD  (Cipriani  et  al.,  2010;;  Chen  et  al.,  2012),  and  the  levels  
are  lower  in  patients  with  PD  (Schwarzschild  et  al.,  2011).  However,  patients  with  PD  
and   their   drug   treatment   as   well   as   lifestyle   factors   such   as   dietary   habits   and  
physical  exercise,  might  influence  the  metabolism  of  uric  acid.  
Levels   of   CSF   β-­amyloid   (1–42)   and   tau   have   been   used   as   a   marker   of  
neurodegenerative   disease,   in   particular   dementia,   but   also   to   predict   cognitive  
decline  in  PD.  In  PD,  tau  levels  are  unchanged  and  there  is  only  a  small  decrease  in  
β-­amyloid  (Přikrylová  Vranová  et  al.,  2012).    
Low  levels  of  plasma  ApoA1  have  also  been  proposed  as  a  significant  risk  factor  for  
PD,   and   the   concentrations   also   correlate   with   putaminal   loss   on   Dopamine  
Transporter   (DaT)   scans   (Qiang   et   al.,   2013).   Lower  ApoA1   levels   are   associated  
with  more  severe  DaT  deficit,  even  after  adjusting   for  age  and  gender.   In  addition,  
ApoA1  levels  are  modifiable  with  statin  medications,  which  increase  HDL,  and  statins  
are  associated  with  a  reduced  risk  for  PD  (Gao,  2012).    
  
  Imaging  markers  
Single-­photon  emission  tomography  (SPECT),  positron  emission  tomography  (PET),  
magnetic   resonance   imaging   (MRI)   or   transcranial   sonography   (TCS)   can   provide  
useful   information   on   the   loss   of   nigrostriatal   dopamine   neurons   as   well   as  
information   about   the   time   frame   of   neuron   loss.   They   represent   a   non-­invasive  
approach  and  scans  may  be  abnormal  before  motor  signs  appear  and  can  progress  
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as   neurodegeneration   continues.   However,   with   the   exception   of   TCS,   they   are  
expensive   and   do   not   always   correlate   with   the   clinical   findings,   especially   in   the  
early  stages  of   the  disease  (Vogt  et  al.,  2011),   limiting   their  usefulness   in  standard  
diagnostic   situations.   Furthermore,   these   imaging   modalities   do   not   make   the  
distinction  between  different  parkinsonian  syndromes,  and   they  can  be  affected  by  
dopaminergic  medication.   For   instance,   L-­dopa   causes   a   decline   in   both  PET  and  
SPECT.   Thus,   they   are   limited   as   a   biomarker,   but   are   a   useful   diagnostic   tool   in  
certain  situations. 
  
In  idiopathic  PD,  TCS  detects  SN  hyper-­echogenicity  in  90%  of  patients,  which  likely  
reflects  increases  in  local   iron  content  and  microglial  activation.  However,  there  are  
concerns  regarding  the  specificity  and  sensitivity  of  this  technique  in  PD.  TCS  is  very  
dependent   on   operator   skill,   and   requires   an   adequate   temporal   acoustic   bone  
window   for  good   imaging.  SN  echogenicity   is  a   finding   that  may  also  change  over  
time   in   a   normal   individual   (Hagenah   et   al.,   2010).   Furthermore,   there   is   no  
relationship  of  the  TCS  abnormalities  to  PD  stage  or  progression.    
  
Evolving   neuroimaging   techniques   that   visualise   nigrostriatal   structural   changes  
might   prove   helpful   to   improve   diagnostic   accuracy.   MRI   with   diffusion   weighted  
imaging   could   help   to   distinguish   patients   with   progressive   supranuclear   palsy   or  
multiple  system  atrophy  from  those  with  PD.    Findings  from  these  techniques  include  
changes  in  diffusivity  or  fractional  anisotropy  in  the  SN  and  the  striatum  on  diffusion-­
tensor  MRI  (Scherfler  et  al.,  2006)  and  changes  in  the  SN  morphology  on  high-­field  
MRI  (Cho  et  al.,  2011;;  Kwon  et  al.,  2012).  Reductions  seen  in  fractional  anisotropy  in  
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the   SN   correlate   with   motor   severity   and   therefore,   may   correlate   with   disease  
progression.  
  
  Pathological  markers  
Post-­mortem   studies   of   those   with   incidental   LB   pathology   suggest   that   SNCA  
pathology  may  begin  in  the  tissues  of  the  gastrointestinal  (GI)  tract,  salivary  glands,  
and   olfactory   system   (Braak   et   al.,   2006;;   Beach   et   al.,   2010).   Recent   data  
demonstrates  the  presence  of  SNCA  and  LBs  in  the  gut  of  patients  with  PD  in  colon  
biopsies  2-­5  years  before  PD  onset  (Shannon  et  al.,  2012).  This  suggests  that  colon  
biopsies   could   serve   as   a   biomarker   for   premotor   PD   and/or   as   a  marker   for   the  




Although,   there   is   considerable  promise   for   predictive  markers  of  PD,   It   is   unlikely  
that  one  single  measure  will  be  able  to  predict   the  disease  with  good  reliability  and  
sensitivity.  It  is  much  more  likely  that  a  combination  of  markers  will  be  required  and  
this   may   include   clinical,   biochemical   and   imaging   markers   to   define   at-­risk  
individuals.  When   planning   for   the   eventual   use   of   these  markers,   it  may   become  
necessary   to   design   a   simple   non-­invasive   screen   which   could   be   applied   to   the  
general   population,   followed   by   more   specific   confirmatory   tests   for   those   who  
screen  positive.  The  key  feature  of  any  biomarker   is  not   just   to  diagnose  PD  early,  
but  to  further  reflect  the  pathogenesis  and  progression  of  the  disease  against  which  
a  disease-­modifying  strategy  could  be  judged.  
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2.3  A  unique  cohort  of  at-­risk  individuals  
In  an  age  of  neuroprotection,  it  is  important  to  identify  those  at  high  disease  risk  for  
developing  PD  who  will  be  motivated  to  undergo  even  relatively  invasive  procedures  
to   determine   the  need   for   therapy.  However,   high-­risk   populations  are   not   easy   to  
find.  Defined  causative  gene  mutations  are   identifiable   in  some  patients,  and  these  
gene   carriers   are   ideal   candidates   for   studies   of   predictive   markers.   Many  
environmental   risk   factors   (e.g.   pesticide   use,   non-­smoking)   can   also   increase   the  
risk  of  PD.    
If   there   are   no  methods   to   reliably   identify   persons   at   substantial   risk   of   disease,  
screening   may   need   to   be   population-­wide.   This   adds   considerable   additional  
challenges.   In   addition   to   being   sensitive   and   specific,   screens  must   now   also   be  
non-­invasive  and   inexpensive.   Invasive  or  expensive   tests  may  eventually  be  used  
predominantly  as  secondary  confirmation  of  a  positive  screen  or  primary  screens  for  
the  few  who  are  definable  as  high-­risk.  
To  investigate  potential  early  markers  of  PD,  I  studied  asymptomatic  individuals  from  
the  Royal  Free  London  and  Addenbrooke’s  Hospital  Cambridge  who  had  mutations  
in  the  GBA  gene.  These  mutations  increase  the  risk  of  developing  PD  by  20-­30  times  
and   are   present   in   around   one   in   ten   PD   patients.   A   range   of   baseline   clinical  
assessments   were   carried   out   on   the   participants,   including   motor   function   and  
cognition,   and   a   number   of   subtle   abnormalities  were   identified   in   the   participants  
that   were   significant   in   comparison   to   matched   controls.   This   supported   the  
hypothesis   that   a   proportion   of   the   individuals   would   develop   PD   based   on   the  
knowledge   that   the   presence   of   the  GBA  mutation   is   a   significant   risk   factor.   Two  
years   later   I   repeated   the   assessments   and   for   a   proportion   of   them   the  
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abnormalities   present   at   baseline   had   progressed   and   1   individual   has   developed  
PD.    
I   am   now   attempting   to   distinguish   a   pattern   of   abnormalities   that   determine   in  
individuals  with  a  GBA  mutation  whether  they  are  at  a  greater  risk  of  developing  PD  
before   deterioration   in   function   indicates   the   start   of   disease.   The   idea   is   that   by  
following  the  evolution  of  individuals  with  GBA  mutations,  it  will  be  possible  to  see  if  
they  exhibit  abnormalities  that  might  be  detected  in  the  general  PD  population.  The  
hope  is  that  should  a  therapy  become  available  that  can  slow  the  disease  down,  then  
this  would  be  targeted  at   those  individuals   in  particular.  What  my  results  support   in  
principle   is   that   it   may   be   feasible   to   tell   individuals   that   they   are   at   low   risk   of  
developing   PD,   which   is   a   great   benefit   to   them,   or,   alternatively,   at   higher   risk,  
which  could  mean  in  the  future  we  are  able  to  offer  them  treatments  that  will  slow  the  










2.4    Assessing   prodromal   clinical   markers   of   Parkinson’s   disease  
in  a  glucocerebrosidase  mutation  positive  cohort  
  
I  began  my  PhD  by  re-­examining  a  GBA  mutation  positive  cohort  at  high  risk  for  the  
development   of   PD.   The   aim   was   to   identify   biomarkers   or   symptoms   indicating  
progression   to   early   PD.   The   first   clinical   evaluation   of   this   cohort   has   been  
published  previously  (McNeill  et  al.,  2012b)  and  the  results  presented  here  represent  
the  two  year  follow  up.    
This  cohort  of  GBA-­positive  individuals  has  been  established  in  collaboration  with  the  
Lysosomal  Storage  Disease  Units  at   the  Royal  Free  and  Addenbrooke’s  Hospitals.  
Initial  examinations  were  performed  in  2010  and  prodromal  features  were   identified  
(McNeill   et   al.,   2012b).   Assessments   included   tests   for   motor   function,   olfaction,  
cognition,  sleep,  and  depression.  
My  results  have  identified  individuals  who  are  exhibiting  signs  of  an  evolving  clinical  
prodrome  of  PD  (but  do  not  yet  have  PD).  The  aim  is  to  provide  a  clinical  road  map  
of   the  pre-­motor,  pre-­diagnostic  prodrome  of  PD   to  enable  biomarker  development  
and  early  diagnostic  markers  in  this  population.  
  
OBJECTIVE                                                                                                           
To  continue  the  clinical  evaluation  of  GBA  mutation  positive  individuals  for  prodromal  
features   of   PD.   Clinical   assessment   will   include   tests   for   non-­motor   symptoms,  
including   olfactory   and   autonomic   dysfunction,   sleep   behaviour   disorder,   mood  
changes  and  cognitive  impairment.  
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  Introduction                                                       
Homozygous  GBA  mutations  cause  GD,  a  lysosomal  storage  disorder.  It  is  presently  
estimated  that  homozygous  or  heterozygous  GBA  mutations  confer  an  increased  risk  
for  PD  of  20-­30  fold  (Bultron  et  al.,  2010;;  McNeill  et  al.,  2012a)  and  at  least  7%  of  PD  
patients  have  GBA  mutations   (McNeill   et  al.,   2012a),(Sidransky  et  al.,   2009a),  and  
this   is   higher   in   the   Ashkenazi   Jewish   population   (Zimran   et   al.,   1991).   The  
penetrance  of  GBA  mutation  carriers  to  develop  PD  has  been  estimated  as  13·7%  at  
age  60  years  and  29·7%  at  age  80  years  (Anheim  et  al.,  2012),  and  so  a  method  to  
determine  individual  risk  for  PD  expression  in  this  population  would  be  very  valuable.  
In  addition,   those  with  dementia  with  Lewy  bodies  (DLB)  are  8   times  more   likely   to  
carry  a  mutation  in  GBA  than  healthy  controls,  suggesting  a  role  for  GBA  mutations  
in  other  Lewy  body  disorders  (Nalls  et  al.,  2013).    
For  any  neuroprotective  treatment  or  disease  modifying  therapy  to  be  most  effective,  
PD   should   be   detected   at   as   early   a   stage   as   possible.   The   recognition   that   the  
pathological   process   may   start   outside   of   the   substantia   nigra   (Braak   et   al.,   n.d.)  
explains  why  non-­motor  symptoms  (NMS)  manifest  before  motor  problems  emerge,  
and   can   therefore   precede   the   diagnosis   of   PD.   Moreover,   NMS   occur   more  
frequently   in  GBA-­PD   (McNeill  et  al.,  2012a).  Therefore,   further  screening   for  non-­
motor   manifestations   is   needed   in  GBA  mutation-­positive   individuals   prior   to  
conversion   to   PD,   to   develop   an   early   biomarker   set   to   predict   individual   pre-­
symptomatic  risk  of  conversion  to  clinical  PD.  In  this  study,  I  have  used  early  clinical  
markers   to   quantify   non-­motor   symptoms   such   as   hyposmia,   rapid   eye  movement  
sleep  behaviour  disorder  (RBD),  depression,  cognition,  and  autonomic  dysfunction.  
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The  aim  of   this  study  was   to  provide   longitudinal  data  on  a  GBA  mutation  positive  
cohort   at   high   risk   for   the   development   of   PD,   and   to   identify   biomarkers   or  
symptoms  indicating  progression  to  early  PD.    
  
  Method                                      
Participants    
Type  1  GD  patients  were  recruited  from  the  Lysosomal  Storage  Disorder  Unit  at  the  
Royal   Free   London   NHS   Foundation   Trust   in   2010.   Potential   heterozygous  GBA  
mutation   positive   carrier   relatives   (parents:   78·6%;;   siblings:   10·7%;;   children   >21  
years:  10·7%)  and  genetically  unrelated  controls   (spouses/partners)  were   identified  
by  taking  a  detailed  family  history  from  each  GD  patient,  and  recruited  with  consent.  
Individuals  were  also  recruited  from  the  UK  Gaucher  Disease  Association.  In  all,  this  
unique  cohort  included  one  hundred  and  thirty-­five  participants.  Among  them,  ninety  
participants  have  been   followed   longitudinally  with   target   follow-­up  assessments  at  
two   year   intervals   beginning   in   2012.   For   both  GD   and   carrier   subjects,   exclusion  
criteria   included   a   diagnosis   of   PD   or   dementia   and   for   controls,   any   existing  
neurological   disease.   The   diagnosis   of   PD   was   made   according   to   the   UK  
Parkinson’s   Disease   Society   Brain   Bank   Criteria   (Hughes   et   al.,   1992).   Dementia  
was   diagnosed   according   to   DSM-­IV   criteria   in   patients   with   a   Mini-­Mental   State  
Examination  score  of  ≤24.  The  GBA  mutation  status  in  all  participants  was  confirmed  
by   Sanger   sequencing   of   the  GBA   gene,   as   previously   described   (McNeill   et   al.,  
2012b).  The  senior  researcher  was  blinded  to  genotype.  The  study  was  approved  by  
the   Hampstead   Research   Ethics   Committee   (reference   number   10/H0720/21).   All  





Of   ninety   individuals   who   were   evaluated   at   baseline   (2010-­2011)   (McNeill   et   al.,  
2012b),  four  participants  (4·4%)  were  lost  to  follow-­up  because  they  either  declined  
to  participate  (n= 2)  or  were  uncontactable  (n= 2).  In  addition,  two  deaths  (2·2%)  had  
occurred:   one   caused   by   pneumonia,   and   one   by   breast   carcinoma.   Therefore,  
eighty-­four   (93·3%)   participants   (thirty   previously   diagnosed   Type   1   GD   patients,  
twenty-­eight   heterozygous   GBA   mutation   carriers,   and   twenty-­six   controls)  
completed   the   follow-­up  evaluation   that   comprised:  a   structured  clinical  work-­up,  a  
standardised  clinical  history,  complete  neurological  assessment  including  the  Unified  
Parkinson's   Disease   Rating   Scale   activities   of   daily   living   and   motor   subscale  
(UPDRS   parts   II   and   III),   olfactory   function   using   the   University   of   Pennsylvania  
Smell   Identification   Test   (UPSIT),   cognitive   function   using   the   Mini-­Mental   State  
Examination   (MMSE)   and   Montreal   Cognitive   assessment   (MoCA),   RBD   with   the  
RBD   Questionnaire   (RBDQ),   depression   using   the   Beck’s   Depression   Inventory  
(BDI),   and   autonomic   dysfunction   using   a   subscale   of   the  Unified  Multiple  System  
Atrophy   Rating   Scale   (UMSARS).   Anosmia   was   interpreted   using   age-­   and   sex-­
adjusted   normative   scores   (www.sensonics.com).   All   participants   were   examined  
independently   by   a   movement   disorders-­trained   physician   (M.B.).   All   procedures  
were  performed  and  scored  identically  at  follow-­up  to  those  carried  out  at  baseline.  A  
senior   neurologist   expert   on   movement   disorders   (A.H.V.S.)   evaluated   individuals  
where   there   was   a   significant   difference   between   UPDRS   scores   measured   at  





The   data   was   analysed   using   IBM   SPSS   Statistics   (version   21).   To   assess   the  
differences   between   the   group   means   across   the   two   different   time   points,   I  
performed   a   two-­way   ANCOVA   with   factors   Group   (e.g.   Gaucher   vs.   Carrier   vs.  
Control)  and  Time  (Time  1  vs.  Time  2).  The  covariates  age,  gender,  education,  and  
family   relationship   were   added   to   the   design   matrix,   in   order   to   account   for  
differences   in   these  between  the  groups.  Post-­hoc  tests  were  used  to  compare  the  
groups   at   follow-­up.   Paired   t-­tests   were   used   to   compare   the   scores   within   each  
group   before   and   after   follow   up.     Differences   in   age,   sex,   and   ethnicity   between  
groups  were  checked  using   the  One-­way  ANOVA  and   the  Chi-­squared   test.   I   also  
accounted   for   performing   multiple   statistical   tests   across   dependent   variables  
(UPSIT,  UMSARS,  RBDQ,  MMSE,  MoCA,  UPDRS  II,  UPDRS  III,  BDI)  by  defining  a  
significance  threshold  for  statistical   tests  of  P  <  ·05,  and  correcting  this   for  multiple  
comparisons   using   the   Benjamini-­Hochberg   FDR   (False   Discovery   Rate).   In   brief,  




The   eighty-­four   participants   (40   men   [47·6%])   had   a   mean   follow-­up   duration   of  
1·9 ± 0·2   years   (range,   1·5-­2·3   years).   The   demographic,   clinical   and   genetic  
characteristics,  with   statistical   comparisons,   of   the   cohort   are   shown   in  Table   2.1.  
Participants   with   Type   1   GD   did   not   differ   significantly   from   heterozygous   GBA  
positive  carriers  or  controls  in  terms  of  age,  sex,  and  ethnicity  (One-­way  ANOVA  and  
Chi-­squared   test,   in  all  P  >   ·05).  Both  Type  1  GD  patients  and  heterozygous  GBA  
mutation  carriers  were  significantly  more   likely   to  have  a   family  history  of  PD   than  
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controls  (P  =  ·03).  As  described  previously  (McNeill  et  al.,  2012b),  the  most  common  
genotype   in   GD   patients   was   N370S/L444P   (11/30;;   36·7%).   No   GD   patients   had  
features  of  Type  III  disease  such  as  generalized  seizures  or  progressive  myoclonic  
epilepsy.  In  carriers,  the  most  common  genotype  was  N370S  (14/28;;  50%).    
  
  
Table   2.1.   Demographic,   clinical   and   genetic   characteristics   of   the   study  
cohort  









Age,  years     61·0  (2·1)   63·6  (2·0)   61·7  
(2·2)  
·19a  
Gender  (F/M)   16/14   16/12   12/14   ·29b  
Ethnicity  (Ashkenazi/White  
British)  
10/20   5/23   6/20   ·38b  
Family  history  of  PD,  (%)   16·7   7·1   0·0   ·03bc  
Most  frequent  genotype   N370S/L444P   N370S   -­   -­  
GD  treatment  
(ERT/SRT/none)  
25/2/3   -­   -­   -­  
Results  are  presented  as  mean  and  SEM.  Significance  was  taken  at  the  5%  level.  
Abbreviations:  ERT  Enzyme  Replacement  Therapy.  SRT  Substrate  Reduction  Therapy.  
a      One-­way  ANOVA.      
b    Chi-­squared  test.  







GBA   mutation   positive   individuals   show   significant   deterioration   in   clinical  
markers  
The   results   of   prodromal   clinical   features   of   PD   at   baseline   and   follow-­up   are  
reported  in  Table  2.2  (see  also  Figure  7.3  and  Figure  7.4).  Please  refer  to  Table  2.2  
for  the  exact  P  values.  There  was  a  significant  deterioration  in  RBDQ,  UPDRS  II  and  
III   scores   for   GD   patients   over   the   mean   two   years   of   follow-­up.   Over   the   same  
period,   the   GBA   mutation   carriers   showed   a   significant   deterioration   in   RBDQ,  
UPDRS  II  and  III,  and  BDI  scores.  There  was  a  marginal  but  significant  deterioration  
only   in   the   UPDRS   II   score   in   the   matched   controls.      There   was   no   difference  
between  baseline  and   follow-­up  scores   for  all  groups   for  assessments  of  olfaction,  
cognition  and  autonomic  dysfunction.    
At   2   years   follow-­up,  GD  patients   showed  a   significant   difference   in  mean  UPSIT,  
MMSE,  MoCA,  UPDRS  II  and  III  scores  when  compared  to  controls.  Similarly,  at  2  
years,   GBA   mutation   carriers   showed   a   significant   difference   in   mean   follow-­up  
UPSIT,   MMSE,   and   MoCA   scores   when   compared   to   controls.   When   the   GD  
patients   and   GBA   mutation   carriers   were   compared   at   baseline,   there   was   a  
significant   difference   in   the   mean   BDI   score.   At   2   years   follow-­up,   GD   patients  
demonstrated  significantly  worse  mean  BDI,  UPDRS   II  and   III   scores  compared   to  
carriers.   There   was   no   significant   difference   between   mean   UPSIT,   UMSARS,  






Table   2.2.   Baseline   and   follow-­up   clinical   markers   in   a   group   comparison  








Type  1  GD  




































































































0·63  (0·16)   0·53  (0·16)   0·13  (0·07)  
  
  











































































































































































































































































































Abbreviations:   UPSIT   Smell   Identification   Test,   UMSARS   Unified   Multiple   System   Atrophy   Rating  
Scale,  MoCA  Montreal  Cognitive   assessment,  MMSE  Mini-­Mental  State  Examination,  RBDQ  Rapid  
Eye  Movement  Sleep  Behaviour  Disorder  Questionnaire,  UPDRS  Unified  Parkinson's  Disease  Rating  
Scale,  BDI  Becks  Depression  Inventory.      
Results  are  presented  as  mean  and  SEM.  Significance  was   taken  at   the  5%   level   for  all   variables.  
Only  values  which  survived  multiple  comparisons  with  the  FDR  procedure  were  denoted  significant.    
  
Reported  P  values  compare  the  mean  values  for  clinical  markers  within  groups  (baseline  and  follow-­
up)  and  between  groups  (Type  1  GD,  carriers  and  controls)  at  follow-­up.  
  
1  Controls  versus  Type  1  GD  patients.  
2    Controls  versus  heterozygote  GBA  mutation  carriers.  
3    Type  1  GD  patients  versus  heterozygote  GBA  mutation  carriers.  
a  Paired  t-­test.    
b  Two-­way  ANCOVA  with  Bonferroni  correction.    




When   the   results   from   individuals   with   homozygous   or   heterozygous  mutations   in  
GBA  were  combined   in  a  secondary,  pooled  analysis   (see  Table  2.3),   there  was  a  
significant   deterioration   in   mean   RBDQ,   BDI,   UPDRS   II   and   III   scores   in   GBA  
mutation   positive   individuals   over   the   two   years   of   follow-­up.   At   baseline,   GBA  
mutation   positive   individuals   showed   significant   differences   in   mean   UPSIT   and  
MoCA  scores  when  compared  to  controls  (McNeill  et  al.,  2012b).  At  2  years  follow-­
up,  GBA  mutation  positive  individuals  showed  significant  differences  in  mean  UPSIT,  














Table   2.3.   Baseline   and   follow-­up   clinical   markers   in   a   pooled   analysis  









Type  1  GD  patients  and  
Heterozygous  GBA  mutation  































































































































































































































   0·58  (0·19)  
  










































































Abbreviations:   UPSIT   Smell   Identification   Test,   UMSARS   Unified   Multiple   System   Atrophy   Rating  
Scale,  MoCA  Montreal  Cognitive   assessment,  MMSE  Mini-­Mental  State  Examination,  RBDQ  Rapid  
Eye  Movement  Sleep  Behaviour  Disorder  Questionnaire,  UPDRS  Unified  Parkinson's  Disease  Rating  
Scale,  BDI  Becks  Depression  Inventory.      
Results  are  presented  as  mean  and  SEM.  Significance  was  taken  at  the  5%  level  for  all  variables.      
Only  values  which  survived  multiple  comparisons  with  the  FDR  procedure  were  denoted  significant.  
  
Reported  P  values  compare  the  mean  values  for  clinical  markers  within  groups  (baseline  and  follow-­
up)  and  between  groups  (Controls  and  GBA  mutation  positive  individuals)  at  follow-­up.  
  
1  Controls  versus  GBA  mutation  positive  individuals.  
a  Paired  t-­  test.    
b    Two-­way  ANCOVA  with  Bonferroni  correction.  
c  Statistically significant difference.  
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Specific  GD  patients  and  GBA  heterozygotes  show  parkinsonian  motor  signs  
and  significant  deterioration  across  more  than  one  clinical  marker     
     
At   baseline,   three  GD  patients   had  parkinsonian  motor   signs,   but   insufficient   for   a  
diagnosis  of  PD.     As  described  previously   (McNeill  et  al.,  2012b),  GD05   (male,  78 
years   old,   Ashkenazi   Jewish)   had   bilateral   rigidity   with   activation   manoeuvre,  
asymmetric  bradykinesia  of  all  limbs,  and  gait  impairment.  GD18  (male,  83 years  old,  
Ashkenazi  Jewish)  had   left  arm  rest   tremor  and  bilateral  arm  rigidity  with  activation  
manoeuvre.  GD27   (male,   69 years   old,  White   British)   had   flexed   posture,   bilateral  
rigidity,   and   postural   and   kinetic   tremor   of   the   upper   limbs.      At   follow-­up,   the  
parkinsonian  signs  present  at  baseline  in  these  study  subjects  had  worsened  but  did  
not  meet   the  diagnostic  criteria   for  PD   (Lees  et  al.,  2009).  GD05  had  developed  a  
tremor   in   both   hands   (intermittent,   present   at   rest   and   worse   on   intention).   GD18  
now  had  bilateral   rigidity  without   activation  manoeuvre   and  gait   impairment.  GD27  
had  developed  a  head  tremor  and  the  postural  and  kinetic  tremor  of  the  upper  limbs  
had   worsened   (now   present   at   rest).   In   addition,   one   subject   that   did   not   have  
parkinsonian   signs   at   baseline   had   developed   them   at   follow-­up.   GD11   (male,   73 
years  old,  Ashkenazi  Jewish)  had  developed  a  very  slight  tremor  of  his  right  thumb  
(non  pill  rolling)  present  at  rest  but  with  no  other  features  of  parkinsonism.          
Similarly,  two  GBA  carriers  had  parkinsonian  motor  signs  at  baseline.  As  described  
previously   (McNeill   et   al.,   2012b),   C17   (female,   78 years   old,   White   British)   had  
bilateral   rigidity,  mask-­like   facies,   and   bradykinesia  while  C31   (male,   78 years   old,  
White  British)  had  masked  facies,  bilateral  rigidity  with  activation  manoeuvre,  left  arm  
kinetic   tremor,   and   flexed  posture.     At   follow-­up,   the  parkinsonian  signs  present   in  
these  study  subjects  remained  unchanged  from  baseline.    
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When   specific   GD   patients   and  GBA   heterozygotes   with   features   of   parkinsonism  
(6/58;;  10·3%)  were  excluded,  the  follow-­up  data  remained  significant.  The  remaining  
GD   patients   and   carriers   (52/58;;   89·7%)   still   showed   a   significant   deterioration   in  
RBDQ,  UPDRS  II  and  III,  and  BDI  scores  after  two  years  (see  Table  2.4).    
  
Premotor   signs   present   at   baseline   that   could   predict   parkinsonian   motor  
signs    
When  clinical  markers  were  compared  between  specific  GD  patients  (GD05,  GD11,  
GD18,  and  GD27)  and  GBA  heterozygotes  (C17  and  C31)  with  parkinsonian  motor  
signs  and  GBA  mutation  positive  individuals  without  features  of  parkinsonism,  there  
were  significant  differences   in  age   (P  =   ·002)  and  cognition   (P  =   ·009)  at  baseline  
(see  Table  2.5  and  Table  2.6).  Baseline  UPSIT  scores  were  also  noted  to  be  lower  
in   those   individuals  with   features   of   parkinsonism  but   this   difference  did   not   reach  











Table   2.4.   Two   year   follow-­up   data   when  GBA   mutation   positive   individuals  
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0·13  (0·07)    
  
  


























































































P  (within)  a  
  
  













































27·73  (0·26)    
  
P  (within)  a  
  















































































































































Abbreviations:   UPSIT   Smell   Identification   Test,   UMSARS   Unified   Multiple   System   Atrophy   Rating  
Scale,  MoCA  Montreal  Cognitive   assessment,  MMSE  Mini-­Mental  State  Examination,  RBDQ  Rapid  
Eye  Movement  Sleep  Behaviour  Disorder  Questionnaire,  UPDRS  Unified  Parkinson’s  Disease  Rating  
Scale,  BDI  Becks  Depression  Inventory.      
Results  are  presented  as  mean  and  SEM.  Significance  was   taken  at   the  5%   level   for  all   variables.  
Only  values  which  survived  multiple  comparisons  with  the  FDR  procedure  were  denoted  significant.    
  
Reported  P  values  compare  the  mean  values  for  clinical  markers  within  groups  (baseline  and  follow-­
up)  and  between  groups  (Type  1  GD,  carriers  and  controls)  at  follow-­up.  
1  Controls  versus  Type  1  GD  patients.  
2    Controls  versus  heterozygote  GBA  mutation  carriers.  
3    Type  1  GD  patients  versus  heterozygote  GBA  mutation  carriers.  
a  Paired  t-­test.    
b  Two-­way  ANCOVA  with  Bonferroni  correction.    
c    Statistically  significant  difference.    
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Table  2.5.  Demographic,  clinical  and  genetic  characteristics  of  GBA  mutation  
positive  individuals  with  parkinsonism  versus  those  without  parkinsonism.  
                                        GBA  mutation  positive  individuals  
   Parkinsonism*  
(n=6)                                                      
No  Parkinsonism  
(n=52)      
P  value                                                                                                                                                                                                                                                                                    
Age,  years     74·3  (3·2)   59·9  (1·5)   ·002ac  
Gender  (F/M)   1/5   26/26   ·14b  
Ethnicity  (Ashkenazi/White  British)   3/3   3/7   ·17b  
Family  history  of  PD,  %   0   13·5   ·32  
Most  frequent  GBA  allele   N370S   N370S   -­  
  
Results  are  presented  as  mean  and  SEM.  Significance  was  taken  at  the  5%  level.  
Abbreviations:  ERT  Enzyme  Replacement  Therapy.  SRT  Substrate  Reduction  Therapy.    
*Patients  without  Parkinson’s  disease  but  with  subtle  evolving  features  of  parkinsonism.  
a      One-­way  ANOVA.      
b    Chi-­squared  test.  





















Table   2.6.   Baseline   and   follow-­up   clinical   markers   in   a   comparison   of  GBA  
mutation   positive   individuals   with   parkinsonism   and  GBA   mutation   positive  
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Abbreviations:   UPSIT   Smell   Identification   Test,   UMSARS   Unified   Multiple   System   Atrophy   Rating  
Scale,  MoCA  Montreal  Cognitive   assessment,  MMSE  Mini-­Mental  State  Examination,  RBDQ  Rapid  
Eye  Movement  Sleep  Behaviour  Disorder  Questionnaire,  UPDRS  Unified  Parkinson's  Disease  Rating  
Scale,  BDI  Becks  Depression  Inventory.      
  
*Patients  without  Parkinson’s  disease  but  with  subtle  evolving  features  of  parkinsonism.  
  
Results  are  presented  as  mean  and  SEM.  Significance  was   taken  at   the  5%   level   for  all   variables.  
Only  values  which  survived  multiple  comparisons  with  the  FDR  procedure  were  denoted  significant.  
  
Reported  P  values  compare  the  mean  values  for  clinical  markers  within  groups  (baseline  and  follow-­
up)  and  between  groups  (Parkinsonism  and  no  Parkinsonism)  at  baseline.  
  
1  Parkinsonism  versus  no  Parkinsonism.  
a  Paired  t-­test.    
b  One-­way  ANOVA  with  Bonferroni  correction.    
c    Statistically  significant  difference.    
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  Discussion        
This   study  was   designed   to   investigate   the   progression   of   clinical   biomarkers   in   a  
cohort  of  individuals  at  high  risk  for  PD.  My  results  demonstrate  that  clinical  features  
associated  with  pre-­motor  PD,  and  motor  features  of  PD  have  both  evolved  since  the  
initial   testing,   and   support   the   hypothesis   that   some   GBA   mutation   positive  
individuals   within   this   cohort   are   exhibiting   clinical   features   of   early  
neurodegeneration.      
  
In   the  cohort  studied,  both  Type  1  GD  patients  and  heterozygous  mutation  carriers  
were,  as  a  group,  hyposmic  at  baseline  (McNeill  et  al.,  2012b).  At  2  years,  follow-­up  
olfactory   scores   in   GD   patients   and   heterozygous   carriers   remained   significantly  
lower   than   those   reported   for   controls,   but   unchanged   from   baseline.   This   could  
reflect  the  short  length  of  the  follow-­up  period,  considering  olfactory  impairment  may  
progress  slowly.    
  
An   impaired   sense   of   smell   does   appear   to   correlate   with   other   modalities   in   the  
prodromal   phase   of   PD   e.g.   RBD   (Berg   et   al.,   2013).   I   did   identify   a   significantly  
increased   frequency   of   symptoms   of   RBD   at   the   follow-­up   assessment   in   GBA  
mutation  positive  individuals  compared  to  controls.  It  is  arguable  whether  a  score  of  
five   or   six   should   be   the   cut   off   point   for   a   scale   that   is   structured   to   determine   if  
there  is  RBD  or  not.  It  should  be  noted,  however,  that  the  proportion  of  RBDQ  scores  
greater   than   five   was   higher   in   GBA   mutation   positive   individuals   compared   to  
controls  at  follow-­up,  albeit  this  difference  did  not  reach  significance  (P  =  0·39,  Chi-­
squared  test).    
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There   was   an   increase   in   the   report   of   depressive   symptoms   in   GBA   mutation  
positive   individuals   at   follow-­up.   Patients   with   GD   can   exhibit   moderate   to   severe  
psychological  complications,  similar  to  patients  with  other  long-­term  chronic  illnesses  
(Packman  et  al.,  2006).   In  addition,  BDI  scores  of  1-­10  are  consistent  with  minimal  
depression  and  the  specificity  of  depression  alone  as  a  clinical  marker  of  prodromal  
PD  is  low,  but  may  be  usefully  combined  with  other  features  (Liepelt-­Scarfone  et  al.,  
2011).    
There   are   several   lines   of   evidence   now   for   greater   cognitive   impairment   in   those  
with  established  GBA-­PD  versus  sporadic  PD  (Brockmann  et  al.,  2011;;  Alcalay  et  al.,  
2012),(Zokaei   et   al.,   2014),   and   this  may   reflect   a   higher   burden   of   LB   disease   in  
GBA-­related  parkinsonism  (Clark  et  al.,  2009;;  Neumann  et  al.,  2009).  Interestingly,  in  
a  subgroup  of  six  GBA  mutation  positive   individuals  with  parkinsonian  motor  signs,  
mild  cognitive  impairment  (MoCA  score  </=24  in  5/6,  83·3%)  was  the  main  premotor  
sign   present   at   baseline   that   could   have   predicted   their   motor   deterioration.  
Compared   to   controls,   the   remaining   GBA   mutation   positive   individuals  
demonstrated  significantly  lower  MMSE  and  MoCA  scores  at  follow-­up,  albeit  these  
were   unchanged   from   baseline   and   still   within   the   normal   range   for   cognitive  
function.    
Control  subjects  showed  a  small  but  significant  change   in   the  UPDRS  part   II  score  
from  baseline.  I  believe  what  drove  the  changes  in  the  controls  were  a  small  group  of  
individuals   (n=6)   who   were   older.      The   mean   age   of   the   6   controls   that   had  
deteriorated  on  the  UPDRS  II  was  70.5  years  (range  62.6-­77.8).  The  UPDRS  II  may  
not  distinguish  well  between  those  symptoms  occurring  as  part  of  normal  aging  and  
those  related  to  PD,  and  I  accept  the  UPDRS  II  was  never  designed  or  validated  as  
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a   tool   for   activities  of   daily   living   (ADL)   in  aging  controls.  Particular  aspects  of   the  
UPDRS  II  that  had  worsened  in  controls  included:  2.11  (getting  out  of  a  bed,  a  car  or  
a  deep  chair),  2.12  (walking  e.g.  use  of  a  walking  aid),  2.5  (dressing  e.g.  help  with  
buttons).  I  have  had  to  take  this  into  consideration  when  interpreting  the  analysis  for  
the  controls  and  also   for  our  assessment  of  GBA  mutation  positive   individuals  who  
are  older.  When  compared,  a  significantly  higher   follow-­up  UPDRS  part   II   score   in  
GD  patients  distinguished  these  individuals  from  age-­matched  controls.    
There   were   some  GBA   mutation   positive   individuals   (10%)   with   significant   motor  
findings   identified   using   the   UPDRS   part   III,   which   did   not   overlap   with   normal  
physiology  (e.g.  bilateral  postural  tremor)  or  existing  bone/joint  abnormalities.  These  
individuals  did  not  meet  the  diagnostic  criteria  for  PD  but  could  represent  a  subgroup  
of  GBA  mutation  positive  individuals  that  are  progressing  towards  clinical  PD.    
I  considered  the   impact  of  GD  or  GD  therapy  on   the  clinical  markers   tested.  There  
were  GD  individuals  with  significant  motor  findings  identified  using  the  UPDRS  part  
III,   but   these   did   not   overlap   with   existing   bone   or   joint   abnormalities.   Cognitive  
dysfunction  has  been  reported  in  Type  I  GD,  and  substrate  reduction  therapy  (SRT)  
may   induce  memory   problems   (Elstein   et   al.,   2005).  However,   only   2  GD  patients  
were   receiving  SRT  when  evaluated  at   baseline  and  at   follow-­up,   and  neither   had  
cognitive   impairment.   Olfactory   abnormalities   are   found   in   those   with   PD   with  
mutations  in  GBA,  but  are  not  a  reported  feature  of  GD  or  its  treatment.  The  majority  
of   Type   1  GD   patients   (83%)  were   receiving   enzyme   replacement   therapy   (ERT).  
This   does   not   cross   the   blood  brain   barrier   and  has   no   reported   neurological   side  
effects.  Furthermore,  ERT  has  no  known  impact  on  dysautonomia.    
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My  study  is  the  first  to  undertake  the  longitudinal  follow-­up  of  a  large  cohort  of  GBA  
mutation   positive   individuals,   prior   to   the   development   of   PD.   Much   of   the   work  
published   thus   far   in   the   literature   has   focussed   on   patients   with   established   PD.  
This  has  been  essential   to  make   important  comparisons  between  sporadic  PD  and  
GBA-­related   parkinsonism   and   to   observe   subtle   differences.   The   opportunity   to  
follow  patients  prospectively  within  a  unique  at-­risk  cohort  such  as   this   is  essential  
for  defining  the  optimal  time  to  intervene  with  neuroprotective  therapy.    
One   limitation   of   the   study  was   that   not   all   investigators  were   blind   to   the   genetic  
status   of   individuals.   The   senior   researcher   was   blinded   to   genotype   but   the  
remaining   clinical   researchers   knew   the   medical   and   genetic   status   of   the  
participants.  Of   the   ninety   individuals   examined   at   baseline,   I   tried   to   follow-­up   all  
individuals.  To  minimise  any  observer  bias,  standardised  scores  were  used  and  all  
follow-­up  data  were  re-­examined.  I  did  not  exclude  any  individual  who  did  not  show  a  
large  change  between  time  points  1  and  2.  For  the  present  study,  this  potential  bias  
has  been  noted  as  a  limitation.    
Other   potential   criticisms   are   the   use   of   prodromal   markers   and   their   sensitivity,  
specificity,   and   positive   and   negative   predictive   values.   The   presence   of   clinical  
markers  alone  may  be  insufficient  accurately  to  predict  a  neurodegenerative  disorder  
in  the  majority  of  cases.  However,  clinical  markers  may  be  used  in  combination  with  
other  biochemical  or   imaging  markers   for  prodromal  PD  to  develop  a  more  reliable  
method  for  PD  prediction.      
In  this  study,  I  looked  at  the  subtle  changes  in  each  clinical  marker  between  the  two  
time  points  rather  than  a  clinically  meaningful  threshold.  In  GBA  positive  individuals,  
there  were  significant  differences  at  follow-­up  when  compared  to  controls  but  in  most  
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cases,   a   clinically   meaningful   change   has   not   been   defined.   When   assigned   to  
categories   of   severity   based   upon   age-­   and   sex-­adjusted   centiles   (www.  
sensonics.com),  Type  1  GD  patients  and  heterozygous  mutation  carriers  had,  as  a  
group,   mild   hyposmia   (UPSIT   score   30-­34/40)   at   baseline   and   at   follow-­up.   As   a  
group,   mean   MMSE   and   MoCA   scores   remained   within   the   normal   range   for  
cognitive   function  but  were  significantly   lower  when  compared  to  controls  at   follow-­
up.  BDI  scores  of  1-­10  are  consistent  with  minimal  depression  and  the  specificity  of  
depression  alone  as  a  clinical  marker  of  prodromal  PD   is   low,  but   the   frequency  of  
depressive   symptoms   was   higher   in   GBA   positive   individuals   at   follow-­up.   The  
Unified  Parkinson's  Disease  Rating  Scale  (UPDRS)  does  not  have  a  set  cut  point.  It  
is  a  rating  scale  used  to  follow  the  longitudinal  course  of  PD.  Over  2  years,  UPDRS  
III  scores  were  significantly  worse  in  GD  patients  and  GBA  heterozygotes.  Following  
UPDRS  scores  in  GBA  mutation  positive  individuals  over  time  should  provide  insight  
into  the  progression  of  the  clinical  prodrome  of  PD.    
For  individuals,  rather  than  looking  at  scatter  plots  for  each  of  the  groups  as  a  whole,  
I  looked  specifically  at  the  trajectories  for  a  subgroup  of  GBA  positive  individuals  with  
parkinsonian   motor   signs.   I   felt   that   this   would   provide   a   better   insight   into   the  
development  of  PD  in  this  group  of  GBA  positive  individuals,  but  also  in  general  how  
PD  could  develop  in  an  individual  over  time.    
The  purpose  of  this  study  was  the  longitudinal  clinical  evaluation  of  a  GBA  mutation  
positive   cohort   and   the   evolution   of   the   prodromal   features   of   PD.   This   study  
indicates   that   as   a   group,  GBA  mutation   positive   individuals   show   deterioration   in  
clinical  markers  consistent  with  the  prodrome  of  PD.  Within  this  group,  10%  appear  
to  be  evolving  at  a  more  rapid  rate.  
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3.1  A  high  prevalence  of  tremor  in  Type  1  Gaucher  disease  
  
While   examining   the   study   cohort,   I   also   found   a   high   prevalence   of   an   essential  
tremor   (ET)-­like   disorder   in   the   Type   1  GD   population,  with   increasing   prevalence  
with  advancing  age  associated  with  UPDRS  changes,  but  not  the  full  clinical  picture  
of   PD.   Tremor   is   more   common   than   would   be   expected   in   this   cohort   of   GBA  
carriers  and  extends  the  clinical  phenotype  associated  with  this  mutation.  
  
  Introduction        
Prevalence  data  on  different  types  of  tremor  among  patients  with  Type  1  GD  remain  







Patients   were   participants   in   a   study   of   the   prodrome   of   PD   and   were   recruited  
between  2010  and  2011  from  the  Lysosomal  Storage  Disorder  Unit  at  the  Royal  Free  
Hospital,   London.   Sixty   Type   1   GD   patients,   with   no   prior   diagnosis   of   PD   or  
dementia,  were  evaluated.  All  participants  provided  written  informed  consent  and  the  
study   was   approved   by   Hampstead   Research   Ethics   Committee.   The   mutation  
status   in   all   participants   was   confirmed   by   molecular   genetic   analysis.      Each  
participant  underwent  an  assessment  comprising:  clinical  history,  Mini-­Mental  State  
Examination  (MMSE),  Montreal  Cognitive  Assessment  (MoCA),  Parts  II-­III  of  Unified  
Parkinson's  Disease  Rating  Scale  (UPDRS),  Rapid  Eye  Movement  Sleep  Behaviour  
Disorder   Questionnaire   (RBDQ)   and   full   neurological   examination.   A   senior  
neurologist  trained  in  movement  disorders  (A.H.V.S)  confirmed  the  clinical  diagnosis  
of  tremor,  and  subsequent  tremor  analysis  was  performed  in  2/7  patients.    
  
Tremor  recordings                            
Two  of   the   seven  patients   consented   to   undergo   tremor   recordings.  Patients  were  
comfortably  seated  in  a  chair.  A  triaxial  accelerometer  (Biometrics  Ltd;;  sensitivity  ±50  
mV/G)   was   attached   to   the   dorsal   surface   index   finger   bilaterally.   Patients   were  
recorded   for   at   least   1  minute  at   rest  with  arms   relaxed  and  hands  hanging   freely  
from   the   arm   rest;;   on   posture,   with   the   arms   outstretched   in   front   of   the   patient,  
parallel  to  the  ground;;  this  same  position  with  500g  mass  attached  to  the  dorsum  of  
the   hand   (weight   loading);;   on   action   while   performing   a   goal-­directed   task.   Fast  
Fourier  analysis  of  the  signals  derived  from  accelerometry  was  performed  to  define  
the  peak  tremor  frequency  and  total  power  of  the  spectra  between  1  and  30  Hz  as  a  
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measure  of  tremor  amplitude.  All  parameters  were  calculated  for  each  accelerometer  
axis  then  averaged.  
  
Statistical  analysis  
The   data   was   analysed   using   IBM   SPSS   Statistics   (version   21).   To   assess   the  
differences  between   the  group  means,   I  performed  a   two-­way  ANOVA  with   factors  
Group   (Tremor   vs.   Non-­tremor)   and   Time   (Time   1   vs.   Time   2),   with   the   clinical  
marker  as  the  dependent  variable.    Post-­hoc  tests  were  used  to  compare  the  groups.  
Differences  in  age,  sex,  and  ethnicity  between  groups  were  checked  using  the  One-­
way   ANOVA   and   the   Chi-­squared   test.   I   also   accounted   for   performing   multiple  
statistical   tests  across  our  dependent   variables   (RBDQ,  MMSE,  MoCA,  UPDRS   II,  
UPDRS  III,  BDI)  by  defining  a  significance   threshold   for  statistical   tests  of  P  <   ·05,  
and   correcting   this   for   multiple   comparisons   using   the   Benjamini-­Hochberg   FDR  
(False   Discovery   Rate).   In   brief,   this   procedure   involves   ordering   all   P   values   in  
ascending  order  and  applying  a  sequential  threshold.  
  
  Results  
Overall,   tremor   was   observed   in   7   of   60   patients,   yielding   a   prevalence   rate   of  
11.7%.  Of   those   identified  with   tremor,  4   individuals  were  men  and  3  were  women  
(6.7%   and   5.0%,   respectively),   4/7   were   Ashkenazi   Jewish   (57.1%),   and   7   were  
available  for  follow-­up.  The  mean  age  of  GD  patients  without  tremor  was  51.5  years,  
while  those  with  tremor  were  older  (mean  age  73.0  years),  but  this  difference  did  not  
reach   statistical   significance   (P   =   0.06).   Age,   gender   and   ethnicity   were   not  
statistically  different  between  the  groups  (26/60  (43.3%)  female  subjects,  mean  age  
51.5  years,  12/60  (20.0%)  Ashkenazi  Jewish).  Mean  age  at   tremor  onset  was  66.9  
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years.  The  mean  duration  of  tremor  was  11.5  years.  Prevalence  for  tremor  appeared  
age-­related,  being  present  in  43.8%  (7/16)  in  those  aged  ≥60  years.  The  prevalence  
rates   for   tremor   were   not   higher   for   men   than   for   women   (6.7%   and   5.0%,  
respectively).  The  most   frequent  genotype  was  N370S/N370S,  but   the  presence  of  
the  N370S  allele  had  no  effect  on  tremor  frequency  (P  =  0.58,  Fisher’s  Exact  test).  
Current   treatment   for   patients   with   tremor   included   enzyme   replacement   therapy  
(ERT)   in   6/7   (85.7%).   No   patient   with   tremor   was   currently   receiving   substrate  
reduction   therapy   (SRT)  with  Miglustat,   but   3/7   had   received  Miglustat   previously;;  
the  mean  duration  of  Miglustat  treatment  was  1.7±2.1  years.    
In  7  GD  patients  with  tremor,  5  (71.4%)  presented  with  a  predominant  postural  and  
action   tremor.   Essential   tremor   (ET)   was   diagnosed   by   clinical   examination   in   3/5  
subjects   for   a   prevalence   rate   of   5.0%   (3/60).   ET   involved   the   upper   limbs   in   2  
patients,   and   the   head   and   neck   in   1   patient   (yes-­yes   head   titubation).   In   2/5  
subjects,   ET   was   diagnosed   but   was   accompanied   by   dystonic   features.   This  
involved  mild  dystonia  of   the  neck   in  1  patient  and   irregularity  of   tremor  amplitude  
and   frequency   in   another   patient.   Other   types   of   tremor   included   a   unilateral   rest  
tremor  of  the  right  thumb  (non  pill  rolling)  (1.7%;;  n  =  1)  and  a  bilateral  rest  tremor  of  
the  upper   limbs  (1.7%;;  n  =  1)  with  no  other   features  of  parkinsonism.  There  was  a  
positive   family  history  of   tremor   in  2/2  patients  with  ET  and  dystonia,  and  a   family  
history  of  PD  in  1/3  patients  with  ET.  
  
Neuroimaging  
Of   the   7   Type   1   GD   patients   with   tremor,   DaT   scans   were   performed   in   three  
patients:   two   patients   with   ET   with   dystonia   and   in   one   patient   with   a   unilateral  
resting  tremor  of  the  right  thumb.  All  scans  were  reported  as  normal.     
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Tremor  analysis       
Two   patients   underwent   tremor   analysis   performed   by   Dr.   Mark   Edwards   at   the  
Sobell  Department  of  Motor  Neuroscience  and  Movement  Disorders,  UCL  Institute  of  
Neurology,   London,   UK.   In   one   there   was   no   recordable   rest   tremor   and   in   the  
second   patient   very   minimal   rest   tremor   which   was   not   clinically   apparent.   Both  
patients  had  a  postural   tremor  with  a   frequency  of  approximately  7Hz.  This   tremor  
did  not  alter  significantly  in  frequency  or  total  power  with  weight  loading.  One  patient  
was   unable   to   complete   recordings   of   tremor   during   action   due   to   fatigue.   In   the  
patient  who  could  complete  this  part  of  the  recordings,  the  total  power  (amplitude)  of  
the   tremor   was   higher   during   action   compared   to   posture   and   was   noticeably  
asymmetrical  (see  Figure  7.5).    
  
Comparison  between  tremulous  and  non-­tremulous  patients                                               
The  characteristics  of  patients  with  tremor  at  baseline  and  follow-­up  are  reported  in  
Table  3.1.  The   results  of  motor   tests  and   the  degree  of  motor  decline  at   follow-­up  
significantly  separated  tremulous  patients  from  non-­tremulous  patients.  As  described  
previously   (McNeill   et   al.,   2012b),   anosmia   was   interpreted   using   age-­   and   sex-­
adjusted  normative  scores.  Mean  UPSIT  scores  were  worse  at  follow-­up,  but  did  not  
differ   significantly   between   those  with   tremor   and   those  without   tremor   (P   =   0.54).  
Follow-­up  RBDQ  scores  were   significantly  worse   than   those   recorded   at   baseline,  
but   scores   were   not   statistically   different   between   tremulous   and   non-­tremulous  
patients  (P  =  0.35).  Cognitive  assessment  scores  were  worse  in  the  tremor  group  but  
this   difference   did   not   reach   significance   (P  =   .08),   and   results   did   not   differ   from  
baseline   in   either   group.  The  mean  UPDRS   III   score  at   follow-­up  was   significantly  
worse   than   scores   recorded   at   baseline   for   GD   patients   with   tremor   and   those  
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without   tremor   (in   both,  P  <   .05).   However,   the   degree   of  motor   progression   was  
significantly  worse  in  the  tremor  group  (P  <  .001).  With  tremor  scores  excluded,  GD  
patients’  UPDRS  III  scores  remained  higher  in  those  with  tremor  than  those  without  
tremor  (P  <  .001).  
  
Table  3.1.  Comparison  between   tremulous  and  non-­tremulous  patients  within  
the  GD  group.  
               Gaucher  disease  (n  =  60)                                                                                        
Tremor  (7)                        Non-­tremor  (53)              P  (between)b    
Age,  years   73.0  (4.6)   51.5  (2.2)   .11  
Gender  (F/M)   3/4   23/30   .61  
Ethnicity  (White/Ashkenazi)   3/4   36/8   .13  
Most  frequent  genotype   N370S/N370S   N370S/N370S   .58  
History  of  receiving  Miglustat,  %   42.9   14.8   .07  
Age  of  tremor  onset,  years   66.9  (5.6)   -­   -­  






















































































Abbreviations:   UPSIT   Smell   Identification   Test,   UMSARS   Unified   Multiple   System   Atrophy   Rating  
Scale,  MoCA  Montreal  Cognitive   assessment,  MMSE  Mini-­Mental  State  Examination,  RBDQ  Rapid  
Eye  Movement  Sleep  Behaviour  Disorder  Questionnaire,  UPDRS  Unified  Parkinson's  Disease  Rating  
Scale,  BDI  Becks  Depression  Inventory.      
  
Results  are  presented  as  mean  and  SEM.  Significance  was   taken  at   the  5%   level   for  all   variables.  
Only  values  which  survived  multiple  comparisons  with  the  FDR  procedure  were  denoted  significant.    
  
Reported  P  values  compare  the  mean  values  for  clinical  markers  within  groups  (baseline  and  follow-­
up)  and  between  groups  (tremor  and  non-­tremor)  at  follow-­up.  
  
a  Paired  t-­test.    
b  Student  t  test  and  Chi  squared  test  for  differences  in  age,  sex,  ethnicity,  treatment,  family  history;;  
Fisher’s  exact  test  for  differences  in  genotype;;  Two-­way  ANOVA  with  Bonferroni  correction  for  
differences  between  groups  and  time  of  evaluation  for  UPSIT,  MoCA,  RBDQ  and  UPDRS  scores.  





  Discussion    
This  study  is  the  first  estimate  of  the  prevalence  of  tremor  in  Type  1  GD.  I  found  an  
unexpectedly  high  prevalence  of  postural  and  action   tremor   (8.3%  all  ages;;  20.0%  
age  ≥65  years)  in  this  population.                   
ET  accounted  for  the  majority  of  tremor,  for  a  prevalence  rate  of  5.0%  (3/60).  There  
has   been  much   speculation   regarding   the   possibility   of   a   relationship   between  ET  
and  PD.  In  a  recent  prospective  study,  patients  with  ET  were  four  times  more  likely  
to   develop  PD   than   controls   during   follow-­up   (Benito-­León   et   al.,   2009).   However,  
others  argue  this  may  well  be  coincidence  and  the  actual  cause  of  PD  in  these  cases  
could   relate   to   other   factors   (Adler   et   al.,   2011).   The   finding   that   ET   is   an   aging-­
associated   disease,   together   with   an   observed   concurrence   of   both   PD   and  
Alzheimer's   disease   does   lend   support   to   the   suggestion   that   ET   is   a  
neurodegenerative  disease   (LaRoia  and  Louis,  2011).  Neurodegenerative  diseases  
have   been   linked   to   defects   in   autophagy   and   the   ubiquitin-­proteasome   system  
(UPS)   (Korolchuk   et   al.,   2009),   and   it   has   been   proposed   that   lysosomal   storage  
disorders  could  also  be  diseases  of  autophagy.  Of   interest   is  a  recent  study,  which  
observed  changes  in  macroautophagy  within  the  cerebellum  of  ET  cases  compared  
to   that   of   age-­matched   controls,   and   suggests   perturbed   macroautophagy   could  
contribute   to   Purkinje   cell   pathology   in   ET   (Kuo   et   al.,   2012).   This   highlights   a  
potential   role   for   the   lysosome   in   ET   pathogenesis,   an   organelle   increasingly  
connected  to  neurodegenerative  disease.       
Normal   DaT   scans   were   reported   in   three   of   the   tremor   patients.   These   patients  
could  represent  an  important  subgroup  of  patients  suspected  clinically  to  have  early  
PD,  but  who  have  scans  without  evidence  of  dopaminergic  deficit   (SWEDD).   It  can  
be  difficult   to  distinguish  these  patients   from  those  with  PD  on  clinical  grounds,  but  
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SWEDD   cases   can   present   with   atypical   or   dystonic   tremor   (Bajaj   et   al.,   2010).  
However,   there   is   debate   as   to   whether   these   patients   have   early   PD   or   whether  
adult-­onset  dystonia  is  the  underlying  diagnosis  (Schwingenschuh  et  al.,  2010).       
I  considered  a  diagnosis  of  drug-­induced  tremor,  particularly  if  there  was  a  history  of  
receiving  substrate  reduction  therapy  (SRT)  with  Miglustat,  a  known  cause  of  tremor  
(Kuter  et  al.,  2013).  In  3/7  tremor  cases,  SRT  had  been  administered  previously  but  
it   should   be   noted   that   in   all   cases,   tremor   was   present   before   the   treatment  
commenced.    
The  high  prevalence  of   tremor   in   this   type  1  GD  population,  with  prevalence   rates  
increasing  with  age,  combined  with  a  significant  decline  on  motor  tests  during  follow-­
up,  could  lend  support  to  the  association  of  GD  with  PD  that  has  been  highlighted  in  
the  literature  (Bultron  et  al.,  2010),  although  larger  numbers  and  longer  follow-­up  will  
be  needed  to  confirm  this,  and  to  determine  if  the  tremor  in  these  cases  has  any  link  
to   PD,   or   simply   represents   an   incidental   finding.   The   tremor   in   this   cohort   was  
atypical   for   PD   tremor,   and   in   some   patients   the   tremor   has   been   longstanding,  
making   PD   less   likely   as   a   cause.   My   work   could,   therefore,   suggest   that   GBA  
represents   a  shared   risk   factor   for   two   pathophysiologically  separate   movement  
disorders.  This  remains  to  be  supported  by  genetic  studies.  For  instance,  in  the  first  
comprehensive  analysis  of   the   frequency  of   the  GBA  gene  mutation   in  ET,  authors  
found  a  similar  frequency  of  GBA  mutations  in  ET  cases  versus  controls  (Clark  et  al.,  
2010).  Larger  studies  are  needed   to  determine  whether   the  GBA  gene  mutation   is  
specifically   associated   with   PD,   or   whether   it   affects   the   risk   for   other  




3.2  A  case  of  type  1  Gaucher  disease  with  parkinsonism    
  
  Introduction  
The   majority   of   patients   with   type   I   GD   never   develop   neurological   signs   or  
symptoms.  However,  several  case  reports  of  PD  disease  associated  with  type  I  GD  
have   been   published,   confirming   a   genetic   link   between   the   two   diseases.   In   the  
clinical   setting,   it   can   be   difficult   to   distinguish  GBA-­related  PD   from   sporadic  PD.  
Here  I  present  a  right  handed  Sri  Lankan  man  in  whom  parkinsonism  was  associated  
with  type  I  GD.  Findings  of  the  brain  DaT  scan  are  presented.  
  
  Case  report  
A  53-­year-­old  man  with  known  type  I  GD  was  a  participant  in  a  study  of  the  aetiology  
and  prodrome  of  PD.  He  was  recruited  in  2010  from  the  Lysosomal  Storage  Disorder  
Unit   at   the   Royal   Free   Hospital,   London.   He   had   no   prior   diagnosis   of   PD   or  
dementia.  He  was  working  as  a  Tesco  checkout  assistant.    
  
At   the   age   of   12,   he   had   removal   of   an   enlarged   spleen.   Thereafter,   he   also  
developed  an  enlarged   liver,  by  which  time  he  was   living   in   the  United  Kingdom.  A  
diagnosis   of   GD   was   made   based   on   the   following   typical   findings;;   hepa-­
tosplenomegaly,   Gaucher   cells   on   bone   marrow   biopsy,   reduction   in   blood   β-­
glucosidase  activity,  and  N370S/L444P  mutation  of  the  glucocerebrosidase  gene  on  
genetic   analysis.   He   has   been   on   enzyme   replacement   therapy   with   1200   IU   of  
Velaglucerase  alpha  every  2  weeks  (recently  reduced  to  800  IU  as  he  felt  his  current  
presentation  was  worse  following  his  infusions).  
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At  baseline  in  2010,  he  had  no  existing  neurological  disease.  He  was  found  to  have  
moderate  hyposmia  with  a  score  of  20/40  on   the  University  of  Pennsylvania  Smell  
Identification  Test.  At   two  years  follow-­up,  he  had  severe  hyposmia  with  a  score  of  
14/40.  At   three  years   into   the   research  study,  he  had  noticed  a  deterioration   in  his  
walking  for  1  year.  This  had  become  slow  and  he  had  taken  to  using  a  walking  stick.  
He  had  noticed  a  tremor  in  his  right  leg  and  occasional  tremor  in  his  right  arm.  The  
tremor  was  present  almost  continuously.  His  speech  had  become  slow  and  he  felt  he  
had  become  more  forgetful.  His  sleep  was  particularly  fragmented  but  there  were  no  
features  of  RBD.  For  two  years,  he  had  noticed  a  reduction  in  his  sense  of  smell.  His  
writing  had  become  micrographic  but  bladder  function  remained  normal.  There  was  
no  family  history  of  PD  and  I  understand  his  mother  has  motor  neurone  disease.  
  
Examination   confirmed   hypophonia.   Cranial   nerve   examination   revealed   some  
reduction   in   saccadic   eye  movement   but   the  external   ocular  movements  were   full.  
There   was   a   resting   tremor   in   the   right   leg   and   evidence   of   mild   to   moderate  
bradykinesia  and  rigidity,  particularly  on  the  right.  The  remainder  of  the  neurological  
examination  was  normal.  Examination  of  his  gait  revealed  poor  arm  swing  and  small  
steps.  His  postural   reflexes  were  still   intact.  The  clinical   features  were   indicative  of  
PD.    
  
DaT  scan  (see  Figure  7.6)  revealed  clear-­cut  reduction  of  uptake  within  the  putamen  
bilaterally.   In   addition,   there  was   reduced  uptake  within   the   right   caudate   nucleus.  
Findings  were  consistent  with  idiopathic  PD.  He  was  commenced  on  L-­dopa  therapy  
with   Sinemet.   This   has   led   to   some   improvement   but   it   is   felt   that   he   will   need  
increasing  concentrations  of  L-­dopa  therapy.    
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At   four   years   into   the   research   study,   he   has   now   developed   moderate   cognitive  
impairment  with  a  score  of  21/30  on  the  Montreal  Cognitive  Assessment  (MoCA)  and  
20/30   on   the   Mini   Mental   State   Examination   (MMSE).   This   compares   to   a   MoCA  
score  of  29/30  and  MMSE  score  of  30/30  at  his  initial  baseline  evaluation  in  2010.    
  
  Discussion  
In  this  case  report  of  PD  associated  with  type  1  GD,  I  describe  the  type  of  trajectory  
a  patient  with  GBA-­PD   is   likely   to  have.  PD   is   typically  characterized  by   the  motor  
symptoms  of   resting   tremor,   bradykinesia,   rigidity,   and  postural   instability.  Patients  
with  GD  who  develop  parkinsonism   typically  exhibit   the  symptoms  of  sporadic  PD.  
The   majority   of   patients   with   type   1   GD   who   develop   PD   therefore   present   with  
asymmetric  onset,  tremor,  and  bradykinesia  (Goker-­Alpan  et  al.,  2008),  the  cardinal  
features   of   ‘idiopathic’   PD.   However,   there   are   some   notable   differences.   In  most  
published  cases,  the  age  at  onset  of  PD  is  younger  than  that  seen  in  typical  PD  by  5  
years   and   there   is   a   higher   frequency   of   cognitive   impairment.   In   an   early   case  
series  of  six  type  1  GD  patients  (Neudorfer  et  al.,  1996),  parkinsonism  developed  at  
a   mean   age   of   49   years   and   manifested   atypical   findings   such   as   psychiatric  
symptoms,  myoclonus,  and  an  unresponsiveness   to  L-­dopa  therapy.  Other  atypical  
features  have  also  been  observed  such  as  perceptive  deafness  (Bembi  et  al.,  2003),  
dementia   (Tayebi  et  al.,   2003),  and  horizontal   saccadic  eye  movements   (Bembi  et  
al.,  2003).  In  the  present  case,  parkinsonism  responded  well  to  L-­dopa  therapy,  and  
dopamine  imaging  by  single  photon  emission  tomography  (SPECT)  of  the  dopamine  
transporter   was   abnormal   in   this   patient   with   GBA-­PD   in   a   pattern   identical   to  
idiopathic   PD.   However,   onset   as   early   as   the   5th   decade   of   life   and   significant  
cognitive  impairment  are  not  typical  features  of  idiopathic  PD.    
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The  evidence   from   longitudinal   studies   demonstrate   that  GBA-­PD  patients   show  a  
more   rapid   disease   progression   and   a   greater   preponderance   to   dementia   or  
cognitive   decline   (Brockmann   et   al.,   2014)   (Winder-­Rhodes   et   al.,   2013).   The  
association   between   the   distribution   of   LB   pathology   and   the   cognitive   impairment  
seen   in  GBA-­PD   is  well   established.  Brains   from  PD  patients  with  GBA  mutations  
reveal   more   diffuse   neocortical   LB–type   pathology   compared   with   those   from  
sporadic  PD  patients  (Neumann  et  al.,  2009).    
  
It   would   be   interesting   to   know   when   the   process   of   rapid   progression   in   GBA-­
associated  PD  starts.  At  the  time  of  diagnosis,  it  is  difficult  to  distinguish  PD  patients  
with   and   without   GBA   mutations.   In   a   recent   prospective   longitudinal   study   to  
evaluate   progression   of   motor   and   non-­motor   symptoms   in   sporadic   PD   patients  
depending   on   the   mutational  GBA   status,   the  GBA   positive   subgroup   were   more  
severely   affected   by   motor   impairment,   disease   staging,   and   cognitive   decline  
(Brockmann   et   al.,   2014).   In   GBA-­PD   patients,   the   acceleration   of   disease  
progression   appeared   to   be   relatively   late   (8-­9   years   disease   duration).   Authors  
suggest   this   could   be   due   to   compensatory   mechanisms   in   the   first   years   of   the  
disease  but  that  at  some  point  this  system  becomes  overburdened,  resulting  in  rapid  
progression.    
  
Experimental   evidence   puts   forward   a   self-­perpetuating   model   and   suggests   a  
bidirectional   pathogenic   loop:  GCase   interacts  directly  with  SNCA  and   this   binding  
between  the  wild  type  enzyme  and  SNCA,  under  lysosomal  conditions,  could  have  a  
beneficial   effect   by   either   promoting   SNCA   degradation   by   the   lysosome   and/or  
preventing  aggregation  (Yap  et  al.,  2011).  Mutations  in  GBA  or  reduced  levels  of  wild  
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type  GCase  reaching  the  lysosome  could  weaken  the  beneficial  interaction  between  
SNCA   and   GCase,   reduce   lysosomal   protein   degradation,   and   contribute   to   the  
SNCA   aggregation   characteristic   of   PD   pathology.   The   resultant   accumulation   of  
substrate   and   SNCA   would   then   mediate   the   interaction   of   the   SNCA-­GCase  
complex  on  intralysosomal  vesicles,  leading  to  a  further  loss  of  GCase  activity  (Yap  
et  al.,  2013).  
  
Overall,   this  case  supports   the   idea   that   the  GBA  mutation  could   represent  a  poor  

























4.1  Development   and   characterization   of   cell   culture  models   from  
individuals  within  the  clinical  cohort  studied  
  
OBJECTIVE                                                                                                           
To  establish  the  relevant  cell  models  from  controls  and  individuals  carrying  the  GBA  
mutations,   with   or   without   PD,   in   order   to   characterise   the   biochemical   defects  
associated  to  mutant  GBA  and  to  PD.    
  
  Establishing  human  cell  models  for  Parkinson’s  disease  
I   want   to   define   the   downstream   biochemical   signature   of   GBA   mutations,   and  
fibroblasts  provide  a  good  model   to  do   that  –  studying  a  disease   in  patient-­specific  
cells.  However,  fibroblasts  are  limited  for  interrogating  the  complete  pathway  in  PD  in  
comparison  to  neuronal  models,  owing  to  the  lack  of  SNCA  expression  in  fibroblasts  
and  other  neuronal  features.  A  neuronal  model  would  be  ideal  where  levels  of  SNCA  
can   also   be   measured   in   the   dopaminergic   (DA)   neurons,   and   which   will   more  
accurately   reflect  what   is  happening   in   the  brain.  To   this  end,   I   plan   to   investigate  
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whether   small   molecular   chaperones,   ambroxol   (ABX)   and   isofagomine   (IFG),  
increase  GCase  activity  and  reduce  SNCA  levels,  in  a  human  DA  neuronal  model  of  
PD.  
Many   different   neuronal   cell   models   have   been   developed   in   an   attempt   to  
recapitulate   PD.   One   of   the   major   limitations   to   research   into   PD   has   been   the  
inaccessibility  of  dopaminergic  (DA)  neurons  and  the  lack  of  genuine  in  vitro  models.    
One  technology  that  has  emerged  is  the  use  of  induced  pluripotent  stem  cells  (iPSC)  
generated  from  patients  themselves.  To  create  patient-­specific  DA  neuronal  cultures,  
iPSCs   can   be   generated   by   reprogramming   patient   fibroblasts   using   pluripotency  
factors   such   as  Oct4,   SOX2,  Nanog   and  Klf4.  One   of   the  major   limitations   to   this  
technology   is   the   variability   between   iPSC   lines.      From   each   culture   of  
reprogrammed  fibroblasts,  colonies  are  selected  and  are  subjected  to  quality-­control  
measures   such   as   transgene   silencing   and   karyotype   analysis.   However,   these  
clones,   colonies   derived   from   the   same   human   donor,   still   exhibit   large   variability  
(Devine   et   al.,   2011).   This   can   lead   to   considerable   phenotypic   variability   that   is  
unrelated  to  their  genotype  and  a  differing  efficiency  to  which  iPSC  lines  differentiate  
into   neurons   (Sánchez-­Danés   et   al.,   2012).   Genome   editing   has   become   a  
necessary  step  to  introduce  point  mutations  into  the  genome,  resulting  in  clonal  cell  
lines  that  are  isogenic  (Soldner  et  al.,  2011).  Variability  between  clones  can  also  be  
reduced   by   using   non-­disruptive   methods   of   reprogramming,   such   as   episomal  
plasmids  (Okita  et  al.,  2011)  or  non-­integrating  viruses,  e.g.  Sendai  virus  (FUSAKI  et  
al.,  2009).  This  variability  between  lines  can  reduce  the  ability  to  achieve  meaningful  
results,  especially  when  only  a  few  lines  are  used  for  study.  One  other   issue  is  the  
potential  consequence  of  long-­term  culture  of  iPSCs  over  time.  This  can  result  in  the  
generation   of   chromosomal   abnormalities,   and   although   each   line   is   subjected   to  
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analyses  of  karyotype,  detailed  examination   reveals  small   copy  number  variants   in  
iPSC   lines   that  may  go  undetected  (Soldner  et  al.,  2011).   In  summary,   iPSC  are  a  
good   way   of   studying   the   effects   of   a   human   mutation   in   human   cells,   but   there  
remain   some   important   limitations   including   a   low   transfection   efficiency   (~10%  or  
incomplete  reprogramming),  genomic  instability,  tumour  formation  in  vivo,  and  some  
argue   that   the   iPSC-­derived   DA   neurons   are   immature   and   do   not   behave   like  
neurons.  
  
A  novel   technique  has  been  developed  with  which  neural   crest   stem  cells   (NCSC)  
can   be   isolated   from   patient’s   fat   tissue.   Human   adipose   tissue   has   distinct  
developmental   origins   including  mesoderm   and   neural   crest   lineage,   and   contains  
many   different   types   of   cells.   Human   adipose   NCSC   have   the   capability   of  
differentiation   to  mesodermal,  endodermal  and  ectodermal   lineages   (Hauser  et  al.,  
2012;;  Motohashi  and  Kunisada,  2015).  This  ability  of  adipose-­derived  stem  cells   to  
differentiate  into  DA  neurons  opens  a  new  window  into  developing  a  physiologically  
relevant,   in  vitro  model  of  PD.  This  approach  will  allow   the  exploitation  of  a   readily  
available  and  abundant  source  of  adult  stem  cells,  and  bypasses  the  time  consuming  
reprogramming  and  cloning  phases  associated  with   iPSC   technology.   I  used   these  
NCSC  to  develop  human  NCSC-­derived  DA  neurons  as  a  model  for  the  study  of  PD.  
This  cell  model  was  developed  and  prepared  for  my  study  through  collaboration  with  
Dr.  Shi-­Yu  Yang.    
  
  Sample  collection  
All   cells   were   generated  in   vitro  after   written   informed   consent   using   protocols  
approved   by   the   Royal   Free   research   ethics   committee,   Royal   Free   Hospital,  
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London,  UK.    PD  was  diagnosed  according   to  UK  Brain  Bank  criteria  (Litvan  et  al.,  
2003).   The   GBA   mutation   status   in   all   participants   was   confirmed   by   Sanger  
sequencing  of   the  GBA   gene,  as  previously  described   (McNeill   et  al.,   2012b).  Any  
clinical   sign   of   a   neurodegenerative   disorder   led   to   exclusion   from   the   study.  
Differences   in   age   and   sex   between   groups   were   checked   using   the   One-­way  
ANOVA.  See  Appendix  Table  9.6   for   the   full   list  of  skin  biopsies  obtained   from  the  
patient  cohort.    
  
  Patient-­derived  fibroblasts  
Human   skin   fibroblasts   (Table   4.1)   were   obtained   from   the   patient   cohort   and  
included   five   healthy   controls,   five   heterozygous   GBA   mutation   carriers   with   PD  
(N370S/wt;;   L444P/wt),   five   heterozygous   GBA   mutation   carriers   without   PD  
(N370S/wt;;   L444P/wt),   and   five   PD   patients   negative   for   the   GBA   mutation.  
Fibroblasts   were   grown   in   the   standard   conditions:   Dulbecco’s   modified   Eagle  
medium   (DMEM)   supplemented   with   10%   fetal   bovine   serum   (FBS),   5%   sodium  
pyruvate,  1%  fungizone  and  1%  penicillin–streptomycin  at  37  °C  in  the  presence  of  
5%   CO2,   with   medium   changed   every   2   days.      Cultures   were   not   left   to   become  
confluent.      Passage   numbers   were   limited   from   8   to   12,   and   cell   cultures   were  
matched  for  passage  number.  
  
  Identification  and  isolation  of  neural  crest  stem  cells  from  human  adipose  
tissues      
Human  adipose  NCSC  (Table  4.2)  were  isolated  from  the  subcutaneous  fat  collected  
from   wild   type,   heterozygous   GBA   mutation   positive   (N370S/wt)   carrier   and   PD  
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patients   who   underwent   a   skin   punch   biopsy,   and   differentiated   into   functional  
human  dopaminergic  neurons.  
  
Table  4.1.  Summary  of  patient-­derived  fibroblast  lines  
Subject  Code   Genotype   Gender   Diagnosis   Age  at  biopsy  
C1   wt/wt   Female   CTRL   67  
C2   wt/wt   Female   CTRL   70  
C3   wt/wt   Male   CTRL   81  
C4   wt/wt   Female   CTRL   82  
C5   wt/wt   Male   CTRL   52  
Het1   N370S/wt   Female   GBA  Carrier   67  
Het2   N370S/wt   Female   GBA  Carrier   60  
Het5   N370S/wt   Male   GBA-­PD   80  
Het6   N370S/wt   Female   GBA-­PD   75  
Het7   N370S/wt   Female   GBA-­PD   53  
Het8   L444P/wt   Male   GBA  Carrier   62  
Het9   L444P/wt   Female   GBA  Carrier   45  
Het10   L444P/wt   Male   GBA  Carrier   67  
Het11   L444P/wt   Male   GBA-­PD   72  
Het12   L444P/wt   Male   GBA-­PD   85  
GD1   N370S/N370S   Male   GD   70  
PD1   wt/wt   Female   IPD   85  
PD2   wt/wt   Male   IPD   79  
PD3   wt/wt   Female   IPD   81  
PD4   wt/wt   Female   IPD   72  
PD5   wt/wt   Male   IPD   80  
                                                                                                                                                                                                                                                                                                        
CTRL,   healthy   control;;   IPD,   Idiopathic   Parkinson’s   disease;;   GBA   Carrier,  
heterozygous  GBA   mutation   carrier;;   GBA-­PD,   heterozygous  GBA   mutation   carrier  




Table  4.2.  Summary  of  patient-­derived  adipose  neural  crest  stem  cells  
Subject  Code   Genotype   Gender   Diagnosis   Age  at  biopsy  
C1   wt/wt   Female   CTRL   67  
C2   wt/wt   Female   CTRL   70  
C3   wt/wt   Male   CTRL   81  
Het1   N370S/wt   Female   GBA  Carrier   67  
Het3   N370S/wt   Female   GBA  Carrier   82  
Het4   N370S/wt   Male   GBA  Carrier   52  
PD5   wt/wt   Male   IPD   80  
PD6   wt/wt   Female   IPD   75  
PD7   wt/wt   Female   IPD   53  
                                                                                                                                                                                                                                                                                                        
CTRL,   healthy   control;;   IPD,   Idiopathic   Parkinson’s   disease;;   GBA   Carrier,  
heterozygous  GBA  mutation  carrier.  
  
  Human  adipose  neural  crest  stem  cell  culture  
Human   adipose  NCSC  were   cultured   in  DMEM   supplemented  with   10%  FBS,   5%  
sodium   pyruvate,   0.5%   uridine,   1%   fungizone   and   1%   penicillin–streptomycin   at  
37  °C  in  the  presence  of  5%  CO2,  with  medium  changed  every  2-­3  days.     Cultures  
were  not  left  to  become  confluent.    Passage  numbers  were  limited  from  3  to15,  and  
cell  cultures  were  matched  for  passage  number.  
  
  Characterisation  of  adipose  neural  crest  stem  cells  
The  adipose  NCSC  used  for   this  study  have  been  extensively  characterised  by  Dr.  
Shi-­Yu   Yang   who   has   shown   that   adipose   NCSC   are   capable   of   forming  
neurospheres  and  are  positive  on  immunostaining  and  RT-­PCR  for  neural  crest  stem  
cell  markers  (data  not  shown  here).  Immunostaining  was  performed  for  pluripotency  
markers   Nanog,   Oct-­4,   P75,   SOX10,   SSEA4   and   TRA-­1-­18   to   characterise  
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pluripotent   properties   of   healthy   and  GBA  mutant   positive   NCSC   (see  Figure   7.7  
and  Figure  7.8).    
  
  Karyotyping  
Karyotyping  was   performed   by   full  G-­band   analysis   of   20   cells   in   3   human   neural  
crest  stem  cell  cultures  (1x  wild  type,  1x  heterozygous  GBA  mutation  carrier,  and  1x  
PD)   to   examine   the   integrity   of   the   chromosomes   by   The   Doctor’s   Laboratory   at  
Whitfield  Street,  London.  All  cells  tested  showed  a  normal  banding  pattern.  
  
  Dopaminergic   neuronal   differentiation   of   human   adipose   neural   crest  
stem  cells  
Adipose   NCSC   were   differentiated   to   functional   DA   neuronal   cells   using   a   fully  
defined   step-­wise   differentiation   protocol   (see   section   4.3.2).   Following  
differentiation,   human   adipose   NCSC   adopt   a   neuronal   morphology.   These   cells  
express  specific  neuronal  markers  such  as  Nestin,  NeuN,  class  III  β-­tubulin,  and  DA  
neuronal   markers   tyrosine   hydroxylase   and   the   DA   transporter.   The   neurons  
respond   to   glutamate-­   and   KCL-­induced   plasma   membrane   depolarisations   with  
robust   Ca2+   and   Na+   fluxes,   confirming   that,   in   terms   of   Ca2+   and   Na+  





4.2    Characterisation  of  the  fibroblast  model  related  to  Parkinson’s  
disease  and  the  biochemical  effect  of  the  GBA  mutation  
  
OBJECTIVE                                                                                                           
To   use   the   relevant   cell   models   from   controls   and   individuals   carrying   the   GBA  
mutations,   with   or   without   PD,   in   order   to   characterise   the   biochemical   defects  
associated  to  mutant  GBA  and  to  PD.    
  
  Introduction  
The   discovery   of   an   association   of   the  GBA   mutation   with   PD   (Sidransky   et   al.,  
2009a)  has  proved  an   important  development   for   research  on   the  pathogenesis  of  
PD,  and  has  provided  support  for   increasing  evidence  that   lysosomal  pathways  are  
implicated  in  PD  (Dehay  et  al.,  2013).    
The  relationship  between  GD  and  PD  is  not  yet  fully  understood.  It  could  arise  from  
the  gain  of   a  new   toxic   function  by  mutated  GBA,   a   loss  of   enzyme   function,   or   a  
combination  of  both.  Most  mutations   in  GBA  cause  GCase   to   fold  abnormally.  The  
misfolded   protein   is   retained   in   the   endoplasmic   reticulum   (ER)   and   after  
unsuccessful   attempts   at   refolding,   finally   undergoes   degradation   by   the   ER-­
associated   degradation   (ERAD)   system.   This   reduces   the   GCase   reaching   the  
lysosome,   could   compromise   lysosome   function   and   have   consequences   for   the  
lysosomal-­autophagy   pathway,   considered   to   be   the  main   pathway   through   which  
SNCA   is   degraded   (Vogiatzi   et   al.,   2008;;   Machiya   et   al.,   2010).   In   GD   patients  
homozygous  for  the  GBA  mutation,  there  is  a  significant  reduction  in  GCase  activity.  
In   the   asymptomatic   heterozygous   carrier,   there   is   varying   degrees   of   activity  
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ranging   from   50%   to   normal.   However,   even   this   moderate   reduction   of   GCase  
activity   may   be   sufficient   to   lead   to   suboptimal   lysosomal   function,   SNCA  
accumulation  and  an  increased  frequency  of  PD  (Mazzulli  et  al.,  2011).    
Previously  our  lab  has  demonstrated  some  of  the  molecular  changes  associated  with  
the  GBA  mutation   that   might   predispose   to   PD.   Here,   I   have   extended   the  
investigation  into  the  biochemical  consequences  of  the  GBA  mutation  relevant  to  PD  
pathogenesis.  I  have  shown  for  the  first  time  that  there  is  a  defective  localisation  of  
GBA  in  GBA  mutant  fibroblasts  by  immunocytochemistry.  I  have  also  shown  for  the  
first   time   that   the  UPR  protein  BiP/GRP78BiP,  a  marker  of   the  UPR,   is   reduced   in  
heterozygous  GBA  mutation  carriers  and  could  suggest  an  inadequate  UPR  in  these  
cells.  Furthermore,  I  have  identified  defects   in   lysosomal  autophagy  in  GBA  mutant  
fibroblasts  which  were  not  identified  previously  (McNeill  et  al.,  2014).  
  
  Method  
Lysosomal  enzymatic  activity  assays  
Cell  pellets  were  re-­suspended  in  water  and  sonicated  in  a  water-­bath  sonicator  for  1  
minute.   GCase   activity   was   determined   in   cell   lysate   of   about   20μg   protein   by  
hydrolysis  of  5mM  4-­methylumbelliferyl-­β-­D-­glucopyranoside  in  McIIvaine  buffer  (pH  
5.4)  in  the  presence  of  22mM  sodium  taurocholate  at  37°C  for  1  hour  (Wenger  et  al.,  
1978).   The   reaction   was   stopped   by   addition   of   0.25M   glycine   (pH   10.4)   and   4-­
methylumbelliferone   fluorescence   measured,   against   the   reference   at   excitation  
365nm,   emission   450nm.   Contribution   from   non-­lysosomal   GCase   (GBA2)   was  
distinguished   by   using   the   corresponding   inhibitor   conduritol-­β-­epoxide  (CβE)   (see  
Appendix  Figure  9.6  and  Figure  9.7).    
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β-­Hexosaminidase  was  assayed  in  the  above  cell   lysate  of  about  2μg  protein  using  
the   fluorogenic   substrate   4-­methylumbelliferyl-­N-­acetyl-­glucosamide   substrate  
(2mM)   in   sodium   citrate   buffer   (pH  4.2)   at   37°C   for   30  minutes.   The   reaction  was  
stopped  by  addition  of  0.25M  glycine  (pH  10.4),  and  fluorescence  was  measured  as  
above  (Wendeler  and  Sandhoff,  2009).    
β-­Galactosidase  was  assayed  in  the  above  cell  lysate  of  about  2μg  protein  using  the  
fluorogenic   substrate   4-­methylumbelliferyl-­β-­D-­galactopyranoside   (2mM)   in   sodium  
citrate  buffer  (pH  4.1)  at  37°C  for  30  minutes.  The  reaction  was  stopped  by  addition  
of   0.25M   glycine   (pH   10.4),   and   4-­methylumbelliferone   fluorescence   measured   at  
excitation  365nm,  emission  450nm.    
The  total  protein  concentration  of  the  cell  lysate  was  determined  by  the  Bicinchoninic  
Acid  (BCA)  method.  5μl  of  the  above  cell  lysate  was  loaded  in  20μl  of  water.  A  set  of  
protein  standards  were  also  measured.  The  fluorescence  was  measured  at  562  nm.  
The  protein  concentration  of  the  standards  was  used  to  create  a  standard  curve.  The  
standard  curve  was  used   to  calculate   the  protein  concentration  of   the  cell   lysate   in  
mg/ml.    
Enzyme  activities  were  calculated  by  substracting  the  background  fluorescence  from  
the   mean   fluorescence   measured   for   a   given   cell   lysate,   then   dividing   by   the  
standard  to  calculate  the  nmol/hr/ml  activity.  This  result  was  then  divided  by  the  total  
protein   concentration,   as   determined   using   the   BCA   method,   to   calculate   the  
enzymatic  activity   in  nmol/hr/mg.  All  enzyme  assays  were  validated   (see  Appendix  




Western  blot  analysis  
Cells   were   harvested,   washed   with   PBS,   and   processed   as   previously   described  
(McNeill  et  al.,  2014).  In  total,  20μg  of  the  protein  lysate  was  loaded  on  a  4–12%  Bis-­
Tris   Gel   (NuPAGE,   Invitrogen)   and   transferred   to   a   polyvinylidene   difluoride  
membrane  (Millipore,  Watford,  England).  The  following  antibodies  were  used:  mouse  
anti-­GBA   (Calbiochem),   rabbit  anti-­β-­actin   (Abcam),   rabbit  anti-­BiP   (Abcam),   rabbit  
anti-­LAMP1   (Abcam),   rabbit   anti-­LAMP2a   (Abcam),   rabbit   anti-­Hsc70   (Abcam),  
rabbit   anti-­GAPDH   (Abcam),   rabbit   anti-­LC3   (Cell   signaling),   and   mouse   anti-­p62  
(BD   Biosciences).   Horseradish   peroxidase   goat   anti-­mouse   (Dako),   anti-­rabbit  
(Dako)   or   anti-­goat   (Dako)   secondary   antibodies   and   Clarity   Western   ECL   kits  
(BioRad)  were  used.  Analyses  were  prepared  using   Image  Lab  software   (BioRad).  
See  Appendix   Table   9.4   for   the   full   list   of   antibodies   used.  Full-­length   images   of  
immunoblots  are  shown  in  Appendix  Figure  9.10.  
  
Autophagy  studies  
Where   indicated,  cells  were   treated  with  0.2µM  bafilomycin  (EMD,  Millipore)  or  with  
DMEM  without  supplements  (starvation)  for  4  hours  at  37  °C  in  the  presence  of  5%  
CO2,   and   then   fixed   or   lysed   for   western   blot   analysis.   LC3/LC3-­II   levels   were  
quantified   by   densitometry   and   normalized   for   β-­actin.   LC3   flux   was   quantified   by  





Quantitative  Real-­Time  PCR  
Total   RNA   was   extracted   with   the   RNeasy®   kit   (Qiagen)   and   converted   to  
complementary   DNA   with   the   QuantiTect   reverse   transcription   kit   (Qiagen).  
Quantitative   RT–PCR   reaction   was   performed   using   a   TaqMan   Assay   (Life  
Technologies).   Fold-­change   in   gene   expression   was   calculated   using   the  
2−ΔΔCTmethod,  based  on  biological   reference  samples  and  β-­actin  messenger  RNA  
levels   for   normalization.   All   the   results   were   obtained   from   the   evaluation   of   two  
technical  duplicates  of   three   independent  experiments.  See  Appendix  Table  9.5   for  
the  list  of  primers  used.  
  
Immunocytochemistry  
Cells   were   fixed   in   4%   paraformaldehyde   for   15 min,   permeabilized   in   ice   cold  
methanol,  rinsed  with  PBS  and  blocked  by  10%  normal  goat  serum  before  incubation  
with  primary  and  secondary  antibodies.  Anti-­glucocerebrosidase   (Sigma)  was  used  
at   a   concentration   of   1:50   and   anti-­cathepsin   D   (Abcam)   at   1:200.   Images   were  
captured  with  a  Zeiss  LSM  510  (Carl  Zeiss)  confocal  microscope  using  a  40  ×  1.3NA  
plan-­apochromat  oil  objective,  at  an  excitation  of  488nm  (for  Alexa  Fluor  Green)  or  
568nm  (for  Alexa  Fluor  Red).  Individual  cells  were  marked  and  mean  fluorescence  of  
individual  cells  measured  by  the  ImageJ  software  (NIH,  USA);;  where  the  image  was  
captured  with  z-­stack,  z-­projection  was  performed  using  maximum  intensity  and  net  
fluorescence   was   obtained   by   subtracting   the   background   fluorescence.     Co-­
localization  of  GBA/cathepsin  D  in  fibroblasts  was  quantified  with  the  ‘JACoP’  plug-­in  




Data   are   expressed   as   mean   ±   SEM   and   statistical   significance   between   groups  
determined  by  one-­way  ANOVA  followed  by  the  two-­tailed  t-­Test.  A  p  value  of  <  0.05  
was  considered  as  significantly  different.  All  data  were  analysed  by  GraphPad  Prism  
6  statistical  software  (GraphPad  Software).  
  
  Results  
Reduced  GCase  activity,  protein  and  gene  expression  levels  in  GBA  mutant  
fibroblasts  
GCase  activity   was   significantly   reduced   in  heterozygous   GBA   mutation   carrier  
fibroblasts   compared   to   healthy   control   cells.   Quantitative   analysis   of  
intracellular  GBA  protein   levels   in   cells   of   different   patients   by   western-­blotting  
revealed  that  protein   levels  of   the  enzyme  were  also  reduced  in  heterozygous  GBA  
mutation  carriers  compared  with  healthy  control  cells.  I  compared  the  levels  of  GBA  
mRNA   using   quantitative   PCR.   I   found   that   the   amount   of  GBA  mRNA   expressed  
in  heterozygous   GBA   mutation   carriers   was   significantly   reduced   compared   to  
controls  (Figure  7.9).    
  
Defective  localization  of  GBA  protein  in  GBA  mutant  fibroblasts  
To  evaluate  the  localization  of  GBA,  I  performed  immunocytochemistry  for  each  cell  
line   using   antibodies   to   cathepsin   D,   a   lysosomal   marker,   and  GBA.   The   GBA  
signals  were   clearly   stronger   in   control   and   idiopathic  PD   (IPD)   cells   compared   to  
heterozygous   GBA   mutation   carrier   cells.   Control   and   IPD   cells   showed  
colocalization   of   GBA   and   cathepsin   D.   Overall,   the   strength   of   signal   and   the  
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distribution   of  GBA  did   not   differ   between   control   and   IPD   cell   lines.   In   contrast,   I  
observed   a   decreased   degree   of   co-­localization   between   GBA  and  cathepsin   D  
in  heterozygous  GBA  mutation   carrier   cells  when   compared   to   control   cells,  which  
may  suggest  impaired  trafficking  of  GBA  in  GBA  mutant  fibroblasts  (Figure  7.10).    
  
Inadequate  unfolded  protein  response  (UPR)  in  GBA  mutant  and  PD  
fibroblasts    
To  evaluate   the  effect   of   the  GBA  mutation  on   the  UPR,   I   performed  western  blot  
analysis  of   the  major  UPR  protein  BiP/GRP78.  My   results  demonstrated  a  marked  
reduction   in  UPR  signal   in  heterozygous  GBA  mutation  carriers  (Figure  7.11).  This  
reduction  was  also  seen  in  PD,  independent  of  GBA  mutation  status.  Heterozygous  
GBA  mutation  carriers  and  PD  cells   show   reduced  GRP78  expression,   suggesting  
an  inadequate  UPR.      
  
Lysosomal  content  and  function  is  unaltered  in  GBA  mutant  fibroblasts  
To   assess   the   effect   of   the   GBA  mutation   on   lysosomal   content   and   function,   I  
analysed   the   autophagic/lysosomal   machinery   in  GBA  mutant   fibroblasts.   Enzyme  
assays  were  performed  for  hexosaminidase  and  β-­galactosidase  activity.  There  were  
no   changes   in   the   activity   of   the   lysosomal   enzymes   between   the   cell   lines;;  
hexosaminidase  and  β-­galactosidase  activity  were  not  significantly  different  between  
control,   heterozygous  GBA  mutation  carrier  or   IPD  cells   (Figure  7.12).     To  extend  
my   investigation,   I  measured   the   lysosomal   content   of   the   cells   by   LAMP1   levels.  
Immunoblotting   for   LAMP1,   a   lysosomal   marker,   did   not   reveal   any   significant  
increase  in  LAMP1  protein   in  heterozygous  GBA  mutation  carriers,  IPD  and  control  
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fibroblasts,  suggesting  no  accumulation  of  lysosomes  (Figure  7.12).  Taken  together,  
these   data   indicate   that   there   is   no   alteration   of   lysosomal   mass   or   number   in  
heterozygous  GBA  mutation  carriers.     
  
Lysosomal  autophagic  defects  in  GBA  mutant  fibroblasts  
Autophagy  has  a  role  in  quality  control  and  activation  of  autophagy  forms  part  of  the  
cellular   response   to   ER   stress   (Schneider   and   Cuervo,   2014a).   To   examine  
lysosomal   function   and   macroautophagy,   I   first   investigated   the   autophagosome  
content   by  measuring   levels   of   endogenous   light   chain   type   3   protein   (LC3),   a  
marker  of  autophagosomes  by  western  blot.  This  revealed  a  significant  decrease  in  
basal  levels  of  LC3-­II  in  GBA  mutation  carrier  fibroblasts,  suggesting  an  impairment  
of   the   rate   of   autophagosome   formation.   Treatment   with   bafilomycin   revealed  
significant  increases  in  LC3-­II  flux  in  all  cell  lines,  and  therefore  no  impairment  of  the  
fusion  of  autophagosomes  with   lysosomes  in  GBA  mutant  fibroblasts  (Figure  7.13).    
In  comparison,  under  basal  conditions  there  was  a  further  significant  decrease  in  p62  
levels   in   heterozygous   GBA   mutation   carriers   compared   to   controls   (data   not  
shown).                       
Given   the   potential   cross-­talk   among   proteolytic   systems   and   the   evidence   of  
potential   macroautophagic   compromise,   I   investigated   the   chaperone   mediated  
autophagy  (CMA)  pathway.  Using  the  heat  shock  cognate  protein  of  70kDa  (Hsc70)  
which   targets   substrates   to   the   lysosome   surface,   and   the   lysosome-­associated  
membrane   protein   type   2A   (LAMP2a)   receptor   as   markers   for   CMA,   a   significant  
reduction   of   LAMP2a   protein   associated   with   the   presence   of  GBA  mutation   was  
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seen   in   heterozygous  GBA   mutation   carriers,   while   levels   of   Hsc70   did   not   differ  
between  controls,  heterozygous  GBA  mutation  carriers,  or  PD  cells  (Figure  7.13).    
  
  Discussion  
The  contribution  of  mutations  of  GBA  and  reductions  in  GCase  activity  in  fibroblasts  
was   recently   studied   in   samples   from   PD   patients   with   and   without  the  
GBA  mutation,  and  in  GD  (McNeill  et  al.,  2014).  I  have  extended  these  investigations  
to   help   define   the   exact   mechanisms   by   which   GBA   mutations   predispose   to  
neurodegeneration   in   order   to   facilitate   the   development   of   a   novel   treatment  
strategy.  I  have  shown  for  the  first  time  that  there  is  a  defective  localisation  of  GBA  in  
GBA   mutant   fibroblasts,   the   UPR   protein   BiP   is   reduced   and   could   reflect   an  
inadequate   UPR,   and   finally,   GBA   mutant   fibroblasts   demonstrate   defects   in  
lysosomal  autophagy.  
  
My   data   supports   those   of   others   (Sun   et   al.,   2012;;   Bendikov-­Bar   et   al.,   2013;;  
McNeill   et   al.,   2014)   by   confirming   that   the   GBA  mutation   is   associated   with   a  
reduction   in  GCase   activity.     However,   the   level   of  GCase   activity   varied   between  
mutations   and   is   to   some   degree,   patient   dependent.   I   measured   GCase   activity  
predominantly  from  those  heterozygous  for   the  GBA  mutation,  where   levels  ranged  
between   50-­70%   of   the   wild   type   level.   In   a   patient   homozygous   for   the   GBA  
mutation,   the  GCase  activity  was  ~2.5%  of   the  wild   type   level  (Figure  7.27),  which  
matches  previous  data  (McNeill  et  al.,  2014).  Loss  of  GCase  activity  was  associated  
with  decreased  protein  levels  of  GBA  and  mRNA  levels  indicating  this  loss  of  activity  
was  induced  by  decreased  transcription.  In  a  recent  study,  other  lysosomal  enzymes  
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were   altered   in   fibroblasts   from   PD   patients   positive   for   the   GBA  mutation   with  
increases   seen   in   cathepsin   D   and   β-­hexosaminidase,   laying   support   for   a   global  
dysregulation  of  lysosome  functioning  (McNeill  et  al.,  2014).  In  the  present  study,  the  
activity  of  β-­hexosaminidase  and  β-­galactosidase  did  not  show  significant  change  in  
any   of   the   fibroblasts   studied.   There   was   minimal   change   identified   in   lysosomal  
marker  LAMP1.  These  data   suggest   that   the  defect   in  GCase  may  be   selective   in  
PD,  with  no  overall  change  in  lysosomal  number  or  mass.      
  
Studies  of  PD  brain  have  identified  reductions  in  GCase  activity  involving  substantia  
nigra   (reduced   58%),   putamen   (48%),   amygdala   (40%)   and   cerebellum   (47%)   in  
those  positive   for   the  GBA  mutation.  What  was  perhaps  surprising  was   the   finding  
that   GCase   activity   was   also   significantly   decreased   in   the   substantia   nigra   (33%  
decrease)   and   cerebellum   (24%  decrease)   of   sporadic  PD  brain.  This   implied   that  
reductions   in   GCase   activity   could   hold   a   wider   significance,   not   just   for   those  
carrying  the  GBA  mutation,  but  for  PD  in  general.  I  also  noted  reductions  of  GCase  
activity   and   protein   in   skin   cells   obtained   from   PD   patients   negative   for   the  GBA  
mutation,  albeit  this  reduction  was  not  statistically  significant.  There  is  now  evidence  
not   only   for   decreasing   lysosomal   numbers   and   function   with   age,   but   an   age-­
dependent  reduction  in  GCase  activity  which  may  lower  the  threshold  for  developing  
PD   (Rocha   et   al.,   2015).   It   is  worth   noting   that   the  PD  patient   group   in   this   study  
were  older,  and  if  the  GCase  activity  measurements  were  repeated,  I  would  ensure  
that  patient-­derived  fibroblasts  were  more  closely  age  matched.    
  
The  majority  of  GBA  mutations  result  in  a  misfolded  protein  which  is  retained  in  the  
endoplasmic  reticulum  (ER)  demonstrated  by  an  increase  in  the  endoglycosidase-­H  
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sensitive   fraction   of   GCase   (McNeill   et   al.,   2014).   The   presence   of   misfolded  
proteins,  such  as  GCase,  in  the  ER  is  proposed  to  induce  ER  stress  and  contribute  
to   the   development   of   PD   (McNeill   et   al.,   2014).     ER   stress   activates   a   signalling  
network   known   as   the   UPR   to   reduce   ER   stress   and   restore   ER   homeostasis  
(Oslowski   and   Urano,   2011).   Accumulation   of   protein   can   activate   the   unfolded  
protein  response  (UPR)  and  endoplasmic  reticulum  associated  degradation  (ERAD).  
The  2  most  common  GBA  mutations  associated  with  PD  (N370S  and  L444P)  have  
been   reported   to  become   trapped   in   the  ER  and   trigger   the  UPR  and  ERAD   (Ron  
and  Horowitz,  2005;;  Mu  et  al.,  2008;;  Lu  et  al.,  2010).    Markers  of  UPR/ERAD  were  
found  to  be  increased  in  the  GBA-­PD  brain,  supporting  a  role  for  this  pathway  in  the  
pathogenesis  of  PD  in  these  patients.  Aberrant  trafficking  of  GBA  might  contribute  to  
this   increase   in   UPR/ERAD.   However,   ER   stress   can   also   be   a   consequence   of  
perturbed  calcium  homeostasis,  oxidative  stress,  or  mitochondrial  dysfunction,  all  of  
which  are  implicated  in  the  pathogenesis  of  PD.  In  2  GD  mouse  studies,  there  was  
no  evidence  of  UPR/ERAD  activation  in  the  brain  (Farfel-­Becker  et  al.,  2009;;  Cullen  
et  al.,  2011).  Furthermore,  a  recent  study  of  post-­mortem  frontal  cortex  tissue  from  7  
GBA   mutation   carriers   with   DLB,   and   5   GBA   mutation   carriers   with   no   signs   of  
neurological  disease,  reports  the  UPR  regulator  BiP/GRP78  is  reduced  by  the  GBA  
mutation   and   this   is   a   general   phenomenon   in   DLB.   Indeed,   my   data   also  
demonstrates   reductions   in  UPR  signal   in  heterozygous  GBA  mutation  carriers  but  
also   PD   in   general,   independent   of   GBA  mutation   status.   Individuals   with   GBA  
mutations   and   those   with   PD   show   reduced   GRP78   expression,   suggesting   an  




Recent   data   has   provided   increasing   evidence   of   a   role   for   altered   lysosomal  
function  in  the  pathogenesis  of  PD  (Tofaris,  2012;;  McNeill  et  al.,  2014;;  Murphy  et  al.,  
2014a).  Reduced  GCase  activity  has  been  reported  in  PD  brain  (Gegg  et  al.,  2012;;  
Murphy  et  al.,  2014a),  with  and  without  mutations  in  the  GBA  gene.  It  has  also  been  
demonstrated  that  lysosomal  dysfunction  occurs  early  in  GBA  mutation-­negative  PD.  
In   early   stage   PD   anterior   cingulate   cortex,   there   is   a   selective   upregulation   of  
cathepsin   A   and   D   protein   and   reductions   in   LAMP2,   a   marker   of   chaperone-­
mediated  autophagy  (CMA)  (Murphy  et  al.,  2014a).  Authors  imply  that  this  might  be  
relevant   to   reduced   degradation   of   SNCA.   My   study   of   fibroblasts  
from  GBA  mutation-­positive  patients,  and  those  of  others  (McNeill  et  al.,  2014),  also  
demonstrate  evidence  of  altered   lysosomal   function.  My   results   reveal  a  significant  
decrease   in  basal   levels  of  LC3-­II   in  GBA  mutation  carrier   fibroblasts   indicating  an  
impairment  of  macroautophagy.  Cells  can  compensate   for   loss  of  macroautophagy  
by   upregulating   CMA   or   the   ubiquitin-­proteasome   system   (Schneider   and   Cuervo,  
2014a).   I   further   identified   reductions   of   CMA.   The   selective   loss   of   lysosomal  
GCase  appears  to  be  directly  related  to  defects  of  lysosomal  autophagy.  
  
SNCA  is  predominantly  turned  over  through  chaperone  mediated  autophagy  (CMA)  
and  to  a   lesser  degree  through  macroautophagy.  Abnormalities  of  CMA  have  been  
identified   in  PD  brain   (Cuervo  et  al.,  2004;;  Alvarez-­Erviti  et  al.,  2010).  Our   lab  has  
also  shown  that   impaired   lysosomal   function  can  enhance   the  exosomal   release  of  
SNCA  (Alvarez-­Erviti  et  al.,  2011).  Furthermore,  decreased  GCase  activity  promotes  
propagation   of   SNCA   aggregates   (Bae   et   al.,   2014).   In  my   studies,   LAMP2a  was  
reduced   in   GBA   mutation   carrier   fibroblasts   but   this   did   not   correlate   with   a  
coexistent   reduction/increase   in   Hsc70.   However,   it   appears   that   the   rate   limiting  
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step  for  CMA  is  the  binding  of  the  substrate  proteins  to  LAMP2a  and,  consequently,  
levels   of   LAMP2a   at   the   lysosomal  membrane   correlate   directly   with  CMA   activity  
(Schneider   and   Cuervo,   2014b).   Therefore,   to   modulate   the   activity   of   this  
autophagic  pathway,  the  cell  stringently  regulates  the  levels  of  the  CMA  receptor  at  
the  lysosomal  membrane  by  controlling  the  degradation  rates  of  LAMP2a  monomers  
in  lysosomes  and  by  de  novo  synthesis  of  LAMP2a  molecules.  In  addition,  transport  
of   substrates   also   depends   on   the   efficiency   of   the   assembly   of   LAMP2a   into   the  
translocation   complex.   This   could   explain   why   reductions   of   LAMP2a   were   noted  
with  no  coexistent  change  in  Hsc70.  
 
In   conclusion,   I   observed   a   50-­70%   decrease   in   the   enzymatic   activity   of  
glucocerebrosidase,   protein   level   and   gene   expression   in  GBA   mutation   carriers.  
This  was  associated  with  lysosomal  abnormalities  including  defective  localization  of  
GBA  protein  and   impaired   lysosomal  autophagy.  These  data  provide  support   for  a  
link   between  GBA  mutations   and   changes   in   the   autophagic/lysosomal   system,  
which  could  predispose  to  neurodegeneration.  My  results   indicate  that  mutations   in  
GBA   could   lead   to   lysosomal   abnormalities,   enhanced   by   an   impaired   UPR,   and  
therefore,   have   the   potential   to   cause   SNCA   accumulation.   The   discovery   of   a  
connection  between  GBA  mutations  and  PD  has  provided  invaluable  insights  into  the  
pathogenesis   of   this   disease   and   provides   opportunities   to   target   the   GCase–






4.3    Characterisation   of   the   adipose   NCSC-­derived   dopaminergic  
model  related  to  Parkinson’s  disease  and  the  biochemical  effect  of  
the  GBA  mutation  
  
OBJECTIVE                                                                                                           
To  use  human  dopaminergic  neurons  derived  from  their  adipose-­derived  neural  crest  
stem   cells   from   controls   and   individuals   carrying   the   GBA   mutation,   in   order   to  
characterise   the  biochemical  defects  associated   to  mutant  GBA  and   to  PD,  and   to  
investigate  the  relationship  between  GCase  and  SNCA  in  PD.  
  
  Introduction  
The  pathological  hallmarks  of  PD   include   the  presence  of   insoluble  oligomeric  and  
fibrillar  SNCA  positive  inclusions,  the  formation  of  LBs  and  the  loss  of  dopaminergic  
neurons   in   the   SNpc.   Numerically,   the   most   important   genetic   risk   factor   for   the  
development  of  PD  is  the  presence  of  a  mutation  of  GBA.      
  
Both  gain-­of-­function  and  loss-­of-­function  of  GCase  effects  have  been  proposed  as  
mechanisms   contributing   to   PD   pathogenesis,   leading   to   substrate   accumulation,  
disturbances   in   lysosomal   function/trafficking,   and   SNCA   aggregation.   It   has   been  
suggested  that  reductions   in  GCase  could  contribute  to  SNCA  aggregation  through  
direct  interaction  with  SNCA  or  interference  with  SNCA  homeostasis  pathways  such  
as   the   unfolded   protein   response   or   autophagy.   However,   the   exact   molecular  




Important   progress   in   understanding  PD   pathogenesis   has   been   based   on   human  
post-­mortem  samples,  chemically-­lesioned  animals,   transgenic  animals  and   in  vitro  
models;;  however  these  models  all  have  limitations.  I  used  a  novel  human  neuronal  
cell  model   originating   from  heterozygous  GBA  mutation  positive   subjects,   in  which  
neural   crest   stem   cells   were   isolated   from   GBA   heterozygous   mutated   subjects’  
adipose  tissues.  The  isolated  neural  crest  stem  cells  were  differentiated  to  functional  
dopaminergic   neurons   with   high   efficiency.   The   activities   of   GCase   enzyme   in  
differentiated  neurons  were  measured;;   and   the  mRNA  and  protein   level   of  GCase  
and  SNCA  were  determined.  The  effect  of  GCase  activity  on  lysosomal  function,  and  
the  expression  and  aggregation  of  SNCA  was  then  investigated.    
  
This   model   has   successfully   mimicked   specific   biochemical   features   of   GBA-­
associated   PD   and   offers   a   unique   opportunity   to   examine   cell-­type   specific  
pathology  in  the  vulnerable  dopaminergic  neurons  derived  from  PD  patients.  These  
cells  provide  a  suitable  platform  for  drug  screening  for  drugs  that  may  target  selected  
pathways  in  PD  pathogenesis.  
  
Finally,   these  data  provide   insight   into   the  relationship  between  GCase,  SNCA  and  
lysosomal   impairment,  and  helps   to  delineate   the  cellular   function  of  GCase   in   the  






Differentiation  of  adipose  NCSC  to  dopaminergic  neurons                                        
Adipose   NCSC   were   differentiated   to   functional   DA   neuronal   cells   using   a   fully  
defined  step-­wise  differentiation  protocol.  Cells  were  collected  by  centrifugation  and  
seeded   at   a   density   of   8000   cells   per   35mm2   dish   coated   with   collagen   (Sigma-­
Aldrich).   On   the   next   day,   DMEM   was   changed   to   Neurobasal/B27   containing  
medium   supplemented   with   1%   fungizone   and   1%   penicillin–streptomycin.   For  
dopaminergic   differentiation,   I   used   a   cocktail   of   sonic   hedgehog   (SHH),   fibroblast  
growth   factor   8   (FGF-­8),   and   basic   fibroblast   growth   factor   (FGF-­β)   under   a   low  
serum  condition   for   10  days.  On  day  10,  brain-­derived  neurotrophic   factor   (BDNF)  
was   added   to   the   differentiation   medium.   After   12   days,   differentiated   human  
adipose  NCSC  adopted  a  neuronal  morphology.  By  day  40,  the  differentiated  NCSC  
lines   were   characterised   by   expression   of  β-­Tubulin   III   (a   marker   of   neurons),  
tyrosine  hydroxylase  (TH)  (a  marker  of  dopaminergic  neurons),  and  nuclear  receptor  
related  1  protein  (NURR1)  (a  marker  of  midbrain  DA  phenotype)  (Figure  7.14).  No  
significant  differences  in  differentiation  potential  were  observed  among  control,  GBA  
mutation  positive  carrier,  and  PD   lines.   Immunostaining   revealed   the  expression  of  
β-­Tubulin   III   proteins   in   the   differentiated   adipose   NCSC   (see   Figure   7.15).  
Functional  analysis  demonstrated  that  56%  of  cells  responded  to  dopamine  (Figure  
7.16).    
  
Lysosomal  enzymatic  activity  assays  
See  section  4.2.2.                             
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Western  blot  analysis  
Cells   were   harvested,   washed   with   PBS,   and   processed   as   previously   described  
(McNeill  et  al.,  2014).  Proteins  were  extracted  using  urea/SDS  buffer  (8M  urea,  2%  
SDS,  10mM  Tris)  containing  protease   inhibitors  on   ice.   In   total,  40μg  of   the  protein  
lysate  was  loaded  on  a  4–12%  Bis-­Tris  Gel  (NuPAGE,  Invitrogen)  and  transferred  to  
a   polyvinylidene   difluoride   membrane   (Millipore,   Watford,   England).   The   following  
antibodies   were   used:  mouse   anti-­GBA   (Calbiochem),   rabbit   anti-­β-­actin   (Abcam),  
rabbit   anti-­LAMP1   (Abcam),   rabbit   anti-­LAMP2a   (Abcam),   rabbit   anti-­Hsc70  
(Abcam),   rabbit  anti-­GAPDH   (Abcam),   rabbit  anti-­LC3   (Cell   signaling),  mouse  anti-­
Synuclein   (Abcam),   rabbit   anti-­tublulin   (Abcam),   and   mouse   anti-­p62   (BD  
Biosciences).  Horseradish  peroxidase  goat  anti-­mouse  (Dako),  anti-­rabbit  (Dako)  or  
anti-­goat  (Dako)  secondary  antibodies  and  Clarity  Western  ECL  kits  (BioRad)  were  
used.  Analyses  were   prepared   using   Image   Lab   software   (BioRad).   See  Appendix  
Table  9.4  for   the   full   list  of  antibodies  used.  Full-­length   images  of   immunoblots  are  
shown  in  Appendix  Figure  9.11.  
  
Autophagy  studies  
Where   indicated,   cells   were   treated   with  0.2µM   bafilomycin   (EMD,   Millipore)   for   6  
hours  at  37  °C   in   the  presence  of  5%  CO2,  and  then  fixed  or   lysed  for  western  blot  
analysis.   LC3/LC3-­II   levels   were   quantified   by   densitometry   and   normalized   for   β-­
actin.  LC3  flux  was  quantified  by  dividing  levels  of  LC3-­II  after  bafilomycin  treatment  





Cells  were  fixed  in  4%  paraformaldehyde  for  10 min,  rinsed  with  PBS,  permeabilized  
in  0.25%  triton  x100  for  10  mins,  rinsed  with  PBS  again  and  blocked  by  10%  normal  
goat  serum  before  incubation  with  primary  and  secondary  antibodies.  Anti-­synuclein  
(Abcam)  was  used  at  a  concentration  of  1:500,  anti-­tubulin   (Abcam)  at  1:500,  anti-­
Nurr1   (Abcam)   at   1:200   and   anti-­tyrosine   hydroxylase   (Abcam)   at   1:1000.   Images  
were  captured  with  a  fluorescent  microscope  using  a  40  ×  objective,  at  an  excitation  
of   488nm   (for  Alexa  Fluor  Green)   or   568nm   (for  Alexa  Fluor  Red).   Individual   cells  
were  marked.  See  Appendix  Table  9.4  for  the  list  of  antibodies  used.    
  
Statistical  analysis  
Data   are   expressed   as   mean   ±   SEM   and   statistical   significance   between   groups  
determined  by  one-­way  ANOVA  followed  by  the  two-­tailed  t-­Test.  A  p  value  of  <  0.05  
was  considered  as  significantly  different.  All  data  were  analysed  by  GraphPad  Prism  
6  statistical  software  (GraphPad  Software).  
  
  Results  
To   characterise   the   chosen   model,   preliminary   experiments   were   performed   at  
different  stages  of  neuronal  differentiation  (0,  12,  20  and  40  days)  in  a  control  and  a  
GBA   mutant   NCSC   line.   These   measurements   confirmed   that   adipose   NCSC-­
derived  neurons  model  many  of   the  biochemical   defects   seen   in   the   fibroblast   cell  
model  and  agree  with   iPSC  data  obtained  by  other  groups  (Schöndorf  et  al.,  2014;;  
Woodard  et  al.,  2014).  Following  these  preliminary  experiments,  I  went  on  to  perform  
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the   main   measurements   for   all   cell   lines   at   differentiation   day   40   in   mature  
dopaminergic  neurons.  
  
GCase  activity  at  different  stages  of  neuronal  differentiation  
Control  and  heterozygous  GBA  mutation  positive  carrier  NCSCs  were  differentiated  
to  DA  neurons  for  12,  20,  and  40  days.  The  GCase  activity  was  measured  at  day  0,  
12,   20   and   40.   The   GCase   activity   was   reduced   in   heterozygous  GBA   mutation  
positive  neurons  compared  with  healthy  control  cells   for  all   time  points  of  neuronal  
differentiation  (Figure  7.17).    
  
GCase  protein  levels  at  different  stages  of  neuronal  differentiation  
Quantitative  analysis  of  intracellular  GCase  protein  levels  in  cells  of  different  patients  
by   western-­blotting   revealed   that   protein   levels   of   the   enzyme   were   also   reduced  
in  heterozygous  GBA  mutation  positive  carriers  compared  with  control  individuals  for  
all  time  points  of  neuronal  differentiation  (Figure  7.18).    
  
SNCA  levels  at  different  stages  of  neuronal  differentitation  
The   SNCA   protein   level   was   increased   in   heterozygous  GBA   mutation   positive  
neurons   compared   with   healthy   control   cells   for   all   time   points   of   neuronal  
differentiation   (Figure   7.19).   This   increase   was   maximal   at   an   early   stage   of  




Macroautophagy  at  different  stages  of  neuronal  differentiation  
Quantitative  analysis  of  LC3  protein   levels   in  cells  of  different  patients  by  western-­
blotting   revealed   that   protein   levels   of   LC3-­II   were   markedly   reduced  
in  heterozygous  GBA  mutation  positive  carriers  compared  with  control  individuals  for  
all   time   points   of   neuronal   differentiation   suggesting   an   impairment   of  
macroautophagy  (Figure  7.20).    
  
Chaperone  mediated  autophagy  at  different  stages  of  neuronal  differentiation  
Given   the   potential   cross-­talk   among   proteolytic   systems   and   the   evidence   of  
potential   macroautophagic   compromise,   I   investigated   chaperone   mediated  
autophagy  (CMA).  Using  lysosome-­associated  membrane  protein  type  2A  (LAMP2a)  
receptor  as  a  marker  for  the  CMA  pathway,  a  significant  increase  of  LAMP2a  protein  
associated   with   the   presence   of  GBA  mutation   was   seen   in   heterozygous   GBA  
mutation   carriers   at   20   days   neuronal   differentiation   (Figure   7.21).   This   suggests  
that   CMA   may   act   as   an   alternative   way   to   compensate   for   the   deficiency   of  
macroautophagy   in   GBA   mutant   NCSC-­derived   neuronal   cells.   The   levels   of  
LAMP2a  decreased  significantly   in  GBA  mutant  stem  cell-­derived  neuronal  cells  at  
40  days  indicating  the  chaperone-­mediated  autophagy  pathway  may  be  upregulated  
at   an   early   stage   of   neuronal   differentiation   to   compensate   for   impaired  
macroautophagy  as  a  way  to  clear  SNCA.    
    
Reduced  GCase  in  GBA  mutant  neurons    
Control,  heterozygous   GBA   mutation   positive   carrier,   and   IPD   NCSCs   were  
differentiated   for  40  days  and  neuronal   cultures  were  predominantly  dopaminergic.  
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The  GCase  activity  was  significantly  reduced  in  heterozygous  GBA  mutation  positive  
neurons  compared  with  healthy  control  cells  (Figure  7.22).  Importantly,  control  lines  
showed   a   significantly   higher   average   of   enzymatic   activity   compared   with   GBA  
positive   lines.   Quantitative   analysis   by   western-­blotting   revealed   that   GBA   protein  
levels  were  also  reduced  in  heterozygous  GBA  mutation  positive  carriers  compared  
with  control  individuals  (Figure  7.22).  
  
Increased  α-­synuclein  levels  in  GBA  mutant  neurons    
A   direct   link   between  GCase  and   SNCA  accumulation   has   previously   been   shown  
(Manning-­Boğ  et  al.,  2009;;  Mazzulli  et  al.,  2011;;  Sardi  et  al.,  2011).  Furthermore,   it  
has   been   shown   that   heterozygous  GBA  mutations   are   linked   to   increased   levels  
of  SNCA.  I  sought  to  confirm  the  effects  of  GBA  mutations  on  SNCA  accumulation  in  
differentiated   NCSCs.   NCSCs   from   controls,  heterozygous  GBA  mutation   positive  
carriers   and   PD   subjects   were   differentiated   for   40   days   to   DA   neurons,  
and  SNCA  levels   were   measured   by   western   blot.   It   is   known   that   differences   in  
expression   levels   of  SNCA  are   influenced   by   individual   genetic   background,   which  
could   explain   the   high   variability   of  SNCA  expression   in   the   general   population  
(Fuchs   et   al.,   2008).   I   measured  SNCA  levels   in   neuronal   cultures   from  GBA  
mutation  positive  NCSC-­derived  neurons  and  corresponding  GBA  negative  controls.  
A   significant   increase   in  SNCA  protein   levels   was   found   in  GBA   mutation   positive  
neurons   carrying   the   N370S   allele   compared   with   controls   (Figure   7.23).  
Immunofluorescent   staining   for  SNCA   revealed   a   significant   increase   in   SNCA  in  
GBA   mutation   positive   NCSC-­derived   neurons   compared   with   healthy   individuals,  
suggesting   an   accumulation   of   SNCA   (Figure   7.23).  Reduced   glucocerebrosidase  
protein  was  associated  with  increased  SNCA  protein  levels  in  GBA  mutant  neurons,  
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while   higher   levels   of   glucocerebrosidase   protein   were   associated   with   reduced  
SNCA   protein   levels   in   control   cells.   This   data   suggests   the   relationship   between  
GCase   and  SNCA  may   be   leveraged   to   reduce  SNCA   levels   in  PD   by   enhancing  
GCase  levels  and  activity  (Figure  7.23).      
  
Lysosomal  and  autophagic  defects  in  GBA  mutant  neurons    
To   extend   these   findings,   I   analysed   the   autophagic/lysosomal   machinery  
in  GBA  mutant   neurons   differentiated   for   40   days.   To   examine  macroautophagy,   I  
first  investigated  the  autophagosome  content  by  immunoblot  for  basal  levels  of  light  
chain   type   3   protein   (LC3),   a  marker   of   autophagosomes.  My   analysis   revealed   a  
decrease,  albeit  not  statistically  significant,  of  LC3-­II  in  GBA  mutation  positive  carrier  
neurons  compared  with  control  neurons  (Figure  7.24).  These  results  were  confirmed  
on   further   immunoblotting,   which   showed   a   coexistent   decrease   in   basal   levels   of  
p62   in  heterozygous   GBA   mutation   positive   carrier   neurons   (Figure   7.24).  
Bafilomycin   treatment   revealed   that   LC3-­II   was   significantly   increased   in   GBA  
mutation   positive   carrier   neurons   compared   to   control   cells   (Figure   7.25).   This  
suggested  no  impairment  of  autophagosome-­lysosome  fusion.  
  
Lysosomal  content  is  unaltered  in  GBA  mutant  neurons    
Immunoblot  staining  for  LAMP1,  a  lysosomal  marker,  revealed  no  significant  change  
in   LAMP1  protein   in   patient   NCSC-­derived   neurons   compared   with   healthy  
individuals,  suggesting  no  significant  change  of  lysosomal  content  (Figure  7.26).  To  
examine   chaperone   mediated   autophagy   (CMA),   I   performed   immunostaining   for  
LAMP2a,   a   marker   of   CMA.  My   analysis   revealed   no   significant   change   in   basal  
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levels   of   LAMP2a   in  GBA   mutation   positive   carrier   neurons   when   compared   to  
control  cells  (Figure  7.26).    
  
  Discussion  
In   this   study,   human   adipose   NCSC   were   isolated   from   the   subcutaneous   fat  
collected   from   wild   type   (n   =3),   heterozygous  GBA   mutation   positive   (N370S/wt)  
carrier   (n   =   3)   and   PD   patients   (n   =   3),   and   differentiated   into   functional   human  
dopaminergic   (DA)   neurons.   N370S   point   mutations   are   the   most   frequent   GD-­
causing  alleles  that  have  been  linked  to  PD  (Sidransky  et  al.,  2009b).  NCSCs  were  
efficiently  differentiated  to  DA  neurons  without  significant  differences.  
The  neuronal  model  used  in  this  study  recapitulates  many  of  the  defects  I  identified  
in  the  fibroblast  model  (section  4.2.3),  as  well  as  those  observed  in  the  human  brain  
(Gegg   et   al.,   2012;;  Murphy   et   al.,   2014b),   including   reductions   in  GCase   enzyme  
activity   and   protein   level,   and   lysosomal   abnormalities   including   impairments   of  
lysosomal   autophagy.   In   addition,   elevated   levels   of   SNCA   have   been   seen   in  
adipose  NCSC-­derived  neuronal   cultures   from  GBA  N370S  patients.  This   supports  
my   hypothesis   that   abnormalities   of   relevance   to   PD   pathogenesis   expressed   in  
human  fibroblasts  are  also  seen  in  dopaminergic  neurons  derived  from  their  adipose-­
derived  NCSC  and  secondly,  reduced  GCase  is  associated  with  increased  SNCA.  
PD   patients   carrying  GBA  mutations   show   classic   PD   pathology   with  
widespread  SNCA  inclusions   (Velayati   et   al.,   2010).   The   exact   mechanism   is  
unknown,  and  both  gain  of   function  and  loss  of   function  hypotheses  have  been  put  
forward.   It   has   been   suggested   that   a   relationship   could   exist   between   the   two  
proteins   and   that  GBA  mutations   could   contribute   to   SNCA   aggregation   through   a  
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direct  interaction.  In  support  of  such  a  gain  of  function  hypothesis  is  the  presence  of  
mutant   GBA   in   SNCA-­positive   LBs,   as   demonstrated   by   immunohistochemistry  
studies   (Goker-­Alpan   et   al.,   2010).   In   support   for   a   loss   of   function   hypothesis,   a  
deficiency  of  GCase  could  lead  to  an  accumulation  of  substrate,  which  could  in  turn  
influence  the  amyloid  formation  of  SNCA,  and  the  resulting  toxic  build-­up  of  insoluble  
SNCA   within   lysosomes   could   in   turn   compromise   lysosomal   protein   degradation,  
and  further  impair  the  trafficking  of  GCase,  exacerbating  substrate  accumulation  and  
SNCA  aggregation  (Mazzulli  et  al.,  2011).  
The   link   between   GCase   and   SNCA   was   first   demonstrated   in   vitro   by   the  
overexpression   of   mutant  GBA,   whereupon   mutant   forms   increased   SNCA   levels  
(Cullen  et  al.,  2011).  GCase  deficiency,  overexpression  of  mutant  GBA,  or  inhibition  
of  GCase   by   condruitol   β-­epoxide   (CβE)   can   all   interfere  with   the   clearance   of   or  
promote   the   aggregation   of   SNCA   (Manning-­Boğ   et   al.,   2009;;  Cullen   et   al.,   2011;;  
Mazzulli   et   al.,   2011;;   Xu   et   al.,   2011;;   Gegg   et   al.,   2012;;   Cleeter   et   al.,   2013;;  
Osellame   et   al.,   2013).   Although,   short-­term   exposure   to   CβE   does   not   increase  
SNCA   levels   in   rat   cortical   neurons   (Dermentzaki   et   al.,   2013).   In   contrast,   the  
overexpression   of   SNCA   leads   to   a   reduction   in  GCase   activity   in   SH-­SY5Y   cells  
(Gegg  et  al.,  2012).    
There   appears   to   be   an   inverse   relationship   between   LB   density   load   and  GCase  
activity   in   PD   brain   (Murphy   et   al.,   2014b).   In  GBA   deficient  mice   (D409V/D409V  
genotype),   increasing   GCase   activity,   through   viral   mediated   expression   of  GBA,  
corrected   the   accumulation   of   SNCA   in   the   brain   (Sardi   et   al.,   2011).   In   addition,  
SNCA  knockout  mice  demonstrate   increases   in  GCase  activity,  and  heterozygosity  
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for   a   GD-­associated   mutation   in   GBA   interferes   with   SNCA   degradation   and  
contributes  to  its  accumulation,  exacerbating  the  phenotype  in  a  mouse  model  of  PD.    
I  utilized  NCSC-­derived  neurons  carrying  heterozygous  GBA  mutations  and  showed  
that  GBA  mutations   are   directly   linked   to   an   increase   of  SNCA  levels.   This   model  
confirms   reports   from  other  studies   in  pluripotent  stem  cells.  The   functional   loss  of  
GCase   in   human   iPS   neurons   compromises   lysosomal   protein   degradation,   and  
causes  the  accumulation  of  SNCA  (Mazzulli  et  al.,  2011).  Cell  types  derived  from  GD  
human  iPSC  can  also  effectively  recapitulate  pathologic  hallmarks  of  the  disease  in  
terms   of   reduced   GCase   activity,   impaired   lysosomal   function   and   increased  
sphingolipids   (Panicker   et   al.,   2014).   In   monozygotic   twins   harbouring   the  
heterozygous  GBA  mutation   N370S   but   clinically   discordant   for   PD,   iPSC-­derived  
DA  neurons  from  both  twins  had  ∼50%  GCase  enzymatic  activity,  ∼3-­fold  elevated  
SNCA  protein   levels,  and  a   reduced  capacity   to  synthesize  and  release  dopamine.  
Interestingly,   the   affected   twin's   neurons   showed   an   even   lower   dopamine   level,  
increased   monoamine   oxidase   B   (MAO-­B)   expression,   and   impaired   intrinsic  
network   activity.   Overexpression   of   wild   type   GBA   and   treatment   with   MAO-­B  
inhibitors  normalized  SNCA  and  dopamine  levels,  suggesting  a  combination  therapy  
for   the   affected   twin.   In   another   iPS   model,   abnormal   calcium   homeostasis   and  
lysosomal   dysfunction  were   identified   in   cells   derived   from  GBA  mutant   individuals  
and   strengthens   the   evidence   for   a   link   between   GBA   mutations   and   complex  
changes   in   the   autophagic/lysosomal   system,   which   could   underlie   vulnerability   to  
neurodegeneration  (Schöndorf  et  al.,  2014).  In  my  study,  I  did  not  investigate  levels  
of  glucosylceramide,  the  substrate  of  GCase,  and  it  is  interesting  to  note  an  increase  
of   glucosylceramide   in   iPSC-­derived   neurons   from   PD   patients   carrying  
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heterozygous  GBA  mutations,   which   in   turn   may   influence  SNCA  levels   and  
aggregation.    
The  interplay  between  GCase  and  SNCA  has  yet  to  be  fully  understood  in  terms  of  
the   molecular   and   biochemical   mechanisms   involved.   Some   suggest   that   GCase  
interacts   directly   with   SNCA   at   membranes,   within   lysosomes   (Yap   et   al.,   2013).  
Others  propose  a  disturbance  of  GCase  trafficking  (Cooper  et  al.,  2006;;  Thayanidhi  
et  al.,  2010).    
  
My  data  shows  that  GBA  mutations  are  linked  to  defects  in  the  autophagic/lysosomal  
system.   I   found   reductions   in   the   basal   levels   of   LC3-­II   but   no   impairment   of   the  
autophagic  flux  in  response  to  bafilomycin.  These  data  are  consistent  with  the  results  
in  fibroblast  cells  and  suggest  a  deficit  in  autophagosome  number  but  no  impairment  
of   the   fusion   between   autophagosomes   and   lysosomes.   This   impairment   of  
macroautophagy   may   explain   the   increased   levels   of  SNCA   seen   in  GBA  mutant  
neurons.   The   decrement   in   lysosomal   activity   in   NCSC-­derived   neurons   was  
accompanied   by   a   reduction   in   the   enzymatic   activity   of   GCase   in  GBA  mutation  
positive   patients   compared   with   control   individuals.   Parkinsonism   has   been  
described   in  many   lysosomal   storage  diseases,   including  GD  and  Anderson-­Fabry  
disease.   This   suggests   that   impairment   of   the   lysosome   could   correlate  with   early  
neurodegenerative   processes.   In   this   context,  GBA   mutations   may   alter   the  
lysosomal  function  through  one  of  several  pathways.  The  loss  of  GCase  could  have  
a  secondary  effect  on  lysosomal  function  and  lead  to  SNCA  accumulation  (Manning-­
Boğ  et  al.,  2009;;  Mazzulli  et  al.,  2011).  In  addition,  an  accumulation  of  lipid  substrate  
could   influence   lysosome   formation   as  well   as  SNCA  aggregation   (Jo   et   al.,   2000;;  
Koga   et   al.,   2010).   In   contrast,   increased   levels   of  SNCA  may   cause   lysosomal  
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dysfunction   in  GBA  mutant   neurons   via   a   positive   feedback   loop   (Mazzulli   et   al.,  
2011).   It   has   been   demonstrated   that   SNCA   overexpression   impairs  
macroautophagy   via   Rab1a   inhibition   in   mammalian   cells   and   in   transgenic   mice,  
and  Rab1a  overexpression  rescues  the  autophagy  defect  caused  by  SNCA  (Winslow  
et  al.,  2010).      
In  view  of  the  crosstalk  between  macroautophagy  and  CMA  (Schneider  and  Cuervo,  
2014b),   I   looked   for   a   measurable   change   in   CMA   in   the   neuronal   model.   CMA  
serves   as   a   backup   mechanism   for   the   removal   of   malfunctioning   proteins   (i.e.  
aberrant  SNCA)  when  macroautophagy  is  compromised,  and  vice  versa  (Wu  et  al.,  
2014).  In   fibroblasts,   the   selective   loss  of   lysosomal  GCase  was  directly   related   to  
reduced  lysosomal  CMA.  In  mature  NCSC-­derived  DA  neurons  at  differentiation  day  
40,   levels   of   LAMP2a   were   unchanged.   Perhaps   this   does   suggest   some  
adaptations   in   the   neuronal   model,   in   the   presence   of   SNCA,   where   levels   of  
LAMP2a   may   initially   increase   in   order   to   compensate   for   a   reduction   in  
macroautophagy.   This   was   certainly   seen   during   the   early   stages   of   neuronal  
differentiation,   where   levels   of   LAMP2a   were   significantly   higher   in   GBA   mutant  
neurons   at   differentiation   day   20.   This   compensatory   increase,   however,   being  
insufficient   to   overcome   the   SNCA   accumulation   observed   in  GBA   heterozygotes,  
LAMP2a  levels  may  return  to  the  basal  level  by  differentiation  day  40.  
In   summary   my   studies   show   that   heterozygous   GBA   mutation   positive   NCSC-­
derived  neurons  have  increased  levels  of  SNCA  as  well  as  complex  changes  in  the  
autophagic/lysosomal   system,  which  may  underlie   the   selective   vulnerability   of  DA  
neurons  to  degeneration  in  PD.  Taken  together,  my  results  suggest  possible  targets  
for   the   development   of   disease-­modifying   drugs   for   patients   with   familial   and  
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idiopathic  PD.  My   results   lay   support   to   intended  strategies   to   influence   lysosomal  
function  and  SNCA  deposition  in  PD,  as  a  mechanism  of  neuroprotection  (Schapira  
et  al.,  2014).    
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Chapter  5:  Pharmacological   Chaperones   to   Obtain   the  
Maximal  Enhancement  of  GCase  Function  
  
  
5.1  Pharmacological  chaperones  for  GCase  
The  relationship  between  GD  and  PD  is  not  yet  fully  understood.  It  could  arise  from  
the  gain  of  a  new  toxic  function  by  mutated  GBA  (Gregersen  N  et  al.,  2006),  a  loss  of  
enzyme   function   (Thompson   AJ   et   al.,   2002),   or   a   combination   of   both.  
Approximately   203/300   (~70%)  GBA   mutations   are   missense,   which   result   in   the  
synthesis   of   GCase,   but   with   decreased   catalytic   function   and   stability.   Missense  
mutations   in  GBA  cause   GCase   to   fold   abnormally.   This   results   in   a   misfolded  
protein   which   becomes   retained   in   the   endoplasmic   reticulum   (ER)   and   after  
unsuccessful   attempts   at   refolding,   finally   undergoes   degradation   by   the   ER-­
associated   degradation   (ERAD)   system.   This   reduces   the   GCase   reaching   the  
lysosome,   and   could   have   consequences   for   lysosomal   function,   by   overwhelming  
the   ubiquitin-­proteasome   pathway   (UPS)   or   by   impairment   of   autophagy.  
Alternatively,   misfolded   GCase   could   lead   to   the   development   of   PD   directly   by  
promoting   SNCA   accumulation   or   preventing   its   degradation.   Parkinsonism   could  
also  arise  from  a  deficiency/reduction  of  wild-­type  (WT)  GCase  resulting  from  a  loss-­




Recent   data   has   placed   the   spotlight   on   pharmacological   chaperones   (PC)   as   an  
emerging   therapeutic   strategy   for   GD   (Bendikov-­Bar   et   al.,   2013),   but   also   their  
potential  use   in  PD   (McNeill  et  al.,  2014).  PC  are  small  molecules   that  are  able   to  
bind  mutant  misfolded  GCase  stalled  in  the  ER  and  enhance  its  folding,  stability  and  
trafficking  to  the  lysosome,  where  the  residual  activity  of  the  enzyme  can  hydrolyse  
its   substrate.   This   sequence   of   events   has   been   termed   chaperoning.   The  
mechanism   of   action   for   any   chaperone   compound   is   competitive   binding   to   the  
active  site  of  the  mutant  enzyme.      
GBA   mutations   cause   a   reduction   in   enzyme   activity,   but   this   may   not   be   the  
mechanism  that  mediates  the  pathogenesis  of  GD.  Protein  misfolding,  mis-­trafficking  
of   GCase   and   endoplasmic   reticulum   stress   are   considered   some   of   the  
mechanisms  contributing  to  the  pathophysiology  of  GD.  Evidence  to  support  protein  
misfolding  as  a  putative  cause  of  GD  is  the  observation  that  common  GBA  mutations  
are   processed   by   endoplasmic-­reticulum-­associated   degradation.   In   PD,   the  
abnormal   accumulation   of   SNCA   and   other   ubiquitinated   proteins   in   LBs   has   also  
implicated  protein  mishandling  as  a  cause.    
The   N370S   missense   mutation   of   the  GBA   gene   is   the   most   prevalent   mutation  
causing  GD,  after  the  L444P  mutation.  For  mutant  GCase,  including  N370S,  PC  are  
being   pursued   as   potential   small-­molecule   ‘enzyme   enhancement’   therapeutics.  
These  active-­site-­specific   inhibitors  have  been  proposed   to   ‘rescue’  a  proportion  of  
the  newly  synthesized  mutant  enzyme  when  present  at  sub-­inhibitory  concentrations,  




PC   therapy   has   been   proposed   for   lysosomal   storage   disorders,   including   GD,  
Anderson-­Fabry,   and  Tay–Sachs  diseases.  Current   treatment   for   patients  with  GD  
include   enzyme   replacement   therapy   (ERT).      Although   ERT   is   highly   effective   in  
reversing   the   visceral   and   hematologic  manifestations,   skeletal   disease   is   slow   to  
respond,  pulmonary  involvement  is  relatively  resistant,  and  ERT  does  not  cross  the  
blood  brain  barrier  and  therefore,  cannot  treat  the  neurological  manifestations  of  GD.  
PC  therapy  is  an  attractive  approach  because  of  its  potential  for  more  uniform  tissue  
distribution  and  its  ability  to  penetrate  the  blood–brain  barrier.    
The  effect  of  PC   is   to  some  degree  mutation  specific,  and  can  also  be  affected  by  
the  cellular  environment,  for  instance  upon  the  individual  genetic  background.  Thus,  
PC  may  not  be  suitable  for  every  patient  with  GD  or  PD,  even  among  those  with  the  
same  genotypes.    
The  first  molecule  identified  as  a  potential  chaperone  for  mutant  GCase  was  N-­  (n-­
Nonyl)   1-­deoxynojirimycin   (NN-­DNJ),   a  member   of   the   iminosugar   family,   naturally  
occurring   glycosidase   inhibitors   (Sawkar   et   al.,   2002).      The   majority   of   PC   are  
enzyme   inhibitors   and   can   be   classed   as   iminosugars   or   similar   analogs   of   the  
natural   substrate,   glucosylceramide.   Iminosugars,   including   isofagomine   (IFG),   are  
potent  competitive  inhibitors  that  bind  to  the  active  site  of  GCase  with  high  affinity  at  
the  neutral  pH  of  the  endoplasmic  reticulum,  where  GCase  has  decreased  stability,  
and  with   low  affinity   in   the  acidic  conditions  of   the   lysosome  where   the  chaperone-­
enzyme  complex  dissociates.    
In   a   simple   yet   reliable   enzyme   assay   using   capillary   electrophoresis   for   inhibitor  
screening  of   five  putative  PC   (IFG,  ABX,  bromhexine,  diltiazem,  and   fluphenazine)  
that  target  the  lysosomal  enzyme  GCase,  IFG  was  confirmed  as  a  potent  competitive  
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inhibitor  of  recombinant  GCase.  In  contrast,  the  four  other  non-­carbohydrate  amines  
were  demonstrated  to  function  as  mixed-­type  inhibitors  with  high  micromolar  activity  
at   neutral   pH   relative   to   acidic   pH   conditions   reflective   of   the   lysosome  
(Shanmuganathan  and  Britz-­McKibbin,  2011).  
There  is  extensive  research  on  the  use  of  PC  to  enhance  lysosomal  GCase  activity,  
and   the   screening   of   chemical   libraries   in   order   to   identify   novel   chaperone  
molecules   with   improved   efficiency   and   efficacy.   Ambroxol   (ABX),   a   drug   used   to  
treat  airway  mucus  hypersecretion  and  hyaline  membrane  disease   in  humans,  was  
isolated   in   a   screen   of   a   library   of   1,040   Food   and   Drug   Administration   (FDA)-­
approved   drugs   from   the   chemical   library   of   the  National   Institute   for  Neurological  
Diseases   and   Stroke   (NINDS)   (Maegawa   et   al.,   2009).   Several   researchers   have  
demonstrated   the   effectiveness   of   chemical   chaperone   treatment   in   GD   e.g.  
Nojirimycin   analogus,   iminosugars   etc.   However,   these   chaperones   have   not   got  
FDA  approval  for  treating  GD.      
ABX,  traditionally  used  in  humans  as  an  oral  over-­the-­counter  cough  medicine  (pills,  
syrup,  or  caplets),  has  been  used  for  more  than  three  decades  in  many  countries  as  
a  mucolytic  agent.  ABX,  a  mixed-­type  inhibitor  of  GCase  (Maegawa  et  al.,  2009),  has  
been  shown  to  interact  with  both  the  active  and  non-­active  sites  of  GCase  in  a  pH-­
dependent  manner.  It  has  a  theoretical  advantage  over  other  iminosugars  because  it  
does   not   require   wash-­out   periods,   which   enables   continued   dosing.   As   a   mixed  
inhibitor,   ABX   has   a   similar   mode   of   action   to   an   enzyme   enhancement   therapy  
agent.  It  has  been  shown  to  enhance  the  activity  of  several  mutant  GCase  variants  
(Bendikov-­Bar  et  al.,   2013).  Moreover,   enhancement  of  GCase  activity   is   selective  
and  activities  of  other  lysosomal  enzymes  are  not  affected.    
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In  an  experiment  to  examine  the  “chaperoning”  half-­life  of  ABX,  GD  fibroblasts  were  
grown   in   medium   containing   60μm   ABX   or   DMSO   (mock-­treated)   for   5   days  
(Maegawa  et   al.,   2009).   The   cells  were   then   “chased”   for   8   days  by   replacing   the  
ABX/DMSO-­containing   media   with   fresh   media   lacking   the   compounds   and  
thereafter   every   other   day.   The   persistence   of   GCase   enhancement   produced   by  
ABX  after  drug  removal  in  N370S/N370S  fibroblasts  was  then  measured  and  chased  
over  a  period  of  8  days.  This  “pulse-­chase”  experiment  was  helpful   in  showing  that  
the   enhanced   N370S   GCase   activity   gradually   decreases   back   to   baseline   levels  
within   approximately   6   days   (Maegawa   et   al.,   2009).   This   suggests   a   reasonably  
long  half-­life   of  ABX   in   cells.   It   should   also  be  noted   that  wild   type  GCase   in   skin  
fibroblasts  has  been  reported  to  have  a  half-­life  of  approximately  60  hours.  
There  are  major  advantages  of  using  ABX  and  IFG  as  PC  in   this  study.  Both  have  
been  shown  to  significantly  increase  GCase  activity  in  human  fibroblasts  (Sun  et  al.,  
2012;;   Bendikov-­Bar   et   al.,   2013).   Studies   in   fibroblasts   derived   from   homozygous  
and  heterozygous  GBA  mutation  carriers,   revealed   the  expected  range  of   reduction  
in  GCase  activity:  severe  in  GD  patients,   intermediate  in  heterozygous  carriers  and  
unaffected   in   PD   patients   without   mutations   (McNeill   et   al.,   2014).   After   5   days  
treatment  with  the  GCase  chaperone  ABX,  there  was  a  significant  increase  in  GCase  
activity   in   GD   patients,   although   in   absolute   terms   this   was   small.   There   was   a  
further   significant   increase   of   GCase   activity   and   protein   levels   in   carriers.   Of  
particular  interest  was  the  increase  in  GCase  activity  seen  in  PD  patient  cells  without  
mutations.   This   effect   was   also   seen   in   controls.   IFG   has   also   been   shown   to  
increase   residual  GCase   activity   in   fibroblasts   originating   from   type   1  GD   patients  
(Chang   et   al.,   2006;;   Steet   et   al.,   2006)   and   also   in   mice   homozygous   for   GBA  




ABX   has   a   long   history   of   use   in   humans,   which   documents   its   very   low   level   of  
toxicity.  This   is   in  contrast   to  most  other  small  molecules,   identified  as  chaperones  
for  GCase,  but  which  have  never  been   tested   in  humans.   In   the   first  pilot  study  of  
ABX   in  GD,  Zimran  et  al.  gave  ambroxol   to  12  subjects  with  GD,  naïve   to   therapy,  
with  symptoms  of  moderate  severity,  for  a  duration  of  6  months  (Zimran  et  al.,  2013).  
This  pilot   investigation  was  conducted  to  assess  the  safety,   tolerability  and  efficacy  
of   ABX   in   patients   with   type   1   GD,   in   order   to   provide   proof   of   concept   and/or  
ascertain  suitability  of  ABX  for  a  larger  clinical  trial.  There  were  no  reports  of  adverse  
events  in  this  6  month  study  (Zimran  et  al.,  2013).  Some  of  the  shortcomings  of  this  
pilot   study  were   the   small   sample   size,   lack   of   data   on   different   dosing   regimens,  
pharmacologic  distribution  and  bioavailability  of  ABX.  However,  there  were  clinically  
significant   improvements.   In  25%  of   subjects   (3/12),   there  was  a  20%  decrease   in  
spleen  volume  and  a  50%  decrease  in  the  activity  of  chitotriosidase  that  persisted  for  
more  than  6  months.  Albeit,  these  improvements  were  seen  in  the  2  thinnest  patients  
suggesting   the   need   for   higher   concentrations.   Isofagomine   has   also   been   used  
orally   in  a  phase  2  clinical  trial  of  6  months  duration  (Amicus  Therapeutics).  Only  1  
patient  showed  clinically  meaningful  improvement.  Again,  the  optimal  concentration,  
regimen  and  treatment  duration  still  needs  to  be  determined.    
Some  of  the  advantages  of  ABX  are  its  simple  oral  administration,  the  fact  that  it   is  
readily  available,  and  its  low  cost.  However,  these  same  properties  may  hinder  ABX  
from  being  tested  by  a  sponsoring  drug  company  as  an  orphan  drug  through  costly  
trials  if  there  is  not  a  sufficient  benefit/cost  margin. 
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PC   are   hydrophobic   in   nature   and   of   low   molecular   mass   and   therefore,   it   was  
proposed  that  these  small  molecules  would  be  able  to  cross  the  blood  brain  barrier.  
The   oral   administration   of   ABX   and   IFG   in   GD   mice   has   confirmed   their   wide  
distribution  and  chaperone  activity   in   tissues,   including   the  brain,  and   lack  of  acute  
toxicity  (Sun  et  al.,  2011;;  Luan  et  al.,  2013).  In  one  such  mouse  model,  IFG  delayed  
the   onset   of   neurological   disease   and   extended   the   life   span   of  mice   (Sun   et   al.,  
2011).   Furthermore,   ABX  was   recently   shown   to   decrease  ER   stress   and   recover  
morphology   in   Drosophila   eye,   in   which   expression   of   GBA   generated  
neurodevelopmental   defects   and   ER   stress   (Suzuki   et   al.,   2013).   However,   the  
response   to   ABX   does   appear   to   be   patient   dependent,   and   this   could   be   due   to  
individual  differences  in  ER  quality  control  machinery.  
  
There   are   other   ways   to   modulate   GCase   activity   e.g.   with   the   use   of   histone  
deactylase   inhibitors,   to   reduce   recognition   of   misfolded   GCase   by   chaperone  
Hsp90β,  decrease  degradation,  and   increase  residual  enzyme   levels.  This  strategy  
has  been  validated  in  GD  patient  fibroblasts.  Another  approach  is  to  increase  GCase  
expression  e.g.  using  gene  therapy.  However,  there  is  a  vast  amount  of  publications  
on  the  use  of  small  molecular  chaperones  to  enhance  lysosomal  GCase  activity  and  
the  main  advantages  for  choosing  ABX  and  IFG  as  PC  is  that  they  are  safe  and  well  
tolerated,  binding  to  GCase  is  highly  pH  dependent,  both  are  readily  available,  both  
have  been  shown  to  significantly   increase  GCase  activity   in  human  fibroblasts,  and  
in  a  mouse  model,  IFG  delayed  onset  of  neurological  disease  and  extended  their  life  




The   GCase–lysosomal–SNCA   pathway   has   become   a   new   target   for   drug  
intervention.   Improving   the   trafficking   of   mutant   GCase   by   PC   will   reduce   ER-­
associated  degradation  (ERAD),  and  increase  the  lysosomal  localisation  but  also  the  
expression   of   GCase.   This   latter   effect   could   be   relevant   to   those   PD   patients  
without  GBA  mutations.   By   improving   the   lysosomal   localisation   or   expression   of  
GCase,  this  could  have  a  beneficial  effect  by  improving  lysosomal  function  which  will  
increase   the   turnover   of   SNCA   by   autophagy,   thereby   reducing   its   propensity   to  
aggregate.  It  is  thought  now  that  enhancing  lysosomal  function  and  reducing  SNCA  
levels  will  reduce  the  release  and  spread  of  SNCA  and  its  related  pathology,  and  that  
importantly,  these  effects  will  not  be  restricted  to  dopaminergic  neurons,  an  essential  












5.2  The  optimal  concentration  and  duration  of  chaperone  treatment  
for  maximal  enhancement  of  GCase  activity  
  
OBJECTIVE  
To  investigate  the  optimal  concentration  and  duration  of  drug  treatment  (in  days)  for  
maximal   enhancement   of   GCase   activity   in   a   type   1   GD   (N370S/N370S)   and   a  
control  fibroblast  line.    
  
  Introduction  
Both  human  skin   fibroblasts  and  human  adipose  NCSC  were  developed   from  skin  
biopsies   obtained   from   patients   within   the   clinical   cohort   at   high   risk   for   PD.   The  
fibroblast  cell  model  was  used  in  the  first  instance  to  investigate  the  potential  for  PC  
treatment  to  restore  GCase  function.    
Experiments   were   performed   to   identify   the   optimal   concentration   and   duration   of  
drug  treatment  (in  days)  for  maximal  enhancement  of  GCase  activity  in  a  type  1  GD  
(N370S/N370S)  and  a  control   fibroblast   line.  The  concentrations  used   for  ABX  and  
IFG  were  guided  by  the  literature.    
It  was  important  to  study  the  influence  of  PC  treatment   in  a  control   line  because  of  
the   potential   benefit   for  PD  patients   negative   for   the  GBA  mutation.  Reductions   in  
GCase   have   been   noted   in   sporadic   PD   brain   (Gegg   et   al.,   2012).  Moreover,   the  
results  from  animal  and  cellular  studies  demonstrate  that  knockdown  or  inhibition  of  
GCase   results   in   the   accumulation   of   SNCA   and   furthermore,   augmenting  GCase  
activity  can  reduce  levels  of  SNCA  (Mazzulli  et  al.,  2011).  Therefore,  the  use  of  PC  
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to   restore  GCase   function,   could   lead   to   a   reduction   in   SNCA   accumulation.   This  
could  be  significant   for   those  with  GBA-­PD,  asymptomatic  GBA  positive  carriers  at  
risk  of  conversion  to  clinical  PD,  or  even  those  with  sporadic  PD.  
  
  Method  
Cell  lines                                           
Human   primary   skin   fibroblast   cultures   that   contained   the   wild   type   (WT)   and   the  
homozygous   N370S/N370S   GBA   mutation   were   obtained   from   the   clinical   study  
cohort.  Preliminary  analysis  of   fibroblast   cultures   following   treatment  with  ABX  has  
previously   demonstrated   a   4-­fold   increase   in   GCase   activity   measured   in   the  
N370S/N370S  GD  line,  and  a  steady-­state  GBA  protein  level  ~50%  of  the  WT.    The  
cells  were  grown  in  the  standard  conditions:  DMEM  supplemented  with  10%  FBS,  at  
37  °C  in  the  presence  of  5%  CO2,  with  medium  changed  every  2-­3  days.     Cultures  
were  not  left  to  become  confluent.    Passage  numbers  were  limited  from  8  to  12.    
  
Drug  treatment  
Sub-­confluent   human   skin   fibroblast   cultures   were   treated   with   selected  
concentrations   of   ABX   (A9797,   Sigma-­Aldrich)   and   IFG   (Santa   Cruz)   for   an  
increasing  number  of  days.  ABX  was  dissolved   in  dimethylsulphoxide  (DMSO)  and  
diluted  in  cell  culture  media  to  give  final  concentrations  of  3.3μM,  10μM  and  60μM.  
IFG  (water  soluble)  was  diluted   in  cell  culture  media   to  give   final  concentrations  of  
10μM  and  50μM.  Media  was  changed  alternate  daily  for  PC  treated  and  control  lines.  
Controls  were  treated  with  DMSO  or  media  only.  At  day  10,  the  cells  were  washed  
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twice  with  phosphate–buffered  saline  (PBS)  prior  to  harvest,  to  collect  as  cell  pellets  
that  were  frozen  in  -­80˚C  for  storage.  
  
Lysosomal  enzymatic  activity  
See  section  4.2.2.    
  
  Results  
I   evaluated   the   effect   of   ABX   and   IFG   treatment   on   residual   GCase   activity.  
Treatment  of  skin  fibroblast  cultures  that  originated  from  a  control  and  a  type  1  GD  
patient,   with   selected   concentrations   of   ABX   over   10   days,   resulted   in   a   2-­fold  
increase   in  activity  of   the  control   line  and  a  4-­fold   increase   in  activity  of   the  mutant  
line   with   60µM   ABX   at   6   days.   Concentrations   of   IFG   of   10μM   in   the   media  
enhanced  GCase  activities  significantly  in  the  wild  type  at  6,  8  and  10  days  as  shown  
in  Figure  7.27,  but  did  not  enhance  GCase  activity  significantly  in  the  mutant  line  for  
any  time  point.  In  comparison,  treatment  with  50µM  IFG  resulted  in  a  2-­fold  increase  
in  activity  of   the  control   line  and  a  3-­fold   increase   in  activity  of   the  mutant   line  at  6  
days;;   these   enhanced   activities   were   ~5%   of   untreated   WT   levels.   The  
concentrations   to  achieve  peak  GCase  activity   in   the  mutant   line   for  ABX  and   IFG  
were   60µM   and   50µM   respectively.   The   duration   of   treatment   to   achieve   peak  
GCase  activity  was  6  days  for  ABX  and  IFG.    It  is  worth  noting  that  treatment  of  skin  
fibroblast   cultures   that   originated   from   a   control   and   a   type   1   GD   patient,   with  
increasing   concentrations   of   ABX   and   IFG   resulted   in   no   significant   change   of  
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lysosomal  hexosaminidase  or  β–galactosidase  activity,   for  any  given  concentration,  
and  at  all  time  points  studied  as  shown  in    Figure  7.28  and  Figure  7.29.        
  
  Discussion                                                                                            
The  results  presented  here  confirm  previous  reports  (Sun  et  al.,  2012;;  Bendikov-­Bar  
et   al.,   2013)   demonstrating   the   ability   of   small   molecular   chaperones   to   enhance  
GCase  enzymatic  activity.  The  data  is  new  in  providing  additional  information  on  the  
optimum  concentration  and  duration  of  treatment  that  would  be  recommended  for  the  
maximal  enhancement  of  GCase  function.  The  data   illustrates  that   the  effect  of   the  
two   drugs   for   enhancing   GCase   activity   in   both   the   WT   and   the   GD   cell   line   is  
comparable.  Furthermore,   the  PC  molecules   tested  appear  selective   for  enhancing  
GCase  function.  It  is  interesting  to  note  that  although  GCase  activity  is  enhanced  up  
to  4-­fold  in  the  mutant  cell  line,  it  remains  at  ~5%  of  the  WT  level.  Despite  this,  this  
small  enhancement  may  be  sufficient  to  produce  significant  physiological  effects.    
Current  treatment  for  patients  with  GD  include  enzyme  replacement  therapy  (ERT),  
but  this  does  not  cross  into  the  brain  and  is  very  expensive,  and  alternatives  such  as  
substrate  reduction  therapy  (SRT)  and  the  use  of  small  molecule  chaperone  therapy.  
The   latter   has   the   added   benefit   of   crossing   the   blood-­brain   barrier,   providing   an  
opportunity   to   treat   additional   features   of   the   disease   e.g.   the   neurological  
manifestations  of  GD.  Enhancing  GCase  activity  using  PC  and  improving  lysosomal  
function   therefore   holds   particular   relevance   for   those   with  GD,   but   could   also   be  
significant   for   those   with   PD   where   the   impairment   of   lysosomal   pathways   is  
increasingly  viewed  as  a  major  pathogenic  event  (Dehay  et  al.,  2013)  and  the  ability  
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to   modulate   GCase   activity   has   important   therapeutic   implications   (Schapira   and  
Gegg,  2013).  
                                                                                                           
My  results  on   the  skin   fibroblast  cultures   reproduce   the  GCase  enhancement  seen  
from  previous  studies  following  treatment  with  chaperone  molecules.  Good  progress  
has   been   made   to   determine   the   optimal   concentration   and   duration   of   drug  
treatment  to  achieve  the  maximal  increase  in  GCase  activity  in  both  a  representative  
control  and  a  type  1  GD  (N370S/N370S)  cell  line.  However,  full  restoration  of  GCase  
has  not  been  obtained  from  the  mutant  GBA  line,  when  compared  to  the  level  found  
in  the  control  cell  line.       
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5.3    The   efficacy   of   pharmacological   chaperone   treatment   in  
restoring  GCase   function,   and   reversing   the  underlying  molecular  
events  
  
OBJECTIVE                                            
To   investigate   whether   the   small   molecular   chaperones,   ABX   and   IFG,   restore  
GCase  activity  and  reduce  SNCA  levels,  in  human  cell  models.  
  
  Introduction  
I   aim   to   demonstrate   that   the   PC   ABX   and   IFG   are   able   to   modulate  
glucocerebrosidase  function  in  fibroblasts.  It  is  unclear  whether  treatment  alone  may  
be   able   to   overcome  all   biochemical   defects   due   to  mutations   in  GBA,   due   to   the  
limitation  of  fibroblasts  as  a  model  for  interrogating  the  complete  pathway  in  PD.  The  
ability   of   ABX   to   increase   GCase   activity   in   fibroblast   cells   and   to   reduce   SNCA  
levels   in  ectopically  expressing  SNCA  SH-­SY5Y  cells   first   highlighted   the  potential  
benefit  of  manipulating  the  lysosomal-­GCase  pathway  to  lower  SNCA  levels  (McNeill  
et  al.,  2014).  Due  to  the  artificial  nature  of  the  overexpressing  SH-­SY5Y  cell  model,  I  
felt  it  was  important  to  repeat  measurements  in  human  dopaminergic  neurons,  which  
in  the  presence  of  SNCA  would  better  recapitulate  what  is  happening  in  the  brain.    
  
  Method  




To  evaluate  the  effect  of  ABX  and  IFG  from  different  suppliers,  I  cultured  control  and  
mutant  (N370S/N370S)  fibroblasts  in  the  presence  of  60μM  ABX  from  Sigma  Aldrich  
or   LKT   Laboratories,   and   50μM   IFG   from   Santa   Cruz   Biotechnology   or   Amicus  
Therapeutics.  The  results  demonstrated  that  GCase  activity  was  maximal   in  both  a  
control   and   mutant   line   for   ABX   from   Sigma   Aldrich,   while   GCase   activity   was  
maximal   in   a   mutant   line   for   IFG   from   Santa   Cruz   Biotechnology.   See   Appendix  
Figure   9.13   and   Figure   9.14.   I   therefore   used   ABX   supplied   by   Sigma   Aldrich  
(A9797)  and  IFG  supplied  by  Santa  Cruz  Biotechnology  for  all  of  my  experiments.    
  
Ambroxol  and  isofagomine  treatment  of  human  fibroblasts  
Sub-­confluent   human   skin   fibroblast   cultures   were   treated   with   pre-­determined  
concentrations  of  ABX  (A9797,  Sigma-­Aldrich)  and  IFG  (Santa  Cruz)  alternate  daily  
for   6   days.   ABX   was   dissolved   in   dimethylsulphoxide   (DMSO)   and   diluted   in   cell  
culture  media  to  give  a  final  concentration  of  60μM.  IFG  (water  soluble)  was  diluted  
in   cell   culture   media   to   give   a   final   concentration   of   50μM.   Media   was   changed  
alternate  daily  for  PC  treated  and  control  lines.  Controls  were  treated  with  DMSO  or  
media  only.  At  day  6,   the  cells  were  washed   twice  with  phosphate–buffered  saline  
(PBS)  prior  to  harvest,  to  collect  as  cell  pellets  that  were  frozen  in  -­80˚C  for  storage.    
  
Ambroxol  treatment  of  human  adipose  NCSC-­derived  neurons  
Adipose   NCSC-­derived   neuronal   cultures   were   treated   at   day   40   of   neuronal  
differentiation  with  the  pre-­determined  concentration  of  ABX  (A9797,  Sigma-­Aldrich)  
alternate   daily   for   6   days.   ABX  was   dissolved   in   dimethylsulphoxide   (DMSO)   and  
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diluted   in   cell   culture   media   to   give   a   final   concentration   of   60μM.   Media   was  
changed  alternate  daily  for  PC  treated  and  control   lines.  Controls  were  treated  with  
media  only.  At  day  6,   the  cells  were  washed   twice  with  phosphate–buffered  saline  
(PBS)  prior  to  harvest,  to  collect  as  cell  pellets  that  were  frozen  in  -­80˚C  for  storage.    
  
  Results  
Pharmacological   chaperones   enhance   enzymatic   activity   and   lysosomal  
localization  of  GCase  in  GBA  mutant  fibroblasts  
Treatment   of   skin   fibroblasts   that   originated   from   heterozygous   GBA   mutation  
carriers,   IPD   patients,   and   healthy   controls  with   ABX   or   IFG   resulted   in   50–100%  
increases   in   the  activity  of   the  mutant  protein   in  all   tested   lines   (Figure  7.30).  The  
data   illustrate   that   the  effect   of  PC   for   enhancing  GCase  activity   in  all   cell   lines   is  
comparable.  Furthermore,   the  PC  molecules   tested  appear  selective   for  enhancing  
GBA  function  (contribution  from  non-­lysosomal  GCase  (GBA2)  was  distinguished  by  
using   the  corresponding   inhibitor   conduritol-­β-­epoxide  (CβE)   (see  Appendix  Figure  
9.6  and  Figure  9.7).  PC  treatment  also  resulted  in  a  significant  elevation  of  GCase  
protein   and   messenger   RNA   levels   (Figure   7.30)   in   heterozygous  GBA  mutation  
carriers,   IPD  patients,   and  healthy   controls.  The  greatest   effect   on  GCase  activity,  
protein  and  mRNA  levels  was  seen  with  the  drug  ABX.  To  evaluate  the  effects  of  PC  
on   GBA   intracellular   trafficking,   fibroblasts   were   treated   with   ABX   and   IFG.   ABX  
treatment  increased  GBA  protein  trafficking  into  the  lysosome  and  resulted  in  partial  
GBA/cathepsin  D  co-­localization.   I  observed  an   increased  degree  of  co-­localization  
between   GBA   and   cathepsin   D  in  all   cell   lines   following   ABX   treatment.  For  
heterozygous  GBA  carriers,  the  effect  of  ABX  was  similar  to  the  untreated  WT.  IFG  
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treatment  did  not  significantly   increase   the  degree  of  co-­localization   in  all  cell   lines  
(Figure  7.31).      
  
Pharmacological   chaperones   expand   the   lysosomal   compartment   in   GBA  
mutant  fibroblasts  
Treatment   of   skin   fibroblasts   that   originated   from   heterozygous   GBA   mutation  
carriers,   IPD   patients,   and   healthy   controls   with   pre-­determined   concentrations   of  
ABX   or   IFG   resulted   in   no   significant   change   of   lysosomal   hexosaminidase   or   β–
galactosidase   activity,   for   any   given   drug,   as   shown   in   Figure   7.32.   These   data  
suggest   PC   are   selective   for   enhancing   the   activity   of   the   lysosomal   enzyme,  
GCase.   In   addition,   immunoblotting   for   lysosomal   marker,   LAMP1,   revealed   a  
significant  increase  in  LAMP1  protein  following  ABX  treatment  in  heterozygous  GBA  
mutation   carrier,   IPD  patients   and   controls   (Figure  7.32).   This   suggests   a   general  
increase   in   lysosomal  mass  and   is   consistent  with  previous   reports   (McNeill   et  al.,  
2014).   Taken   together,   these   data   illustrate   that   ABX   may   cause   an   overall  
expansion  of  the  lysosomal  compartment.  
  
Ambroxol  is  selected  for  the  treatment  of  GBA  mutant  neurons.  
The  testing  of  2  different  PC  molecules  in  human  fibroblast  cells  demonstrated  that  
ABX  produced   the   greatest   enhancement   of  GCase   activity   and   showed   the  most  
potential  for  reversing  the  underlying  molecular  events  relevant  to  the  GBA  mutation.  
ABX  was  the  most  effective  PC  for  enhancing  the  enzymatic  activity  and  lysosomal  
localization  of  GBA   in  all   cell   types.  Due   to   the  superior  efficacy  of  ABX  over   IFG,  
and   the   limited   neuronal   material   available   as   a   result   of   the   cost   and   time   to  
differentiate  NCSC  to  DA  neurons,  neuronal  cultures  were  treated  with  ABX  only.    
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Ambroxol  enhances  GCase  enzyme  activity  in  GBA  mutant  neurons  
Control,  heterozygous   GBA   mutation   positive   carrier,   and   IPD   NCSCs   were  
differentiated   for  40  days  and  neuronal   cultures  were  predominantly  dopaminergic.  
The  GCase  activity  was  significantly  reduced  in  heterozygous  GBA  mutation  positive  
neurons  compared  with  healthy  control  cells  (Figure  7.22).  Importantly,  control  lines  
showed   a   significantly   higher   average   of   enzymatic   activity   compared   with   GBA  
positive   lines.   Treatment   of   NCSC-­derived   neuronal   cultures   that   originated   from  
heterozygous  GBA  mutation  carriers,   IPD  patients,  and  healthy  controls  with  60μM  
ABX   resulted   in   significant   increases   of   GCase   activity   in   all   tested   lines   (Figure  
7.33).   The   data   illustrate   that   the   effect   of   ABX   for   enhancing  GCase   activity  was  
greatest  in  GBA  mutation  positive  carrier  and  PD  cell  lines.    
  
Ambroxol  increases  GCase  protein  levels  in  GBA  mutant  neurons  
Analysis  of  intracellular  GCase  protein  levels  in  cells  of  different  patients  by  western-­
blotting   revealed   that   protein   levels   of   the   enzyme   were   reduced  
in  heterozygous  GBA   mutation   positive   carriers   compared   with   control   individuals  
(Figure   7.22).   ABX   treatment   resulted   in   a   significant   increase   of   GBA   protein  
(Figure  7.34)  in  heterozygous  GBA  mutation  carriers  and  IPD  patients.    
  
Ambroxol  reduces  SNCA  levels  in  GBA  mutant  neurons  
A   significant   increase   in  SNCA  protein   levels   was   found   in  GBA   mutation   positive  
neurons   carrying   the   N370S   allele   compared   with   controls   (Figure   7.23).  
Immunofluorescent   staining   for  SNCA   revealed   a   significant   increase   in   SNCA  in  
GBA   mutation   positive   NCSC-­derived   neurons   compared   with   healthy   individuals,  
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suggesting   an   accumulation   of   SNCA   (Figure   7.23).  This   data   suggested   the  
relationship   between   GCase   and   SNCA   could   be   manipulated   to   reduce   SNCA  
levels   in   PD   by   enhancing   GCase   levels   and   activity.     Following   6   days   of   ABX  
treatment,  I  measured  SNCA  levels  in  neuronal  cultures  from  GBA  mutation  positive  
NCSC-­derived  neurons,  IPD  and  GBA  negative  controls.  Treatment  with  ABX  led  to  
a   significant   reduction   in  SNCA  protein   levels   in  GBA   mutation   positive   and   PD  
neurons  (Figure  7.35).  
  
Ambroxol  upregulates  macroautophagy  in  GBA  mutant  neurons  
Analysis   of   the   autophagic/lysosomal   machinery   in  GBA  mutant   neurons   revealed  
that  basal   levels  of   light  chain   type  3  protein   (LC3),  a  marker  of  autophagosomes,  
were  reduced  in  heterozygous  GBA  mutation  positive  carriers  compared  with  control  
individuals   (Figure   7.24).   Bafilomycin   treatment   revealed   that   the   autophagic   flux  
was  not  significantly  reduced  in  GBA  mutation  positive  carrier  neurons  compared  to  
control   cells   (Figure   7.25)   suggesting   no   impairment   of   autophagosome-­lysosome  
fusion.   Following   6   days   of   ABX   treatment,   I   measured  LC3   and   p62  levels   in  
neuronal  cultures  from  GBA  mutation  positive  NCSC-­derived  neurons,  IPD  and  GBA  
negative  controls.  Treatment  with  ABX  led  to  a  significant  increase  in  both  LC3-­II  and  
p62  protein  levels  in  GBA  mutation  positive  and  PD  neurons  (Figure  7.36).  
  
Reducing  the  concentration  of  ambroxol  produces  the  same  key  biochemical  
effects  in  GBA  mutant  neurons  
Control,   heterozygous   GBA   mutation   positive   carrier,   and   IPD   NCSCs   were  
differentiated  for  40  days.  I  have  previously  shown  that  10μM  ABX  can  produce  a  3-­
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fold   increase   in   GCase   activity   in   a   mutant   fibroblast   cell   line   (Figure   7.27).  
Treatment   of   NCSC-­derived   neuronal   cultures   that   originated   from   heterozygous  
GBA   mutation   carriers,   IPD   patients,   and   healthy   controls   with   selected  
concentrations  of  ABX  over  6  days,  resulted  in  a  ~1.5  fold  increase  in  GCase  activity  
with   10μM   ABX   and   ~2-­fold   increase   in   activity   of   all   cell   lines   with   30μM   ABX  
(Figure  7.37).  This  corresponded  with  a  significant  increase  in  levels  of  GBA  protein  
in   GBA   mutation   positive   NCSC-­derived   neurons   (Figure   7.38).   To   determine  
whether   the   increase  of  GCase  activity  and  protein  was  sufficient   to   reduce  SNCA  
accumulation  in  GBA  mutant  cells,   I  measured  levels  of  SNCA  in  neuronal  cultures  
from  GBA  mutation  positive  NCSC-­derived  neurons.  Both  10μM  and  30μM  ABX  led  
to  significant  reductions  in  SNCA  protein  levels  (Figure  7.39).  
  
  Discussion  
Fibroblast  cultures  derived  from  human  skin  biopsies  provide  an  opportunity  to  study  
the  contribution  of  mutations  in  GBA   in  PD  as  a  cell  model.  I  hypothesized  that  the  
biochemical   defects   present   in   the  GBA-­PD   brain  would   also   be   expressed   in   the  
fibroblasts   (Gegg   et   al.,   2012).   My   data   suggest   they   do   express   the   same  
biochemical  defects,  for  example  reduced  GCase  activity.  They  are  also  a  useful  tool  
to   test   drugs   in   a   high-­throughput   setting.   The   results   presented   here   confirm  
previous   reports   (Sun  et  al.,   2012;;  Bendikov-­Bar  et  al.,   2013;;  McNeill   et  al.,   2014)  
demonstrating   the  ability  of   small  molecular  chaperones   to  enhance   the  enzymatic  
activity,   protein   and   expression   of   GCase.   The   data   is   new   in   providing   a   more  
extensive  report  on  the  effects  of  ABX  and  an  additional  chaperone  molecule,   IFG,  
on   the   upregulation   of   GCase   as   a   novel   therapeutic   strategy   for   modulating  
lysosomal  function  in  human  disease. The  data  is  also  new  in  testing  PC  in  patient-­
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derived  dopaminergic  neurons,   as  a  model   for   their   potential   therapeutic  effects   in  
the  brain.   
I  have  demonstrated  that  ABX  and  IFG  improve  GCase  activity  and  protein  levels  in  
GBA  mutation   fibroblasts,   as   well   as   in   PD   and   control   fibroblasts.   The   greatest  
increase  in  GCase  activity  was  upon  ABX  treatment.  This  could  be  because  ABX  is  a  
mixed-­type  inhibitor,  while  IFG  is  a  potent  inhibitor  of  recombinant  GCase. Although  
a  PC  is  supposed  to  dissociate  in  the  acidic  pH  of  the  lysosome,  some  researchers  
recommend  that  media  containing  IFG  is  removed  and  replaced  with  media  alone  to  
help  remove  any  residual   inhibition   in   the  cells   (a   ‘washout’)   (Khanna  et  al.,  2010).  
This  is  not  ideal  for  a  drug  given  to  patients,  where  a  washout  would  not  be  practical.  
My  data  shows  that  ABX  increases  the  trafficking  of  GBA  to  the  lysosome.  While  IFG  
increases   the   overall   GCase   activity,   there   is   no   significant   improvement   in   the  
fraction  co-­localized  with  the  lysosome.  It  could  be  that  IFG  is  an  activator  of  GCase  
and  improves  the  stability  of  the  enzyme,  but  does  not  increase  the  trafficking  of  the  
protein   to   the   lysosome.  However,   others   have   shown   that   IFG  does   increase   the  
lysosomal  pool  of  GCase  (Khanna  et  al.,  2010).   It   is   important   to  note   that  authors  
performed   measurements   after   a   7-­day   incubation   in   the   presence   of   30μM   IFG,  
followed  by  a  3-­day  washout  period  to  minimize  potential  GCase  inhibition  by  IFG  in  
situ.  I  incubated  fibroblasts  for  6  days  in  the  presence  of  50μM  IFG  but  did  not  follow  
with   a   washout   period.   The   degree   of   potential   GCase   inhibition   may   have   been  
greater  at   the  higher  concentration  of   IFG.  However,   in  an  experiment   to  compare  
the  GCase  activity  of  fibroblast  cells  following  a  24-­hour  washout  versus  no  washout,  
I   found   no   significant   difference   in   the  GCase   activity  measured   (Figure   9.15).   In  
fact,  the  GCase  activity  was  slightly  lower  after  the  washout  period.    
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It   has   been   suggested   that   the   function   of   ABX   may   not   be   restricted   to   a  
‘chaperoning   effect’.   ABX   may   be   inducing   a   more   global   effect   on   lysosomal  
function.  For  instance,  it  has  been  postulated  that  ABX  activates  the  CLEAR  network  
through  the  action  of  Transcription  Factor  EB  (TFEB)  (McNeill  et  al.,  2014).  TFEB  is  
a  transcription  factor  that  controls  at  least  471  genes  and  is  the  master  regulator  of  
lysosomal   biogenesis   (Palmieri   et   al.,   2011).   In   a   recent   study,   it   was   shown   that  
ABX  treatment  led  to  a  significant  upregulation  of  TFEB  messenger  RNA  levels  in  all  
treated   cells   (McNeill   et   al.,   2014).   Furthermore,   authors   demonstrated   that   gene  
expression  profiling  in  ABX  treated  control  cells  demonstrated  strong  upregulation  of  
lysosomal  and  autophagy  genes.  This  provided  strong  evidence  for  an  activation  of  
the  CLEAR  network  by  ABX  and  a  resultant  upregulation  of  TFEB  transcript   levels.  
Therefore,  ABX  could  have  an  additional  mechanism  of  action  aside  from  its  role  as  
a  chaperone.  ABX  could  be  increasing  GCase  activity  in  GBA  mutant  fibroblasts  by  
increasing  the  expression  of  TFEB,  which  is  associated  with  activating  components  
of  the  CLEAR  network  (Sardiello  et  al.,  2009).  My  data,  and  those  of  others  (McNeill  
et  al.,  2014),  does  suggest  a  general  expansion  of  the  lysosomal  compartment.  I  saw  
significant   increases   in   LAMP1   upon   ABX   treatment   in   GBA   mutant   fibroblasts.  
Lysosomes  are  a  major  site  of  SNCA  degradation.   It   is  plausible   that  an   increased  
lysosomal  mass  could  result   in  an   increased  SNCA  degradation  rate  (Alvarez-­Erviti  
et  al.,  2010).  TFEB  directly  regulates  the  biogenesis  of  autophagosomes,  the  fusion  
of  autophagosomes  with  lysosomes  and  the  autophagic  flux  (Palmieri  et  al.,  2011).  If  
ABX   is  mediating   its   affects   through   an   activation   of   TFEB,   this   could   explain   the  
upregulation   of   LC3,   a   marker   of   autophagosomes,   seen   upon   ABX   treatment   in  
GBA   mutant   neurons.   This   upregulation   of   macroautophagy   could   increase   the  
turnover   of   SNCA,   which   could   be   a   critical   step   in  GBA  mutant   neurons   where  
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levels   of   SNCA   are   higher,   and   if   aberrant   SNCA   is   not   removed,   this   could  
accumulate  and  predispose  to  PD.    
For  any  potential  therapy,  it  is  important  to  pick  a  concentration  which  produces  the  
desired  effect  but  with  the  least  side  effects.  Treatment  of  fibroblasts  with  60μM  ABX  
produced   the   greatest   increase   in   GCase   activity   (Figure   7.27).   However,  
cytotoxicity  appeared  upon  every  day  treatment  at  this  concentration  (Figure  9.12).  
In  a  study  of   the  chaperone  activity  and   toxicity  of  ABX   in  GD  cells,   the  viability  of  
fibroblast   cells   was   unchanged   after   incubation   with   ABX   at   concentrations   up   to  
30μM  (Luan  et  al.,  2013).  Cytotoxicity  to  GD  and  normal  cells  appeared  only  at  the  
concentrations   of   60μM   and   100μM.   For   my   experiments,   I   overcame   potential  
cytotoxicity  of  the  60μM  concentration  by  treating  cells  alternate  daily.  This  48-­hour  
treatment   did   not   compromise   the   cell   viability   (Figure   9.12).   However,   for   a  
treatment   that   is   intended   to   be   given   daily,   I   decided   to   evaluate   whether   a  
concentration   of   10μM   or   30μM   ABX   was   sufficient   to   reproduce   the   same  
biochemical   effects   observed.   My   data   have   shown   that   at   concentrations   low  
enough  not  to  cause  cytotoxicity  (Luan  et  al.,  2013),  significant  increases  of  GCase  
activity  and  protein  levels,  and  significant  reductions  of  SNCA  were  still  observed.    
In  summary,  the  small  molecular  chaperone,  ABX,  restores  GCase  activity  in  human  
fibroblasts   and   dopaminergic   neurons   derived   from   their   fat-­derived   NCSC.  
Optimised   treatment  with  ABX   resulted   in   significant   restoration  of  GCase  enzyme  
activity,   protein   and   gene   expression   in   all   cell   lines,   and   an   upregulation   of  
macroautophagy  and  a  reduction  of  SNCA  in  DA  neurons.  ABX  could  be  mediating  
its  effects  by  activating  components  of  the  CLEAR  network  through  TFEB  combined  
with   its   known   chaperone   activity   (McNeill   et   al.,   2014).   My   data   highlight   the  
potential  benefits  of  manipulating   the  GCase  pathway   to   lower  SNCA   levels   in  PD.  
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For  patients,  the  optimal  concentration,  regimen  and  treatment  duration  of  a  PC  still  
needs   to   be   determined.   The   concentration   of   ABX   as   a   mucolytic   may   not   be  
adequate   for   PD.   It   would   be   important   to   make   some   correlation   between   the  
concentrations   used   in   patient-­derived   cells   with   the   equivalent   oral   concentration  























6.1  A  clinical   road  map  of   the  pre-­motor,  pre-­diagnostic  prodrome  
of  Parkinson’s  disease    
Mutations  in  GBA  are  widely  recognized  to  be  an  important  and  common  genetic  risk  
factor  for  PD  (Sidransky  et  al.,  2009b),  and  are  found  in  British  subjects  with  PD  at  a  
higher  frequency  than  any  other  known  PD-­associated  gene  (Neumann  et  al.,  2009).  
Of  particular  interest  is  the  evidence  accumulating  that  GBA  mutant  homozygote  and  
heterozygote  carriers  without  clinical  evidence  of  PD,  exhibit  the  prodromal  features  
of  the  disease.  In  2012,  I  continued  the  clinical  evaluation  of  a  unique  cohort  of  GBA  
mutation  positive   individuals   for   the  early  prodromal   features  of  PD   (Beavan  et  al.,  
2015).  This  study  cohort  is  an  ideal  population  to  study  a  neuroprotective  strategy  or  
disease   modifying   therapy.   What   was   perhaps   surprising   about   this   non-­
parkinsonian  GBA  positive  cohort  at  the  initial  assessment  in  2010  was  a  significant  
difference  from  controls  even  at   the  baseline  evaluation  (McNeill  et  al.,  2012b).     At  
baseline,  GBA   mutation-­positive   individuals   demonstrated   hyposmia   and   cognitive  
impairment   (McNeill  et  al.,  2012b).   Importantly,   I   found   that  olfaction  and  cognition  
remained   significantly   lower   in   GBA   mutation-­positive   individuals   compared   to  
controls  at  two  years  follow-­up  (Beavan  et  al.,  2015).  I  further  identified  a  significant  
deterioration  across  clinical  markers  in  GBA  mutation–positive  individuals  consistent  
with   the  prodrome  of  PD.  Within   this  group,  10%  appeared   to  be  progressing  at  a  
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more  rapid  rate.  It  is  interesting  to  compare  my  results  which  identified  10%  of  GBA  
mutation-­positive   individuals   developing   parkinsonian   motor   features,   with   the  
reported  estimate  that  10%  of  PD  patients  carry  a  mutation  in  GBA  (Sidransky  et  al.,  
2009b).   In   this   subgroup   of   GBA   mutation   positive   individuals   with   parkinsonian  
motor   signs,   mild   cognitive   impairment   was   the   main   premotor   sign   present   at  
baseline  that  could  have  predicted  their  motor  deterioration.  
  
The  aim  of   the  present   study  was   to   investigate   the  development  and  evolution  of  
clinical   biomarkers   for   PD   in   a   high-­risk   population,   in   order   to   ascertain   a  
spectrum/pattern  of  changes  that  would  enable  me  to  develop  an  early  biomarker  set  
that   could  predict  PD.   In  a   subgroup  of   individuals  with  parkinsonian  signs,   I   have  
gone  on  to  perform  analysis  to  identify  premotor  signs  at  baseline  that  could  predict  
the   motor   signs   at   follow-­up.   However,   I   have   also   planned   future   follow-­up  
assessments   to   confirm   that   the   differences   I   am   seeing   are   indeed   predictive   of  
future  PD.    
  
My   data   indicate   that   individuals   with   GBA   mutations   exhibit   identical   prodromal  
abnormalities   to   those   with   idiopathic   PD.   There   appears   to   be   a   relatively   rapid  
evolution   of   non-­motor   and  motor   features   in   this   cohort.   Further   follow   up   of   this  
group  will   enable   early   diagnosis   in   those   progressing   to   clinical   PD   and   perhaps  
allow   identification   of   a   specific   clinical   or   biochemical   pattern   that   distinguishes  
those  with  GBA  mutations  who  will  and  those  who  will  not  develop  PD.   In   terms  of  
the   specific   alterations   that   lead   to   developing   PD   in   a   group   of  GBA   mutation-­
positive   individuals,   I   can   only   hypothesize   that   other   genetic   or   possibly  
environmental   factors   may   be   of   relevance   here.   Study   of  GBA   mutation-­positive  
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individuals   that   do   not   go   on   to   develop  PD   could   provide   insight   into   factors   that  
may  afford  protection  from  PD.    
  
Improved   insight   into   possible   disease   mechanisms,   lays   the   basis   for   the  
development   of   new   therapies   to   slow   the   rate   of   progression   or   stop   the   disease  
process  (Schapira  et  al.,  2014).   It   is   thus   imperative   to  develop  an  early  biomarker  
set   to   identify   individuals  at   greatest   risk   for   the  development  of  PD.   In  my  PhD,   I  
have   attempted   to   identify   subjects   likely   to   develop   PD   through   the   use   of   early  
clinical   markers   (Beavan   et   al.,   2015).   The   data   from   this   cohort   suggest   that  
hyposmia  is  the  earliest  and  most  sensitive  prodromal  marker.  Cognitive  impairment  
is   also   an   early   feature   and   this  may   relate   to   the   increased   cognitive   impairment  
observed   with  GBA-­PD.   Symptoms   of   RBD,   the  most   specific   clinical  marker,   are  
now  present   in  GBA  mutation  positive   individuals.  Depressive  symptoms  have  also  
surfaced  but  must  be  interpreted  with  some  caution  considering  their   low  specificity  
as  a  marker  for  PD.  There  has  also  and  perhaps  most  importantly,  been  a  significant  
decline  on  the  UPDRS,  which  together  with  impaired  RBD  and  depression,  suggest  
that  clinical  markers   in  some   individuals  of   this  GBA  mutation  positive  cohort  have  
evolved,  in  a  pattern  consistent  with  the  clinical  prodrome  of  PD.    
  
6.2  GBA  mutation  escalates  the  onset  of  Parkinson’s  disease  
Patients   with   a  GBA   mutation   have   clinical   deterioration   consistent   with   the   early  
stages  of  PD.  In  a  prospective  cohort  study,  both  patients  with  type  1  GD  and  those  
with   heterozygous   GBA   mutations   have   shown   a   gradual   clinical   deterioration  
consistent  with  the  clinical  prodrome  of  PD  (Beavan  et  al.,  2015).    
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In   the   clinical   setting,   it   can   be   difficult   to   distinguish   individual   PD   patients  
with  GBA  mutations   versus   those   without  GBA   mutations.   GBA-­PD   patients   show  
the   classic   triad   of   bradykinesia,   rigidity   and   tremor,   with   an   asymmetric   onset  
(Goker-­Alpan   et   al.,   2008).   However,   there   are   some   subtle   differences.   In  GBA  
mutation  positive  carriers,  the  age  of  onset  tends  to  be  slightly  younger  and  there  is  
a  greater  risk   for  earlier  and  more  prevalent  cognitive   impairment  (Sidransky  et  al.,  
2009b;;  Winder-­Rhodes  et  al.,  2013).  In  addition,  the  pattern  of  cognitive  impairment  
seen  in  GBA  mutation  positive  carriers  with  PD  is  slightly  different  and  present  even  
in  those  without  PD  at  the  time  of  investigation  (Zokaei  et  al.,  2014).    
Neuroimaging   in   GBA-­PD   with   positron   emission   tomography   or   single   photon  
emission   computed   tomography   for   the   visualisation   of   radioactive   dopamine  
transporter   ligands  demonstrates   an   asymmetry   of   radioligand   uptake  
indistinguishable  from  idiopathic  PD  (Goker-­Alpan  et  al.,  2012;;  McNeill  et  al.,  2013a).  
Furthermore,   the   pathology   of   GBA-­PD   is   identical   to   that   of   idiopathic   disease.  
GBA-­PD   brains   exhibit   the   characteristic   pathology   of   PD   such   as   brainstem   and  
cortical  LBs  (Wong  et  al.,  2004;;  Neumann  et  al.,  2009).  GBA  has  also  been  found  in  
LBs,  and  more  frequently  in  those  with  the  GBA  mutation  (Goker-­Alpan  et  al.,  2010).    
The  response  to  dopaminergic  therapy  in  patients  with  PD  with  or  without  mutations  
in  GBA  appears   to  be   the  same,   including   the  development  of  motor  complications  
(Ziegler   et   al.,   2007).  Most   studies   report   a   good   or   excellent   response   to   L-­dopa  
treatment   in   heterozygote  GBA  mutation   carriers   (Ziegler   et   al.,   2007;;  Neumann  et  
al.,  2009),  but  some  report  a  less  favourable  response  (Tayebi  et  al.,  2003).  
My  data   favours  a   link  between   the  GBA  mutation  and  a  higher   frequency  of  non-­
motor  symptoms  and  rate  of  clinical  progression.  My  work  (Beavan  et  al.,  2015)  and  
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those  of  others  (Winder-­Rhodes  et  al.,  2013;;  Brockmann  et  al.,  2014)  may  suggest  
that   the  GBA  mutation   represents   a   poor   prognostic  marker   for   an   individual   who  
develops   PD.   The   evidence   from   longitudinal   studies   demonstrate   that   GBA-­
associated   PD   patients   show   a   more   rapid   disease   progression   dominated   by  
accelerated  motor   impairment  with  greater   risk   for  progression   to  Hoehn  and  Yahr  
stage  3  (Winder-­Rhodes  et  al.,  2013),  and  a  greater  preponderance  to  dementia  or  
cognitive   decline   (Brockmann  et   al.,   2014).  Some   studies   have   suggested   that   LB  
deposition   is  more  extensive   in  GBA  mutant  positive  brains  (Clark  et  al.,  2009)  but  
this  is  not  universally  found  (Parkkinen  et  al.,  2011).  Therefore,  one  might  argue  that  
it   is   the  GBA  mutation   status,   rather   than   advanced   age   at   onset,   that   presents   a  
predictor   for   disease   progression   in   PD.   In   population-­based   longitudinal   studies,  
motor  impairment,  dementia  and  advanced  age  all  predict  mortality  in  PD  patients.  In  
the  same  vein,  those  carrying  the  GBA  mutation  who  exhibit  more  rapid  progression  
of   motor   impairment   and   cognitive   decline,  also   show   increased   rates   of   mortality  
(Brockmann  et  al.,  2014).    
This   could   have   significant   socioeconomic   implications.   PD   is   the   second   most  
common   neurodegenerative   disease   after   Alzheimer’s   disease   and   affects  
approximately  seven  million  people  globally.  PD  is  more  common  in  the  elderly  and  
prevalence  rises  from  1%  in  those  over  60  years  of  age  to  4%  of  the  population  over  
80.  The  incidence  of  PD  is  between  8  and  18  per  100,000  person–years.  The  costs  
of  PD  to  society  are  high,  but  precise  calculations  are  difficult  due  to  methodological  
issues  in  research  and  differences  between  countries.  The  annual  cost  in  the  UK  is  
estimated   to  be  between  449  million  and  3.3  billion  pounds.  This   variance   reflects  
whether   costs   are   limited   to   drugs   and   devices   (deep   brain   stimulation)   or   also  
include  institutional  support.  A  study  in  Europe  has  shown  that  delaying  the  course  of  
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PD  by  3  months  alone,  and  delaying   institutionalisation  by   the  same  amount  could  
pay  for  the  life-­time  cost  of  a  PD  patient’s  drugs.  Hence  the  focus  of  research  in  PD  
is  on  slowing  progression  of  the  disease.  In  those  carrying  the  GBA  mutation,  a  more  
rapid   progression   of   motor   impairment   and   cognitive   decline,   could   increase   the  
demand  for  nursing  care  and/or  institutional  support.    
In   a   recent   longitudinal   study,   authors   raised   the   question   of   whether   screening  
patients   with   PD   for  GBA  mutations   should   become   part   of   the   routine   diagnostic  
work-­up   in   clinical   practice   (Winder-­Rhodes   et   al.,   2013).   It   is   still   relatively  
expensive  to  perform  whole  exome  and/or  whole  genome  screening  on  every  patient  
with   PD,   but   this   could   be   a   future   consideration   as   we  move   towards   an   era   of  
preventative   genetic   screening   and   the   costs   go   down   with   increased   demand.  
However,   there   are   ethical   considerations   with   mass   screening,   such   as   genetic  
counselling  of   family  members,  albeit   the  penetrance  of  GBA  mutations   is   low,  and  
carrying  the  GBA  mutation  is  not  a  prerequisite  for  developing  PD  in  later  life.  
  
In   summary,   GBA  mutations   are   found   in   10%   of   the   PD   population   worldwide  
(Sidransky  et  al.,  2009b)  and  therefore,  represent  a  significant  proportion  of  patients  
with  PD  who  might  reasonably  be  encountered  by  the  non-­specialist  clinician.  Both  
mutations   and   polymorphisms   in  GBA  could   adversely   affect   the   trajectory   of   PD  
(Winder-­Rhodes  et  al.,  2013),  and   therefore,   the  presence  or  absence  of   the  gene  




6.3  Delineating   the   molecular   mechanism   of   mutant   GBA   to   the  
pathogenesis  of  Parkinson’s  disease  
  
My   data   suggest   that  GBA   mutations   interfere   with   SNCA   clearance.   I   have  
demonstrated  that  mutations  in  GBA  cause  reductions  in  GCase  activity,  impairment  
of   the   UPR,   and   dysfunction   of   lysosomal   autophagy,   potentially   leading   to  
insufficient   SNCA   turnover.   The   analysis   of   GBA-­PD   brain   on   post   mortem   has  
shown   that  LBs  are   immune-­reactive   for  GBA,  which  suggests   that  GBA  mutations  
are  sufficient  for  SNCA  aggregation  (Goker-­Alpan  et  al.,  2010).  
  
The   pathological   hallmark   of   PD   is   SNCA   aggregation.   This   phenotype   has   been  
demonstrated   in   dopaminergic   neurons   derived   from   patients   with   genetic   PD  
including  those  with  SNCA  triplications  (Devine  et  al.,  2011),  Parkin  (Imaizumi  et  al.,  
2012)  and  LRRK2  G2019S  (Nguyen  et  al.,  2011),  and  GBA  N370S/84GG  (Mazzulli  
et   al.,   2011).   In   twins   harbouring  GBA  N370S,   an   increase   in   monomeric   SNCA  
levels  was  observed  (Woodard  et  al.,  2014).  In  my  studies,  when  differentiated  into  
DA  neurons,  cell  lines  harbouring  GBA  N370S  had  significantly  higher  SNCA  levels  
in   the   absence   of   disease,   suggesting   that   the   GBA   mutation   perturbs   SNCA  
processing.  It  would  be  prudent  to  check  whether  SNCA  mRNA  levels  differ  in  these  
cell   lines,   as   an   indication   of   whether   the   GBA   mutation   interferes   with   SNCA  
transcription.  Recent   data   suggests   that   SNCA  mRNA   levels   do   not   differ   in  GBA  
N370S   positive   cell   lines   (Woodard   et   al.,   2014).   It   would   also   be   important   to  
determine   SNCA  mRNA   levels   in   the   presence   of   ABX.   This   could   help   elucidate  
whether   the   drug   is   affecting   the   synthesis   or,   as   implied   by   an   upregulation   of  
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autophagy,   the   turnover   of   SNCA   protein.   In   addition,   measurements   for   SNCA  
release  will  help  demonstrate  whether  more  of  the  protein  is  being  secreted.    
  
In   neurons   derived   from   twins   carrying   heterozygous  GBA  N370S,   there   was   an  
approximately   50%   decrease   in   GCase   activity.   However,   despite   an   increase   in  
monomeric  SNCA  levels,  authors  did  not  discover  SNCA  aggregation.   In  an  animal  
model,   homozygous  GBA  mutations   enhanced  SNCA  aggregation   in  mouse   brains  
(Sardi  et  al.,  2011).  This  implies  that  more  severe  GCase  deficiency  may  be  required  
for  SNCA  aggregation  and/or  additional  factors  are  important  for  the  synucleinopathy  
in  PD  brains  carrying  heterozygous  GBA  mutations.  
  
Human   adipose   derived   NCSC   have   the   potential   to   differentiate   into   functional  
dopaminergic   neurons.   This   finding   offers   the   opportunity   to   generate   a   patient-­
specific   DA   neuronal   model.   Using   this   patient-­specific   DA   neuronal   model   to  
investigate   the   relationship   between  GCase,   SNCA   and   lysosome   impairment   has  
confirmed   GBA   mutation   carriers   demonstrate   decreased   GBA   protein   levels,  
reduced   GCase   activity,   and   impaired   neuronal   cell   macroautophagy;;   these  
pathological  processes  in  turn  may  increase  SNCA  levels  in  neuronal  cells  with  the  
potential   for   leading   to   SNCA   aggregation.   Therefore,   DA   neuronal   cell   models  
derived   from  GBA  mutation   positive   patient   adipose   tissues   could   mimic   the   PD  
pathological  process.  NCSC-­derived  DA  neurons  represent   individual  human  nerve  
cells;;   recapitulate   some   key   PD   pathological   features,   particularly   SNCA  





6.4  Using   the   data   collected   could   pharmacological   chaperones  
represent  a  novel  therapeutic  approach  for  Parkinson’s  disease?  
At   present,   all   treatment   for   PD   is   symptomatic.   It   does   not   slow   down   the  
progression  of  the  disease.  A  drug  that  can  slow  or  stop  the  disease  is  desperately  
needed.   There   are   many   causes   and   factors   that   increase   the   risk   of   PD,   but  
mutations  of  the  GBA  gene  are  the  most  important.  Mutations  of  this  gene  increase  
the  risk  for  PD  by  20-­30  times,  and  are  found  in  at  least  10%  of  PD  cases.  
Studies   of   brains   from   patients   who   have   died   with   PD,   cell   models   and   animal  
models   of   GBA   mutations   and   PD   indicate   that   there   is   a   close   link   between  
glucocerebrosidase   enzyme  GCase,   the   product   of   the  GBA   gene  and  SNCA,   the  
main  protein  involved  in  PD  pathology.  This  relationship  is  reciprocal  in  that  reduced  
GCase   activity,   for   instance   as   a   consequence   of   a   mutation   in   the   GBA   gene,  
causes   an   increase   in   SNCA   such   as   that   seen   in   PD.   Alternatively,   increased  
SNCA,   for   instance  as  a  consequence  of  mutations   in   the  SNCA  gene,   result   in  a  
reduction  in  GCase  activity.  
My  data  support   the  suggested   interaction  between  GCase  and  SNCA.   In  addition,  
mutations   in  GBA   have   been   shown   to   cause   autophagic   dysfunction   leading   to  
insufficient   SNCA   turnover.   The   relationship   between   GCase   and   SNCA   may   be  
leveraged   to   reduce   SNCA   levels   in   PD   by   enhancing   GCase   levels   and   activity.  
This   hypothesis   has   previously   been   suggested   by   preliminary   data   in   cells  
overexpressing  SNCA  (McNeill  et  al.,  2014),  and  offers  an  important  target  pathway  
for   future  neuroprotection   therapy   in  PD.   Importantly,   I  have  shown   in  human  cells  
that   this   relationship   can   in   fact   be  manipulated   so   that   increasing  GCase   activity  
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induces   a   reduction   in  SNCA   levels.   This   is   of   considerable   relevance   to  PD,   and  
offers  the  opportunity  to  develop  novel  drugs  to  target  this  relationship  and  decrease  
SNCA  levels  and  spread  to  slow  or  stop  the  progression  of  PD.    
In  my  PhD  study,  I  have  used  a  drug  which  is  currently  available  for  use  in  patients  
for  an  entirely  different   illness   (as  a  cough  medicine),  and  with  a  very  good  safety  
profile,  in  human  cells  from  PD  patients  to  show  that  it  can  increase  GCase  activity.  
ABX  is  a  drug  class  known  as  a  small  molecule  chaperone  that  interacts  with  GCase  
and  increases  activity  of  both  the  mutant  and  normal  forms  of  this  enzyme.  The  next  
stage   will   move   towards   developing   this   drug   for   PD   patients.   The   drug   has   now  
been   tested   further   in   cell   cultures   from   individuals   with  GBA   mutations,   with   and  
without  PD.  The  results  have  confirmed  the  effect  of  small  molecule  chaperones  to  
increase  GCase  activity.   In  addition,  my  studies  have  confirmed   that   this  drug  can  
reduce  SNCA  levels  in  neuronal  cells.    The  data  highlights  the  potential  effect  of  the  
drug  on  brain  SNCA  to  reduce  levels  and  potentially  the  spread  of  SNCA  pathology.  
However,   the   pathogenesis   of   PD   is   complex,   and   any   successful   therapeutic  
strategy  will  require  stratification  of  genetic  and  non-­genetic  factors.    
I  have  analysed  how  GBA  mutations  increase  the  risk  of  PD  and  how  an  individual's  
symptoms  and  signs  can  signal  their  risk  for  the  disease.  This  will  be  very  important  
in  identifying  those  at  risk  and  who  would  be  best  suited  to  receive  a  drug  prior  to  the  
development   of   PD.   If   the   results   of   subsequent   studies   in   this   laboratory   are  
positive,   and  my   pilot   data   strongly   indicate   they  will   be,   the   next   stage  will   be   to  
move  towards  a  clinical  trial  of  ABX  in  PD  patients,  and  in  parallel,  to  collaborate  with  
industry  to  develop  novel  highly  active  small  molecule  chaperones  for  further  testing  
and  use  in  patients.    
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6.5  If  I  could  do  this  PhD  again,  what  would  I  do  differently  now?  
If   I   went   back   to   re-­examine   the   clinical   cohort   now,   I   would   consider   recruiting   a  
larger   number   of   subjects   as   it   is   difficult   to   reach  meaningful   conclusions   from   a  
small  sample  number.  I  would  also  look  into  whether  some  of  the  assessments  could  
be  performed  online  by  subjects  at  home  or  on  a  computer.  This  might  encourage  
wider   participation   and   improve   follow-­up   rates.   I   would   also   ensure   that   all  
investigators  were  blind  to  the  genetic  status  of  individuals,  as  this  is  a  potential  bias  
when  it  comes  to  the  final  data  analysis.  One  other  improvement  would  be  to  ensure  
that   it   is   the   same   assessor   evaluating   subjects   to   reduce   any   inter-­observer  
differences.  However,  this  may  be  difficult  in  view  of  the  fact  that  it  is  often  a  clinical  
fellow  performing  these  assessments  and  who  is  employed  for  a  limited  time  period  
to  complete  a  PhD  etc.  Finally,  due  to  the  mixed  specificity  and  sensitivity  of  clinical  
biomarkers,   it   would   have   been   useful   to   combine   these   with   biochemical   and  
imaging  markers  in  order  to  more  accurately  predict  PD  in  this  at-­risk  cohort.    
For  my  laboratory  studies,  I  focused  on  human  material  but  it  would  have  been  nice  
to  have  tested  the  drug  compounds  in  an  animal  model  e.g.  a  mouse  model,  which  
would  have  been  complimentary  and  perhaps  reinforced  my  studies.  In  addition,  it  is  
always   beneficial   to   collect   and   test   as   many   samples   as   possible   to   achieve  
meaningful   results  and   robust  conclusions.   I  would  have   liked   to  have   tested  more  
patient  samples  for  a  higher  n  number,  but  I  did  the  minimum  (n=3)  for  my  neuronal  
studies  due  to  the  limitations  of  cost  and  time.  On  a  final  note,  if  I  had  more  time,  I  
would  have  liked  to  have  made  a  more  distinct  correlation  between  the  concentration  
of   ABX   that   produced   the   desired   biochemical   effect   in   cells   with   the   quantity  
required  for  a  patient  to  take  as  an  oral  tablet  to  reduce  SNCA  in  PD.  
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Chapter  7:  Figures  
  
  
Figure  7.1.  The  pathogenesis  of  GBA  mutations  in  Parkinson’s  disease.    
In  normal   functioning   lysosomes,  wild-­type  (WT)  GCase   interacts  with  α-­synuclein   (SNCA),  and   this  
beneficial   interaction   could   promote   the   degradation   of  SNCA   through   lysosomal   autophagy   (A).   In  
some  cases,  mutant  GCase  or  decreased   levels  of  WT  GCase   reaching   the   lysosome  weaken   this  
interaction,  increasing  the  likelihood  of  SNCA  accumulation.  This  event  is  more  likely  with  increasing  
age,   when   the   numbers   and   function   of   lysosomes   decrease   and   cellular   SNCA   concentrations  
increase.   The   inhibitory   effect   of   SNCA   can   further   impair   the   trafficking   of   WT   GCase   via   the  
endoplasmic  reticulum  (ER)/Golgi  (B),  resulting  in  less  WT  GCase  being  delivered  to  the  lysosome  via  
the   lysosomal   integral   membrane   protein-­2   (LIMP-­2)   transporter   (C),   compounding   the   problem.  
Mutations   in  GBA  could  also   increase  the  risk  of  PD  through  abnormalities   in  mitochondrial   function  
by  an  unknown  mechanism  (D).  Misfolded  GCase  trapped  in  the  ER  could  trigger  the  unfolded  protein  
response   (UPR)   and/or   activate   endoplasmic   reticulum-­associated   degradation   (ERAD)   (E).  






Figure   7.2.  The   glucocerebrosidase/SNCA   axis,   potential   targets   for  
therapeutic  intervention  for  PD.    
SNCA  interacts  with  both  wild-­type  (WT)  and  mutant  (Mut)  GCase,  and  modulation  of  this  may  serve  
to   reduce  SNCA   concentrations   and   delay   or   reverse   PD-­related   pathology.   Strategies   to   increase  
lysosomal  GCase  or   to  decrease  extralysosomal  GCase–SNCA  interactions  would  be  anticipated   to  
reduce   SNCA   concentrations.   Chaperones,   histone   deacetylase   inhibitors   (HDACi),   or   increased  
expression   of   by,   for   example,   gene   therapy   (AAV-­GBA)   may   be   examples   of   such   strategies.  







Figure   7.3.   Clinical   markers   show   progression   in   GBA   mutation   positive  
individuals.                                                                                                                                                                                                                                    
Figures  demonstrate  mean  baseline  and  follow-­up  scores  for  olfaction  (A),  mean  baseline  and  follow-­
up  scores   for  autonomic  dysfunction   (B),  mean  baseline  and   follow-­up  MoCA  scores   (C)  and  mean  
baseline   and   follow-­up  MMSE  scores   (D)   for   Type   1  GD  patients   and   heterozygous  GBA  mutation  







Figure   7.4.   Clinical   markers   show   progression   in   GBA   mutation   positive  
individuals.  
Figures   demonstrate   a   statistically   significant   increase   in   depressive   symptoms   for   carriers   at   the  
follow-­up  evaluation   (F),   a   statistically   significant   increase   in  mean   follow-­up  RBDQ  scores   (E)  and  
UPDRS   III   scores   (H)   in   Type   1   GD   patients   and   heterozygous   GBA   mutation   positive   carriers  
compared   to   controls,   and  a   statistically   significant   increase   in  mean   follow-­up  UPDRS   II   scores   in  
Type   1   GD   patients,   heterozygous   GBA   mutation   positive   carriers,   and   controls   (G).   Means   are  








Figure  7.5.  Tremor  recording  in  a  patient  with  essential  tremor.  
Total   power   (G2)   of   the   tremor   in  one  patient   at   rest,   on  posture,   during   loading  and  during  action.  
Power  for  right  and  left  hands  is  shown  separately.  
  
  
Figure  7.6.  Dopamine  Transporter  (DaT)  scan  in  patient  JT.  
Single-­photon  emission   tomography   (SPECT)  demonstrated  clear-­cut   reduction  of  uptake  within   the  
putamina  bilaterally,  and   reduced  uptake  within   the   right  caudate  nucleus.  Findings  were  consistent  




Figure  7.7.  Characterisation  of  pluripotent  properties  in  healthy  NCSC      
Immunostaining  of  wild   type  NCSC  cultures.  Cells  were   stained   for  P75,  SOX10   (red),   and  Nanog,  
Oct-­4,  SSEA4  and  TRA-­1-­18  (all  green).  Nuclei  were  counterstained  with  DAPI  (blue).      
  
  
Figure  7.8.  Characterisation  of  pluripotent  properties  in  GBA  mutant  NCSC    
Immunostaining  of  GBA  mutation  positive  NCSC  cultures.  Cells  were  stained  for  P75,  SOX10  (red),  





Figure   7.9.     GBA  mutation   carriers   show   decreased   GCase   enzyme   activity,  
protein  levels  and  gene  expression.  
Glucocerebrosidase  enzyme  (GCase)  activity  was  measured  in  fibroblasts  from  control,  GBA  mutation  
carriers  with   and  without  PD,   and   idiopathic  PD  patients   (A).   Enzyme  activities  were   expressed   as  
nmol/hr/mg   protein.   GCase  activity   was   significantly   reduced   in  heterozygous  GBA  mutation   carrier  
fibroblasts   compared   with   healthy   control   cells.   GBA   mRNA   levels   in   disease   lines   compared   to  
controls   (B);;   there   were   reduced   mRNA   levels   in   GBA   mutation   carriers   compared   to   controls.  
Quantification   of  GBA   protein   in   each   variant   was   determined   by  western   blot   with   human-­specific  
antibodies   (see  Figure   7.30   for   representative  western   blots).   There  were   significant   reductions   of  
GBA  protein  in  GBA  mutation  carriers  compared  to  controls  (C).    Results  represent  the  mean  ±  SEM,  






Figure  7.10  GBA  mutation  carriers  show  defective  localization  of  GBA  protein.    
Representative   slices   (depth   3μM)   showing  colocalization   (yellow)   of   GBA   (green)   with   lysosomal  
marker  cathepsin  D  (red),  conducted  by  immunofluorescence  staining  (A).  Nuclei  were  counterstained  
with   DAPI   (blue).  GBA   signals   were   significantly   stronger   in   control   and   IPD   cells   compared   to  
heterozygous  GBA  mutation   carrier   cells,   where   GBA   was   nearly   undetectable.   Untreated   control  
GBA  colocalized   (yellow)  with   cathepsin  D   in   the   lysosome.   In   contrast,   colocalization   of  GBA  with  
cathepsin  D   (yellow)  was   significantly   reduced   by   50%   in   heterozygous  GBA  mutation   carrier   cells  
compared  to  control  cells.  Quantification  of  the  level  of  colocalization  relative  to  the  control  (B).  Data  
are  represented  as  mean  +  SEM;;  of  three  independent  experiments.  *p<0.05;;  one-­way  ANOVA  and  




                                                           
  
Figure   7.11.   GBA   mutation   carriers   and   PD   cells   show   reduced   GRP78  
expression,  suggesting  an  inadequate  UPR.      
The  levels  of  ER  protein  BiP/GRP78  were  determined  in  fibroblasts  from  GBA  mutation  carriers  with  
and   without   PD,   idiopathic   PD   patients,   and   in   normal   control   individuals   without  GBA  mutations.  
Quantification  of  the  levels  of  BiP  relative  to  β-­actin  (see  graph  shown).  Relative  levels  of  BiP/GRP78  
were  reduced  in  PD  cases,  independent  of  mutation  status,  by  approximately  35-­50%  and  reduced  in  
GBA  mutation  carriers  by  approximately  50–70%  compared  to  controls.  Data  are  represented  as  the  







                                                                       
  
Figure   7.12.   Lysosomal   content   and   function   is   unchanged   in  GBA  mutation  
carriers.                                                                                                                                                                                                                                                              
Hexosaminidase  and  β-­galactosidase  activity  were  unchanged  in  heterozygous  GBA  mutation  carrier  
fibroblasts   compared  with   healthy   control   cells   (A)   (B).  Quantification   of   the   basal   levels   of   LAMP1  
relative  to  β-­actin  (C).  See  Figure  7.32  for  representative  western  blots.  Data  are  represented  as  the  





Figure  7.13.  GBA  mutation  carriers  show  defects  in  lysosomal  autophagy.                                                                                                                                                                                                                                                          
Representative   western   blots   for   LC3   in   fibroblasts,   untreated   (Basal)   or   treated   with   0.2μM  
bafilomycin   (Baf)  or  DMEM  without   supplements   (Starv)   for  4  hours   (A).  Quantification  of   the  basal  
levels  of  LC3-­II  relative  to  β-­actin  (B).  Quantification  of  LC3  flux  relative  to  β-­actin  (C).  Representative  
western   blots   for   LAMP2a   and   Hsc70   protein   in   human   fibroblasts   (D).   Quantification   of   the   basal  
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levels   of   LAMP2a   relative   to   β-­actin   (E).   Levels   of   LAMP2a   protein   were   significantly   reduced  
in  heterozygous   GBA   mutation   carriers   compared   with   healthy   control   cells.   Quantification   of   the  
basal   levels   of   Hsc70   relative   to   β-­actin   (F).   Data   are   represented   as   the   mean   ±   SEM,   of   three  




Figure  7.14.  Immunocytochemistry  of  differentiated  neuronal  cells  
Immunostaining  of  differentiated  wild  type  NCSC  cultures  at  day  40.  Cells  were  stained  for  β-­Tubulin  
III   (TUB)   (green),   tyrosine  hydroxylase   (TH)   or  NURR1   (both   red).  Nuclei  were   counterstained  with  






Figure  7.15.  Optimization  of  adipose  NCSC  neuronal  differentiation        
Immunostaining  of  neuronal   cultures  at  day  40.  Cells  were  stained   for  β-­Tubulin   III.  Representative  
western  blots  of  β-­Tubulin  III  protein  levels  in  control  and  heterozygous  GBA  mutation  positive  carriers  
at  different  stages  of  neuronal  differentiation  (A).  Quantification  of  β-­Tubulin  III  protein  normalized  to  
GAPDH   (B).  Data   are   represented   as  mean   +  SEM;;   experiments  were   independently   repeated   for  
n=2.  Levels  of  β-­Tubulin   III  were  optimal  at  40  days  neuronal  differentiation   (B)  and  consistent  with  
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Response   to   a   dopamine   flux   in   NCSC-­derived   neurons   differentiated   for   40  
days  as  measured  by  the  level  of  fluorescence  (arbiturary  fluorescence  units,  





Figure  7.16.  Functional  analysis  of  differentiated  neuronal  cells  
Functional   analysis   of   wild   type   neuronal   cultures   at   day   40.   At   day   40,   56%   neuronal   cells   were  





Figure   7.17.   GBA   mutant   NCSC-­derived   neurons   show   decreased  
glucocerebrosidase  activity  at  different  stages  of  differentiation.  
GCase   activity   was   measured   in   neurons   from   control   and   heterozygous  GBA   mutation   positive  
carrier   NCSC-­derived   neurons   at   differentiation   day   0,   12,   20   and   40.      Enzyme   activities   are  
expressed  as  nmol/hr/mg.  Data  are   represented  as  mean  +  SEM.;;  experiments  were   independently  





































Figure   7.18.   GBA   mutant   NCSC-­derived   neurons   show   decreased  
glucocerebrosidase  protein  levels  at  different  stages  of  differentiation.  
Representative   western   blots   of  GCase   protein   levels   in   control   and  heterozygous   GBA   mutation  
positive  carriers  at  different  stages  of  neuronal  differentiation  (A).  There  were  significant  reductions  of  
GBA  protein  in  GBA  mutation  carriers  compared  to  controls.  Quantification  of  GBA  protein  normalized  

















Figure  7.19.  GBA  mutant  NCSC-­derived  neurons  show   increased  α-­synuclein  
(SNCA)  protein  levels  at  different  stages  of  differentiation.  
Representative   western   blots   of  SNCA   protein   levels   in   control   and  heterozygous   GBA   mutation  
positive  carriers  at  different  stages  of  neuronal  differentiation  (A).  There  were  significant  increases  of  
SNCA   protein   in   GBA   mutation   carriers   compared   to   controls.   Quantification   of   SNCA   protein  
normalized   to   β-­actin   (B).  Data   are   represented   as  mean  +  SEM;;   experiments  were   independently  

















Figure  7.20.  Changes   in  autophagy   in  GBA  mutant  NCSC-­derived  neurons  at  
different  stages  of  differentiation.  
Representative  western  blots  of  LC3  protein  levels  in  control  and  heterozygous  GBA  mutation  positive  
carriers  at  different  stages  of  neuronal  differentiation  (A).  There  were  significant  reductions  of  LC3-­II  
protein  in  GBA  mutation  carriers  compared  to  controls  for  all  four  time  points  studied.  Quantification  of  
LC3-­II   protein   normalized   to   β-­actin   (B).  Data   are   represented   as  mean  +  SEM;;   experiments  were  


















Figure  7.21.  Changes   in  autophagy   in  GBA  mutant  NCSC-­derived  neurons  at  
different  stages  of  differentiation.  
Representative   western   blots   of   LAMP2a   protein   levels   in   control   and  heterozygous   GBA  mutation  
positive   carriers  at  different   stages  of  neuronal  differentiation   (A).  Quantification  of  LAMP2a  protein  
normalized   to   β-­actin   (B).  Data   are   represented   as  mean  +  SEM;;   experiments  were   independently  

















Figure   7.22.   GBA   mutant   NCSC-­derived   neurons   show   decreased  
glucocerebrosidase  enzyme  activities  and  protein  levels.  
Glucocerebrosidase  enzyme  activity  was  measured  in  neurons  from  control,  GBA  heterozygous,  and  
IPD   NCSC-­derived   neurons   at   differentiation   day   40   (A).   Enzyme   activities   are   expressed   as  
nmol/hr/mg.   Representative   western   blots   of  GBA   protein   levels   in   control,  heterozygous   GBA  
mutation  positive   carriers,   and  PD  NCSC-­derived  neurons   (B).  There  were   significant   reductions  of  
GBA  protein   in  GBA  mutation   carriers   compared   to   controls   (C).    Data  are   represented  as  mean  +  





                                                                                                                                                    
                         
  
Figure   7.23.   α-­Synuclein   levels   are   increased   in  GBA  mutant   NCSC-­derived  
neurons.  
Representative   western   blots   showing   the   protein   levels   of  SNCA   in   control,   heterozygous   GBA  
mutation   positive   carriers   and   PD   NCSC-­derived   neurons   at   differentiation   day   40   (A).   Optical  
densities   of   SNCA  bands   were   normalized   by   the   averaged   value   of   β-­actin   and   expressed   as   a  
percentage  of  the  control  (CTRL)  line  value  (B).  Data  are  represented  as  mean  +  SEM.;;  experiments  
were   independently   repeated   three   times.   *p<0.05,   one-­way   ANOVA   and   Student’s  t-­test.   The  
reciprocal  relationship  between  GCase  and  SNCA  (C)  (D).  Immunocytochemistry  of  neuronal  cultures  
at   day   40   (E).   Cells   were   stained   for   β-­Tubulin   III   (TUB)   (green),   and   SNCA   (red).   Nuclei   were  




Figure   7.24.   GBA   mutant   NCSC-­derived   neurons   show   changes   in   the  
autophagic/lysosomal  system.  
Representative  western  blots  showing  the  protein  levels  of  LC3  in  NCSC-­derived  neuronal  cultures  at  
differentiation   day   40   (A).   Quantification   of   the   basal   levels   of   LC3-­II   relative   to   β-­actin   (B).  
Quantification  of   the  ratio  of  LC3-­II   to  LC3-­I  normalized   to  β-­actin   (C).  Representative  western  blots  
showing  the  protein  levels  of  p62  in  NCSC-­derived  neuronal  cultures  at  day  40  (D).  Quantification  of  
the  basal   levels  of  p62   relative   to  β-­actin   (E).  Data  are   represented  as  mean  +  SEM.;;  experiments  





Figure   7.25.   Bafilomycin   increases   LC3-­II   in   GBA   mutant   NCSC-­derived  
neurons  
Western  blot  analysis  for  LC3  in  NCSC-­derived  neuronal  cultures  at  differentiation  day  40,  untreated  
(−)  or  treated  with  0.2µM  bafilomycin  for  6  h  (+)  (A).  Quantification  of  the  basal  levels  of  LC3-­II  relative  
to  β-­actin  (B).  Data  are  represented  as  mean  +  SEM;;  experiments  were  independently  repeated  three  







Figure  7.26.  LAMP1  and  LAMP2a  levels  are  unaffected  by  the  GBA  mutation  in  
NCSC-­derived  neurons.  
Immunoblotting   of   differentiated   NCSC   cultures   at   differentiation   day   40   under   basal   conditions.  
Western  blot  analysis   for  LAMP1  in  NCSC-­derived  neuronal  cultures  (A).  Quantification  of   the  basal  
levels  of  Lamp1  relative  to  β-­actin  (B).  Western  blot  analysis  for  LAMP2a  in  NCSC-­derived  neuronal  
cultures  (C).  Quantification  of  the  basal  levels  of  Lamp2a  relative  to  β-­actin  (D).  Data  are  represented  









     
Figure  7.27.  Effect  of  ambroxol  and  isofagomine  on  enzymatic  GCase  activity  
Skin   fibroblast   cultures   from   a   control   (CTRL)   and   a  GD   patient   (N370S/N370S)  were   treated  with  
selected  concentrations  of  ambroxol  (ABX)  and  isofagomine  (IFG),  over  an  increasing  number  of  days  
at   37°C.   Samples   containing   20μg   protein   were   tested   for   GCase   activity   using   5mM   of   4-­
methylumbelliferyl-­β-­D-­glucopyranoside  substrate.  Data  are  expressed  as  the  fold  increase  in  GCase  
activity  in  the  presence  of  ABX  and  IFG,  in  comparison  to  untreated  cells  (0  days  of  treatment).  The  
results   represent   the   mean   ±   SEM,   of   three   independent   experiments.   Data   were   analysed   using  






Figure  7.28.  Effect  of  ambroxol  and  isofagomine  on  hexosaminidase  activity.  
Skin   fibroblast  cultures   from  a  control  and  a  GD  patient   (N370S/N370S)  were   treated  with  selected  
concentrations  of  ambroxol  (ABX)  and  isofagomine  (IFG),  over  an  increasing  number  of  days  at  37°C.  
Samples  containing  20μg  protein  were  tested  for  hexosaminidase  activity  using  4-­methylumbelliferyl-­
N-­acetyl-­glucosamide  substrate.  Data  are  expressed  as  the  fold  increase  in  activity  in  the  presence  of  
ABX  and  IFG,  in  comparison  to  untreated  cells  (0  days  of  treatment).  The  results  represent  the  mean  







Figure  7.29.  Effect  of  ambroxol  and  isofagomine  on  β-­galactosidase  activity.  
Skin   fibroblast  cultures   from  a  control  and  a  GD  patient   (N370S/N370S)  were   treated  with  selected  
concentrations  of  ambroxol  (ABX)  and  isofagomine  (IFG),  over  an  increasing  number  of  days  at  37°C.  
Samples  containing  20μg  protein  were  tested  for  β-­Galactosidase  activity  using  4-­methylumbelliferyl-­
β-­D-­galactopyranoside  substrate.  Data  are  expressed  as  the  fold  increase  in  activity  in  the  presence  
of  ABX  and   IFG,   in   comparison   to   untreated   cells   (0   days   of   treatment).   The   results   represent   the  
mean   ±   SEM,   of   three   independent   experiments.   Data   were   analysed   using   analysis   of   variance  
(One-­way  ANOVA).                  
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Figure  7.30.  Significant  restoration  of  GCase  enzyme  activity,  protein  and  gene  
expression  in  GBA  mutation  carriers  
Fibroblasts   from   controls,   heterozygous  GBA  mutation   carriers,   and   IPD  patients  were   treated  with  
60μM  ambroxol  or  50μM  isofagomine  alternate  daily  for  6  days  at  37  °C.  Data  are  expressed  as  the  
percentage   increase   of   GCase   activity   in   the   presence   of   each   pharmacological   chaperone   in  
comparison   to  untreated  cells   (A).  Quantification  of  GBA  protein   in  each  variant  was  determined  by  
western   blot  with   human-­specific   antibodies.   All   PC-­treated   cells   showed   increases   in  GBA  protein  
levels.   These   are   presented   as   the   percentage   change   relative   to   the   untreated   cells   (B).   PC  
treatment   significantly   increased  GBA   messenger   RNA   levels.   Bar   chart   demonstrating   significant  
increases  in  GBA  messenger  RNA  levels  after  PC  treatment   in  controls,  heterozygous  GBA  carriers  
and   IPD   (C).   Representative  western   blots   of  GBA   protein   levels   in   control,  GBA  mutation   carriers  
with   and   without   PD,   and   idiopathic   PD   fibroblasts   (D).  The   results   represent   the  mean  ±  SEM,   of  
three   independent   experiments.     *p<0.05;;  **p<0.01;;   one-­way   ANOVA   and   Student’s  t-­test.   PC,  




                                                                                       
  
Figure  7.31.  Correction  of  GBA  localization  in  GBA  mutation  carriers  
Representative   slices   (depth   3μM)   showing  colocalization   (yellow)   of   GBA   (green)   with   lysosomal  
marker  cathepsin  D  (red),  conducted  by  immunofluorescence  staining  (A).  Nuclei  were  counterstained  
with  DAPI  (blue).  Quantification  of  the  percentage  increase  of  colocalization  in  the  presence  of  each  
pharmacological  chaperone  in  comparison  to  untreated  cells  (B).  Data  are  represented  as  the  mean  ±  
SEM,   of   three   independent   experiments.  *p<0.05;;   **p<0.01;;   ***p<0.001;;   one-­way   ANOVA   and  





Figure   7.32.   Expansion   of   the   lysosomal   compartment   in   GBA   mutation  
carriers  
Hexosaminidase  and  β-­galactosidase  activity  were  unchanged  in  heterozygous  GBA  mutation  carrier  
fibroblasts   compared   with   healthy   control   cells   (A)   (B).   Representative   western   blots   for   LAMP1  
protein  in  human  fibroblasts  (C)  (D).  Quantification  of  the  basal  levels  of  LAMP1  relative  to  β-­actin  (E).  
Data   are   represented   as   the   mean   ±   SEM,   of   three   independent   experiments.   *p<0.05;;   one-­way  
ANOVA  and  Student’s  t-­test.  PC,  pharmacological  chaperone;;  ABX,  ambroxol;;  IFG,  isofagomine.  
  





Figure  7.33.  Glucocerebrosidase  enzyme  activities  are  enhanced  by  ambroxol  
in  GBA  mutant  NCSC-­derived  neurons.  
NCSC-­derived   neurons   from   controls,   heterozygous  GBA  mutation   carriers,   and   IPD   patients  were  
treated  with  60μM  ambroxol  alternate  daily   for  6  days  at  37  °C.  Samples  containing  20μg  of  protein  
were  tested  for  GCase  activity  as  described.  Data  are  expressed  as  the  increase  of  GCase  activity  in  
the  presence  of  ambroxol  in  comparison  to  untreated  cells.  The  results  represent  the  mean  ±  SEM,  of  









































6 0µM %A BX






Figure   7.34.  Glucocerebrosidase  protein   levels   are   increased  by   ambroxol   in  
GBA  mutant  NCSC-­derived  neurons.  
NCSC     from  controls,  heterozygous  GBA  mutation  carriers,  and   IPD  patients  were  differentiated   for  
40  days  and  treated  with  60μM  ambroxol  alternate  daily  for  6  days  at  37  °C.  Representative  western  
blots  of  GCase  protein  levels  in  control,  heterozygous  GBA  mutation  positive  carriers,  and  PD  NCSC-­
derived   neurons   (A).   Ambroxol   treatment   significantly   increased   GBA   protein   levels.   Bar   chart  
demonstrating  significant   increases   in  GBA  protein   levels  after  ABX  treatment   in  heterozygous  GBA  
carriers   and   IPD   (B).   The   results   represent   the   mean  ±  SEM,   of   three   independent  









Figure   7.35.   α-­Synuclein   protein   levels   are   reduced   by   ambroxol   in   GBA  
mutant  NCSC-­derived  neurons.  
NCSC     from  controls,  heterozygous  GBA  mutation  carriers,  and   IPD  patients  were  differentiated   for  
40  days  and  treated  with  60μM  ambroxol  alternate  daily  for  6  days  at  37  °C.  Representative  western  
blots  of  SNCA  protein  levels  in  control,  heterozygous  GBA  mutation  positive  carriers,  and  PD  NCSC-­
derived   neurons   (A).   Ambroxol   treatment   significantly   reduced   SNCA   protein   levels.   Bar   chart  
demonstrating  significant  reductions  in  SNCA  protein  levels  after  ABX  treatment  in  heterozygous  GBA  
mutation   carriers   and   IPD   (B).   The   results   represent   the   mean  ±  SEM,   of   three   independent  






Figure   7.36.   Markers   of  macroautophagy   are   increased   by   ambroxol   in  GBA  
mutant  NCSC-­derived  neurons.  
NCSC     from  controls,  heterozygous  GBA  mutation  carriers,  and   IPD  patients  were  differentiated   for  
40  days  and  treated  with  60μM  ambroxol  alternate  daily  for  6  days  at  37  °C.  Representative  western  
blots  of  LC3  protein   levels   (A).  Ambroxol   treatment  significantly   increased  LC3-­II  protein   levels.  Bar  
chart  demonstrating  significant  increases  in  LC3-­II  protein  levels  after  ABX  treatment  in  heterozygous  
GBA  carriers  and  IPD  (B).  Representative  western  blots  of  p62  protein  levels  in  control,  heterozygous  
GBA  mutation  positive  carriers,  and  PD  NCSC-­derived  neurons  (C).  Ambroxol  treatment  significantly  
increased  p62  protein  levels.  Bar  chart  demonstrating  significant  increases  in  p62  protein  levels  after  
ABX   treatment   in   heterozygous   GBA   mutation   carriers   and   IPD   (D).   The   results   represent   the  






Figure  7.37.  Glucocerebrosidase  enzyme  activities  are  enhanced  by  10μM  and  
30μM  concentrations  of  ambroxol  in  GBA  mutant  NCSC-­derived  neurons.  
NCSC   cultures   from   controls,   heterozygous   GBA   mutation   carriers,   and   IPD   patients   were  
differentiated  for  40  days  and  treated  with  selected  concentrations  of  ambroxol  (ABX),  over  6  days  at  
37°C.   Samples   containing   20μg   protein   were   tested   for   GCase   activity   using   5mM   of   4-­
methylumbelliferyl-­β-­D-­glucopyranoside  substrate.  Data  are  expressed  as  the  fold  increase  in  GCase  
activity   in   the  presence  of  ABX,   in  comparison   to  untreated  cells   (0  days  of   treatment).  The   results  
represent   the  mean  ±  SEM,  of   three   independent  experiments.     *p<0.05;;  **p<0.01;;  one-­way  ANOVA  







Figure   7.38.   GCase   protein   levels   are   increased   by   10μM   and   30μM  
concentrations  of  ambroxol  in  GBA  mutant  NCSC-­derived  neurons.  
NCSC      from   heterozygous  GBA  mutation   carriers   were   differentiated   for   40   days   and   treated  with  
selected   concentrations   of   ambroxol   (ABX),   over   6   days   at   37°C.   Representative   western   blots  
of  GBA   protein   levels   in   heterozygous  GBA   mutation   positive   carriers   NCSC-­derived   neurons   (A).  
Both  10μM  and  30μM  ambroxol  significantly   increased  GBA  protein   levels.  Bar  chart  demonstrating  
significant   increases   in   GBA   protein   levels   after   ABX   treatment   in   heterozygous   GBA   mutation  
carriers   (B).   The   results   represent   the   mean  ±  SEM,   of   three   independent   experiments.   *p<0.05;;  







Figure   7.39.   α-­Synuclein   protein   levels   are   reduced   by   10μM   and   30μM  
concentrations  of  ambroxol  in  GBA  mutant  NCSC-­derived  neurons.  
NCSC      from   heterozygous  GBA  mutation   carriers   were   differentiated   for   40   days   and   treated  with  
selected   concentrations   of   ambroxol   (ABX),   over   6   days   at   37°C.   Representative   western   blots  
of  SNCA  protein   levels   in  heterozygous  GBA  mutation  positive   carriers  NCSC-­derived  neurons   (A).  
Both  10μM  and  30μM  ambroxol  significantly   reduced  SNCA  protein   levels.  Bar  chart  demonstrating  
significant   reductions   in   SNCA   protein   levels   after   ABX   treatment   in   heterozygous  GBA  mutation  
carriers  (B).  The  results  represent  the  mean  ±  SEM,  of  three  independent  experiments.    *p<0.05;;  one-­
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Chapter  9:    Appendix  
9.1  Validation  of  the  BCA  assay  
The  BCA  assay  was  validated  by   the  use  of  8  samples  of  serially  diluted   fibroblast  
cell  lysates.  I  calculated  that  one  80%  confluent  cell  plate  =  ~1mg/ml  on  BCA  assay.  
Loading  double  the  lysate  concentration  gave  double  the  protein  concentration.  This  
tested   the  pipetting  accuracy  as  well   as   the   linearity  of   the  BCA  assay.  Standards  





Figure  9.1.  Validation  of  BCA  assay  with  varying  volumes  of  cell  lysate  
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9.2  Validations  of  the  GCase  assay  
  Testing  the  GCase  assay  conditions  
  
To   test   the   accuracy   of   the   assay,   I   measured   GCase   activity   for   a   range   of  
conditions   (Table  9.1).  The  GCase  activity   followed   the  predicted  pattern   for   the  8  
conditions   (Table   9.2).   Sodium   taurocholate   enhances   the  GCase   activity   5-­6   fold  
when   compared   to   the   measurement   in   the   presence   of   H20   without   sodium  
taurocholate.  The  sum  of  the  GCase  activity  measured  in  condition  7  (measurement  
of   lysosomal   GCase   in   the   presence   of   1μM   deoxynojirimycin   (DNJ),   a   GBA2  
inhibitor)  and  condition  8  (conduritol  β  epoxide  inhibition  on  GBA1)  should  be  equal  
to   that  measured   in   condition  6   (total  GCase  activity  measured   in   the  presence  of  
H20).  This   is  not  the  case  which  questions  the  specificity  of   the  inhibitors:  DNJ  and  
CBE.  CBE   inhibition   appears   complete   (minimal  GBA   activity   seen   in   conditions   4  
and  8).  DNJ   inhibition  on  GBA2  may  not   be   complete.  The  mutant  GCase  activity  
measured   is   higher   in   the   presence   of   H20   than   in   the   presence   of   sodium  
taurocholate.  This  would  be  consistent  with  a  compensatory  increase  in  GBA  activity  
in   the   presence   of   a   GBA   mutation.   Secondly,   in   the   absence   of   sodium  
taurocholate,   there   is   no   inhibition   on  GBA   activity   and   therefore,   the   total  GCase  







Table  9.1.  A  range  of  GCase  assay  conditions  
  
Condition  
   1   2   3   4   5   6   7   8  
NaT   +   +   +   +   -­   -­   -­   -­  
H20   -­   -­   -­   -­   +   +   +   +  
Lysate   -­   +   +   +   -­   +   +   +  
DNJ   -­   -­   +   -­   -­   -­   +   -­  
CBE   -­   -­   -­   +   -­   -­   -­   +  
Buffer   +   +   +   +   +   +   +   +  
  
NaT:  sodium  taurocholate;;  DNJ:  deoxynojirimycin;;  CBE:  conduritol  B  epoxide;;  H20:  water.  
  
Table  9.2.  The  predicted  GCase  activity  for  a  range  of  assay  conditions  
Condition   Predicted  GCase  activity,  nmol/h/mg  
1   Minimal  
2   ~400  
3   ~300  
4   ~30  
5   Minimal  
6   ~300  
7   ~200  




































  The  activity  of  GCase  against  the  amount  of  loaded  protein    
  
The   GCase   assay   was   validated   with   fibroblast   cell   lines.   The   cell   lysates   were  
serially  diluted  to  obtain  samples  of  decreasing  protein  concentration  (Table  9.3).  By  
plotting   the   GCase   activity   of   the   cell   lysate   samples   against   its   known   protein  
amounts,  calculated  using  the  BCA  assay,  the  linear  range  for  the  GCase  assay  can  
be   isolated   to   be  within   0.5   to   2mg/ml   for   fibroblast   cells.   Therefore,   for   a   normal  
GCase   assay,   I   would   not   want   to   go   above   2mg/ml   or   below   0.5mg/ml,   as   the  
GCase  activity  measured  will  be  outside  the  linear  range  of  normal.  This  is  shown  in  
Figure  9.4.  
  
Table  9.3.  Calculated  protein  concentration  for  serially  diluted  cell  lysate  
Loadings   Expected  protein  concentration,  mg/ml  
Actual  protein  
calculation,  mg/ml  
1   6   3.57  
2   5   3.47  
3   4   2.75  
4   3   1.91  
5   2   1.37  
6   1.3   0.89  
7   0.7   0.31  
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  The  activity  of  GCase  against  the  amount  of  loaded  protein  and  the  
incubation  time  
  
Fibroblast  cell   lysates  were  serially  diluted   to  obtain  samples  of  decreasing  protein  
concentration.   GCase   activity   was   measured   in   the   presence   of   different   protein  
concentrations  of  lysate  and  different  incubation  times.  GCase  activity  enhanced  with  
longer   incubations   but   not   with   increasing   protein   concentrations   (corrected   for   by  
the   BCA   calculation).   GCase   activity   actually   decreased   at   high   lysate   protein  
concentrations,   suggesting   an   inhibitory   effect   on   the  GCase   assay.  Greater   error  
was   seen   at   30   minute   incubations.   Readings   were   more   linear   at   the   1   hour  
incubation.  When   incubating   for   2   hours   compared   to      1   hour   for   1mg/ml   protein  




Figure  9.5.  Validation  of  the  GCase  assay  for  increasing  protein  concentrations  
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  CβE  inhibition  of  GCase  
  
The   conduritol-­β-­epoxide   (CβE)   fraction   of   GCase   activity   was   validated   with   the  
fibroblast  cell  lines.  Samples  containing  20μg  protein  were  tested  for  GCase  activity  
using  5mM  of  4-­methylumbelliferyl-­β-­D-­glucopyranoside  substrate.  1μM  of  CBE  was  
added  to  cell   lysate  of  a  constant  protein  concentration.  Data  are  expressed  as  the  
CβE-­sensitive  or  CβE-­negative   (residual)  GCase  activity.  The   results   represent   the  
mean  ±  SEM,  of   three   independent  experiments.  CβE   inhibition   led   to  90%  GCase  
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Figure   9.7.   Validation   of   CβE   inhibition   of   PC   enhanced  GCase   in   fibroblast  
cells.  
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9.3  Validation  of  the  β-­Hexosaminidase  assay  
  
The  β-­Hexosaminidase  assay  was  validated  with  fibroblasts  in  the  manner  described  
in   the   GCase   assay   validation.   By   plotting   the   activity   of   the   cell   lysate   samples  
against   its   known   protein   amounts,   calculated   using   the   BCA   assay,   Protein  
concentrations  over  1mg/ml  are  within  the  normal  linear  range  of  β-­Hexosaminidase.  




Figure  9.8.  Validation  of  the  β-­Hexosaminidase  assay  with  serially  diluted  
fibroblast  cell  samples.  
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9.4  Validation  of  the  β-­galactosidase  assay  
  
The  β-­galactosidase  assay  was  validated  with  fibroblasts  in  the  manner  described  in  
the  GCase  assay  validation.  By  plotting  the  activity  of  the  cell  lysate  samples  against  
its   known   protein   amounts,   calculated   using   the   BCA   assay,   all   protein  
concentrations   were   within   the   linear   range   for   β-­galactosidase   activity.   This   is  




Figure  9.9.  Validation  of  the  β-­galactosidase  assay  with  serially  diluted  
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9.5  Antibodies  and  primers  used  
  
Table  9.4.  List  of  antibodies  used  for  my  studies  
Antibody   Dilution   Application   Source   Cat.  No.  
GBA   1:1500   WB   Calbiochem   AP1140  
β-­ACTIN   1:5000   WB   Abcam   ab8227  
BiP   1:1000   WB   Abcam   ab21685  
LAMP1   1:1000   WB   Abcam   Ab24170  
LAMP2a   1:500   WB   Abcam   ab18528  
Hsc70   1:1000   WB   Abcam   ab51052  
GAPDH   1:5000   WB   Abcam   ab9485  
LC3   1:1000   WB   Cell  Signaling   2775  
p62   1:1500   WB   BD  Biosciences   610832  
Αlpha-synuclein   1:500   WB/ICC   Abcam   ab1903  
Beta  III  Tubulin   1:500   WB/ICC   Abcam   ab18207  
Tyrosine  Hydroxylase   1:1000   ICC   Abcam   ab6211  
Nurr1   1:200   ICC   Abcam   ab55769  
GBA   1:50   ICC   Sigma  Aldrich   G4171  
Cathepsin  D   1:500   ICC   Abcam   ab6313  
  
ICC,  Immunocytochemistry;;  WB,  Western  Blot.  
  
Table  9.5.  List  of  primers  used  for  my  studies  
Gene   Source   Cat.  No.  
GBA   Life  Technologies   Hs00986836_g1  
PARD3   Life  Technologies   Hs00969077_m1  
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9.6  Full-­length  images  of  immunoblots  for  fibroblast  cells  
GBA                                                                                                                                      LAMP1  
                                                                                                                                                                                                                                                                                                                                                      
β-­actin                                                                                                                              Hsc70  
                
  LC3                                                                                                                                        p62  
                       














































      Lamp2a  –  more  than  one  band                                            Lamp2a  +/-­  blocking  peptide  
                      
BiP  –  more  than  one  band                                                                                                                                
       
 





Figure  9.10.  All  western  blots  are  shown  in  full  scan.  The  corresponding  
figures  and  antibodies  are  indicated.   
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9.7  Full-­length  images  of  immunoblots  for  adipose  NCSC  
GBA                                                                                                                                      Hsc70  +  β-­actin                                                                                                      
                                                                                                                                                                                                                                                                                                                                                           
LAMP1  +  p62  
   
  LC3                                                                                                                                GAPDH  
                      













































      Lamp2a                                                                                                                      Lamp2a  +/-­  blocking  peptide  
                      
      Alpha-­synuclein                                                                                                
    
Predicted  and  observed  band  size  of  16kDa.  Additional  band  at:  80  kDa  (possible  post-­translational  
modification)  as  per  information  from  manufacturer:  
http://www.abcam.com/alpha-­synuclein-­antibody-­4d6-­b1903.html#description_images_2  
  
Figure   9.11.   All   western   blots   are   shown   in   full   scan.   The   corresponding  
figures  and  antibodies  are  indicated.  
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To   evaluate   the   cytotoxicity   of   ABX   and   IFG,   I   cultured   control   fibroblasts   in   the  
presence  of  every  day  vs.  alternate  day  PC  treatment  for  5  days,  and  then  assayed  
the  cell  viability.  After  5  days  in  vitro,  a  sample  of  medium  was  collected.  The  release  
of   the   cytosolic   enzyme   glucose-­6-­phosphate   dehydrogenase   (G6PD)   was  
measured   from   damaged   cells   into   the   media.   The   G6PD   assay   was   performed  
using   the   Vybrant   Cytotoxicity   Assay   Kit   (Life   Technologies)   as   per   the  
manufacturer’s   instructions.    The  results  showed  that  the  viability  of  fibroblasts  was  
unchanged   with   alternate   day   drug   treatment,   but   cytotoxicity   increased   two-­fold  
upon   every   day   treatment   for   both   PC   at   concentrations   of   60μM  ABX   and   50μM  
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Figure  9.12.  Cytoxicity  of  every  day  vs.  alternate  day  drug  treatment.  
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9.9  Evaluating  the  effect  of  different  drug  lots  
  
Skin   fibroblast   cultures   from   a   control   (CTRL)   and   a   mutant   line   (N370S/N370S)  
were   treated   with   different   lots   of   60μM   ambroxol   (ABX)   and   50μM   isofagomine  
(IFG)  for  6  days  at  37°C.  The  results  represent  a  single  experiment.  GCase  activity  
was  maximal   in  both  a  control  and  mutant   line  for  ABX  from  Sigma  Aldrich.  GCase  
activity  was  maximal  in  the  mutant  line  for  IFG  from  Santa  Cruz  Biotechnology.  This  














































9.10  Measurement   of   IFG   enhanced   GCase   following   a   24-­hour  
washout  period  
  
I  performed  an  experiment  to  determine  whether  any  potential  inhibition  of  GCase  by  
IFG  in   situ  could   be   minimised   by   a   washout   period.      GCase   levels   in   control  
fibroblasts   were   measured   after   5   days   incubation   in   the   presence   of   50μM   IFG,  
followed   by   a   24-­hour   washout   period   to   minimize   potential   GCase   inhibition   by  
IFG  in  situ.  For  comparison,  the  effect  of  5  days  incubation  in  the  presence  of  50μM  
IFG,   followed  by  no  washout  period  was  also  assessed.  Samples  containing  20μg  
protein   were   tested   for   GCase   activity   using   5mM   of   4-­methylumbelliferyl-­β-­D-­
glucopyranoside  substrate.  Data  are  expressed  as   the  measured  GCase  activity   in  
the   presence   of   IFG.   The   experiment   was   repeated   independently   5   times.   There  
was  no  significant  difference   (P  >  0.05)   in  GCase  activity  when   the  measurements  
were  performed  after  a  washout  period.  This  is  shown  in  Figure  9.15.  
  
  
Figure   9.15.   Comparison   of   the   measured   GCase   activity   following   IFG  














9.11  Skin  biopsies  I  obtained  from  the  patient  cohort  
  
Table  9.6.  List  of  skin  biopsies  (n=25)  obtained  from  the  patient  cohort  
Subject   Genotype   Gender   Diagnosis   Age  at  biopsy  
C1   wt/wt   Female   CTRL   67  
C2   wt/wt   Female   CTRL   70  
C3   wt/wt   Male   CTRL   81  
C4   wt/wt   Female   CTRL   82  
C5   wt/wt   Male   CTRL   52  
Het1   N370S/wt   Female   GBA  Carrier   67  
Het2   N370S/wt   Female   GBA  Carrier   60  
Het3   N370S/wt   Female   GBA  Carrier   82  
Het4   N370S/wt   Male   GBA  Carrier   52  
Het5   N370S/wt   Male   GBA-­PD   80  
Het6   N370S/wt   Female   GBA-­PD   75  
Het7   N370S/wt   Female   GBA-­PD   53  
Het8   L444P/wt   Male   GBA  Carrier   62  
Het9   L444P/wt   Female   GBA  Carrier   45  
Het10   L444P/wt   Male   GBA  Carrier   67  
Het11   L444P/wt   Male   GBA-­PD   72  
Het12   L444P/wt   Male   GBA-­PD   85  
GD1   N370S/N370S   Male   GD   70  
PD1   wt/wt   Female   IPD   85  
PD2   wt/wt   Male   IPD   79  
PD3   wt/wt   Female   IPD   81  
PD4   wt/wt   Female   IPD   72  
PD5   wt/wt   Male   IPD   80  
PD6   wt/wt   Female   IPD   75  
PD7   wt/wt   Female   IPD   53  
                                                                                                                                                                                                                                                                                                        
CTRL,  healthy  control;;  IPD,  Idiopathic  Parkinson’s  disease;;  GBA  Carrier,  heterozygous  GBA  mutation  
carrier;;  GBA-­PD,  heterozygous  GBA  mutation  carrier  with  PD;;  GD,  Gaucher  disease.  
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